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CHAPTER 1 
General Introduction 
Chapter 1 
Circulating and local renin-angiotensin system(s) 
Traditionally the renin-angiotensin system (RAS) has been viewed as a circulating 
system. Circulating renin, released by the kidneys, cleaves liver-derived angiotensinogen, 
which yields the inactive decapeptide angiotensin I (Ang (1-10) or Ang I) (Figure 1). Ang 
I is subsequently converted into an octapeptide, angiotensin II (Ang (1-8) or Ang II), by 
angiotensin-converting enzyme (ACE), an enzyme that is either located at the huninal 
side of the endothelium or circulating freely in plasma. Ang II is rapidly metabolized by 
so-called angiotensinases. 
Angiotensinogen 
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Figure 1. Generation of angiotensin I, II, III, and angiotensin (1-7) from angiotensinogen and 
activation of the various angiotensin receptors (AT) by angiotensin II and its metabolites. R in 
angiotensinogen consists of 437 amino acids. 
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Ang II is an important agent in the regulation of cardiovascular homeostasis. It was first 
recognized as a potent vasoconstrictor. Other functions that were subsequently described, 
include stimulation of renal sodimn reabsorption and adrenal aldosterone synulesis, ,., 
induction of cellular growth and hypertrophy,'" as well as facilitation of sympathetic 
neurotransmission.7,8 
The actions of Ang 11 are initiated by binding to a receptor. Receptor binding is 
followed by an intracellular cascade of second messenger reactions, which eventually 
lead to a cellular response. At present, at least three different angiotensin receptors have 
been identified based upon different binding characteristics of non-peptide Ang 11 
receptor antagonists: the AT" AT,and AT, receptor.' The AT, receptor preferentially 
binds a metabolite of Ang 11, Ang (3-8) or Ang IV; its natural ligand may however be 
Leu-VaI-VaI-hemorphin 7 rather than Ang IV.IO.II Furthermore, a binding site for another 
angiotensin metabolite, Ang (1-7), has been described; characterisation of this site has not 
yet been completed.' The AT, - and AT, receptor belong to the seven transmembrane 
domain receptor superfamily. The AT, receptor mediates all of the above described 
effects of Ang II. Recent investigations suggest that stimulation of Ule AT, receptor may 
counteract some of the effects mediated by the AT, receptor. 12•1l The AT, receptor 
appears to regulate memory acquisition, memory retrieval and neurite outgrowth.!6 The 
Ang (1-7) receptor is linked to vasodilatation, vasopressin release, and prostaglandin 
synulesis. 17 
Angiotensin binding sites have also been detected in the cytosol and nucleus of 
hepatocytes and vascular smooth muscle cells. The function of these intracellular 
receptors is presently unknown."·19 
The introduction of drugs interfering Witll the RAS (ACE inhibitors" renin 
inhibitors and AT, receptor antagonists) has greatly facilitated our understanding of the 
RAS. It is now well-established that, in addition to angiotensin generation in the 
circulation, angiotensins may also be synthesized at tissue sites.20·23 Tissue angiotensin 
generation is often invoked to explain the long-term beneficial effects of RAS inhibitors 
in heart failure and hypertension."·2S The origin of the renin, angiotensinogen and ACE 
involved in tissue angiotensin production is still a matter of debate. Both local synthesis 
and uptake from the circulation have been proposed. Local synulesis would imply that 
tissue angiotensin generation may occur independently from Ule circulating RAS. 
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Uptake from plasma would imply a close relationship between the circulating RAS and 
the 'tissue RAS'. Most likely, under nonna! circumstances local synthesis of angiotensins 
in the heart and blood vessel wall depends on renin taken up from the circulation.22•26•27 
This may be different tmder pathological conditions." 
Effect of angiotensin II on second messengers 
Binding of Ang II to the AT, receptor activates phospholipase C-P (PLC-P) via a Gq-
protein-dependent mechanism. PLC-P hydrolyses phosphatidylinositol 4,5-biphosphate 
(PIP,) into inositoll,4,5-triphosphate (IP,) and 1,2 diacylglycerol (DAG). IP, releases 
Ca" from intracellular stores, and DAG activates protein kinase C (PKC). The increase 
in intracellular Ca'+ and the activation of PKC are both capable of inducing mitogen-
activated protein (MAP) kinases and phospholipase D (PLD). 
PLD hydrolyses phosphatidylcholine, and to a lesser extent other phospholipids, to fonn 
phosphatidic acid (PA), which either augments Ang II-induced MAP kinase activation or 
affects other undefined events leading to gene transcription. '.29.30 MAP kinases are 
cytosolic serine/threonine kinases {e.g., p44'IAPK (Erkl) and p42'IAPK (Erk2)) that are 
involved in one or more signal transduction pathways linking events at the plasma 
membrane with events in the nucleus.31 
Recent evidence suggests that the AT, receptor shares properties with cytokine 
receptors." Similar to cytokines, Aug II induces tyrosine phosphorylation of intracellular 
kinases such as Jak2 and Tyk2, thereby leading to increased activity of these kinases. This 
increased activity results in the tyrosine phosphorylation of tht> Jak family substrates 
STAT! and STAT2 ('Signal Transducers and Activators of Transcription'). The STAT 
proteins translocate to the nucleus, where they stimulate transcription of early growth 
response genes. Other tyrosine kinases activated by Aug II include the Src family of 
tyrosine kinases. PLC-y is an excellent substrate for members of this family, and it has 
therefore been proposed that not only PLC-P but also PLC-y is involved in Ang II-
induced PIP, hydrolysis. 33 
The various signal transduction pathways that are activated by Ang II may 
subserve different cellular responses, e.g., the Jak/STAT pathway may trigger a stress 
response, wltile the MAPK cascade may favor mitogenesis or hypertrophy. 
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The actual cell response would be detennined by the relative level of activation of these 
pathways and crosstalk among them. 
The intracellular mechanisms that are activated by AT, receptors are not yet fully 
established. Studies in PC-12W pheochromocytoma cells and in NIE-1l5 murine 
neuroblastoma cells indicate that Ang II, via AT, receptors, can stimulate or inhibit 
protein-tyrosine phosphatases."·" In addition, it has been shown that AT, receptors 
mediate activation of a specific tyrosine phosphatase (MAP kinase phosphatase I), which 
leads to MAP kinase inhibition and the induction ofapoptosis.36•37 
Angiotensin II and the response of cardiomyocytes to mechanical stretch 
According to several investigators mechanical stretch of rat cardiomyocytes kept under 
serum-free conditions causes release of Ang II from these cells."~' However, the Ang II 
levels that have been reported vary widely, and not all investigators could detect Ang II 
in the culture medium after the induction of stretch. Ang II release into the medium by 
serum-deprived cardiomyocytes might suggest that these cells are capable of generating 
Ang II independently of circulating renin and angiotensinogen. 43•44 
Mechanical stretch of cardiomyocytes causes activation of multiple second 
messenger systems tllat are similar to growth factor-induced cell signalling systems. The' 
mechanisms underlying the conversion of mechanical stretch into growth and subsequent 
cellular hypertrophy are presently unknown. One possibility is that mechanical stretch, 
via mechanosensing mechanisms, stimulates the production and/or secretion of growth 
factors such as Ang II and endothelin-l, which then induce the hypertrophic response. 
Alternatively, mechanosensors (,stretch receptors') may directly activate second 
messengers. Possible mechanosensors are ion channels, such as nonselective cation 
channels and K+ chatmels."·46 Second, integl'ins, heterodirneric transmembrane receptors 
tllat couple components of the extracellular matrix with the actin cytoskeleton as well as 
tile N-tenninal domain of focal adhesion tyrosine kinase (F AK), might convert 
mechanical signals into intracellular second messenger signalling."'" Thirdly, tyl'osine 
kinases (e.g. Src family tyrosine kinases) have transmembrane segments, and membrane 
stretch may directly cause confonnational changes of tllese tyrosine kinases, thereby 
activating them. 49 
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At present is IDlclear to what degree the stretch-induced hypertrophic response depends 
on Ang II. Furthermore, the mechanism of Ang II production by sermn-deprived 
cardiomyocytes remains to be elucidated: is Ang II generated intracellularly and 
subsequently stored in intracellular storage sites, in order to be released after ti,e 
induction of stretch? In vivo, cardiac Ang II production independent of the circulating 
RAS seems unlikely, at least under nonnal circumstances, because of the low or 
undetectable levels of renin mRNA in the heart."·51 If the sarne applies to cardiomyocytes 
(i.e., lack of renin synthesis), either non-renin enzymes may be involved in the 
intracellular angiotensin generation, or the renin required for angiotensin syntllesis is 
derived from ti,e serum used to culture the cells. 
Evidence for binding andlor uptake of circulating (pro)renin 
Angiotensin release from the isolated perfused rat Langendorffheart or hindquarter (well-
known models to study cardiac and vascular angiotensin production, respectively) 
depends on the addition of renin to the perfusion fluid. S2." The release of Ang I from ti,e 
isolated heart during perfusion with renin was too high to be attributed to Ang I 
generation in either intravascular or interstitial fluid, indicating a role for vascular 
surface-boIDld renin. S2 Interestingly, angiotensin release continued after discontinuation 
of the renin perfusion, i.e., at a time when renin was no longer present in ti,e perfusate. 54." 
Furtilermore, the renin levels in cardiac tissue in vivo are too high to be explained by 
simple diffusion into the interstitial fluid, and renin is enriched in membrane fractions 
prepared from freshly obtained cardiac tissue." Thirty hours after bilateral nephrectomy 
in pigs, renin is no longer detectable in cardiac tissue." In the rat, aortic renin also 
disappeared after nephrectomy, with a longer half life than plasma renin. 56•l1 Taken 
together, tI,ese fmdings suggest that renin is sequestered from ti,e circulation by cardiac 
and vascular tissues, and that tissue-bound renin contributes to local angiotensin 
production. 
The mechanism of renin uptake andlor binding is still unknown. It must be kept 
in mind tI,at renin has an inactive precursor, prorenin. In humans, the circulating levels 
of prorenin are tenfold higller than those of renin. Under certain circumstances (e.g., 
diabetes and pregnancy) tltis difference may become even larger. "~I 
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It is therefore conceivable that not only renin, but also prorenin, is taken up by the tissues. 
Prorenin may either compete wiOI renin for binding sites, Olereby leading to an inhibition 
of local angiotensin generation, or prorenin may be converted locally into renin, thereby 
stimulating local angiotensin generation (Figure 2).62 Studies in which prorenin was 
infused into animals provided no evidence for the release of activated prorenin into the 
circulation, indicating that if prorenin is activated locally, it remains in the tissue rather 
than being released back into the circulation.63•64 
A BO 080 c 
LOCAL ACTIVATION COMPETITION 
! I 
SECOND MESSENGERS 
INTRACELLULAR 
SIGNALLING 
O"prorenln ' 
O"renin 
• "prosegment 
Figure 2. Prorenin binding to (pro)renin binding proteins/receptors may lead to prorenin 
activation (A), either extra- or intraceUularly, thereby stimulating local angiotensin generation, or, 
when activation does not occur (B), it may competitively prevent renin from binding, thereby 
inhibiting local angiotensin generation. Finally, (pro )renin binding may directly activate second 
messengers (C), thereby inducing an intracellular response without angiotensins acting as 
intemlediates. 
At present, both (pro )renin binding proteins and receptors have been described. Au 
intracellular renin-binding protein (RnBP, mol. wt. 40 kDa) was discovered in the early 
eighties in humans, rats and pigs."-6' Binding to this RnBP reduces the Aug I generating 
activity of renin by more than 80%. 
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Recently, this RnBP was found to be equal to the enzyme N-acyl-D-glucosamine 2-
epimerase, indicating that it might be involved in the intracellular processing of renin 
rather than in renin uptake." Subsequently, using chemical cross-linking, two vascular 
RnBPs (mol. wt. 40 and 70 kDa, resp.) were identified by Campbell and colleagues in 
membranes isolated from rat mesenteric arteries or cultured rat aortic smooth muscle 
cells. Interestingly, binding to these RnBPs was iullibited by a specific, active site-
directed renin iullibitor, suggesting that the active site of tile renin molecule right be 
involved in tile binding process." 
More recently, with the use of radiolabelled (pro )renin, high affntity rellin binding 
sites/receptors (Kd ~ I nM) were demonstrated in hwnan mesangial cells and in 
membranes prepared from rat tissues.,,·n In tile rat, tllese binding sites bound prorenin 
and renin equally well, which suggests that neither tile prosegment nor the active site is 
involved in the binding process." This contrasts with Campbell's fmdings. In hlmlatl 
mesangial cells, renin binding led to the induction of DNA synthesis, most likely without 
Aug II playing a role as an intermediary between renin binding and tile hypertrophic 
response." TIlUs, a renin receptor may have been identified that directly transduces an 
intracellular signal (Figure 2). 
If binding does not involve tile prosegment or tile active site, a further possibility 
would be binding to tile carbohydrate portions which both proteins contain. Renin and 
prorenin display isoelectric heterogeneity; up to 5 or 6 forms with different isoelectric 
points have been described in rats and humans. n.71 This heterogeneity most likely results 
from differential glycosylation (glycofOlms). The carbohydrate portion appears to be 
involved in tile clearance of renin by the liver, since deglycosylation greatly (> 90%) 
reduced the hepatic uptake of renin." In studies on the uptake of I2lI-labelled recombinatlt 
hWllan renin by tile liver, Marks et al. were able to show that tile receptor involved in the 
uptake process is tile mamlOse receptor, present on sinusoidal endothelial and Kupffer 
cells.77 This receptor (mol. wI. 175 kDa) binds glycoproteins bearing high mannose chains 
and recycles rapidly between the cell surface, where ligand binding occurs, and various 
acid intracellnlar compartments, where the ligand is discharged." Following binding to 
the matUlOSe receptor, renin was found to be rapidly delivered to Iysosomes, where 
degradation occurred." 
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Maximal inhibition of hepatic renin uptake by maJman (a specific inhibitor of the 
mannose receptor) was 70%, indicating that there may be additional mechanisms involved 
in the hepatic clearance of renin, e.g. binding to the asialoglycoprotein receptor or the 
mannose 6-phosphate receptor.71 
Faust et al. demonstrated that renin, like cathepsin D, acquires phosphomannosyl 
residues during its biosynthesis that enable it to bind to the mannose 6-phosphate 
receptor. 79 According to Aeed and colleagues, the percentage of recombinant human 
(pro )renin carrying the mannose 6-phosphate signal is small, most likely < 10%.80 If the 
uptake of renin by cardiovascular tissues involves the mannose 6-phosphate receptor, this 
low percentage may explain why less than 1% of intravenously infused "'I-labelled renin 
was found to accumulate in these tissues.81•83 
Mannose 6-phosphate receptors 
Synthesis of lysosomal enzymes, secretory proteins, and plasma membrane proteins 
occurs in the rough endoplasmatic reticulum. Following glycosylation at selected 
asparagine residues, the proteins move by vesicular transport to the Golgi apparatus 
where they undergo a variety of post-translational modifications. Subsequently, they have 
to be segregated from one another for targeting to their final destinations." A key step in 
the sorting process is the generation of phosphomannosyl residues on the lysosomal 
enzymes. 
These residues serve as high affmity ligands for binding to mannose 6-phosphate 
receptors (MPRs) in the Golgi. The ligand-receptor complex exits the Golgi via a coated 
vesicle, and is delivered to a prelysosomaI acidified compartrnen~ where the ,ligand 
dissociates. The released lysosomal enzyme is packaged into a lysosome while the 
receptor either returns to the Golgi via a coated vesicle to repeat the process, or moves 
to the plasma membrane where it functions to internalize exogenous lysosomal 
enzymes.84 
At present, two different MPRs have been identified (Figure 3): a large MPR 
(mol. wI. 300 kDa), which binds ligand independent of divalent cations (cation-
independent or CI-MPR)," aJld a small MPR (mol. wI. 46 kDa), which requires divalent 
cations for optimal binding (cation-dependent or CD-MPR)." 
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Figure 3. Schematic representation of the mannose 6-phosphate receptors. The two ligands ofthe 
cation-independent mannose 6-phosphate are depicted. Arginine residues at positions 435 and 
1334 in domains 3 and 9, respectively, are essential for high-affinity binding of mannose 6-
phosphate. Sequences in domain II are involved in binding IGFI!. Modified from references 84 
and 113. 
Both receptors show similar binding specifilies toward phosphorylated 
oligosaccharides"'" In 1987, it was discovered that the CI-MPR and the insulin-like 
growth factor II receptor are the same protein." Thus, tins CI-MPR is now also known 
as the M-6-PIIGFII receptor. The receptor binds IGFlI, winch is non-glycosylated, and 
phosphomaIUlosylated proteins at distinct sites.88,89 Each ligand may however influence 
the binding of the other ligand to the receptor."'" The M-6-PIIGFII receptor binds one 
mole of IGFII,88 and has two M-6-P binding sites, allowing the binding of 2 moles of 
maIU10se 6-phosphate or one mole of a diphosphorylated oligosaccharide per monoUier. 
Diphosphorylated oligosaccharides are bound with much higher affunty (" 10.9 M) tllan 
maIUlOse 6-phosphate (" 10" M)," 
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The CD-MPR binds one mole of the monovalent ligand mannose 6-phosphate and 0.5 
mole of a diphosphorylated high-mannose oligosaccharide per monomeric subunit (with 
affmities of ~ 10" M and ~ 10.7 M, respectively)." 
The M-6-PIIGFII receptor consists of a large extracellular domain, containing 15 
repeat regions, and a small cytoplasmic domain (Figure 3). The extracytoplasmic domain 
of the CD-MPR is similar to each of the repeating units of the extracellular domain of the 
M-6-PIIGFII receptor, suggesting that the two receptors may be derived from a conllllon 
ancestor.92 The M-6-PIIGFII receptor exists as a monomer," whereas the CD-MPR can 
exist as a monomer, dimer or tetramer." MPRs cycle constitutively among the Golgi, 
endosomes, and the plasma membrane. The majority (90%) of the M-6-PIIGFII receptors 
is located in a late endosomallprelysosomal compartment, with the rest being distributed 
over the plasma membrane, early endosomes, and the Golgi." Extracellular lysosomal 
enzymes which bind to the cell surface M-6-PIIGFII receptor are internalized via clathrin-
coated pits. TIley dissociate from the receptor in acidified endosomal compartments and 
are subsequently delivered to lysosomes. The receptor is then reutilized; it can \Uldergo 
many rounds of ligand delivery."·"" Endocytosis of lysosomal enzymes via the CD-MPR 
is of limited importance because of its poor binding of ligand at the cell surface?' 
Binding and internalization of IGFII to tlle M-6-PIIGFII receptor results in the 
lysosomal degradation of this ligand.99 In addition, IGFII mediates growth-stimulatory 
responses via tlus receptor. IOO Thus, its function with regard to IGFII may botll be 
clearance and coupling to second messengers. Furthermore, the M-6-P/IGFII receptor is 
involved in the clearance and activation of other hormones carrying the mannose 6-
phosphate recognition marker, such as thyroglobulin,101 proliferin,l°2 and latent 
transfonning growth factor-~ (TGF_~).lo3 Binding of latent TGF-~ results in cleavage of 
tlus prohormone into its active forni, which is potent growth inhibitor. 
Kang et aI. recently demonstrated tllat the M-6-PIIGFII receptor also binds retinoic 
acid (RA) with lugh affinity at a site that is distinct from those for mannose 6-phosphate 
and IGFII.I'" RA is an important regulator of cell growth in embryonic development and 
oncogenesis. Binding ofRA upregulates the endocytotic functions of the M-6-P/IGFII 
receptor. Taken togetller, these fmdings suggest tllat the M-6-PIIGFII receptor may play 
a critical role in the regulation of cell growth. 
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Indeed, recent findings from transgenic animal experinlents, as well as human studies, 
have shown that the M-6-P!IGFII receptor is essential for normal fetal developmentlO'.I07 
and has anti-cancer activity. lOW' The levels of the receptor are highest in fetal tissues, 
and decline rapidly after birth.Ill,1l2 
Aim of the thesis 
It was the aim of the present study to investigate uptake mechanism(s) of renin and/or 
prorenin in the cardiovascular system. In addition, we studied whether prorenin, once 
bound and/or internalized, is activated to renin. Finally, the role of angiotensin II in the 
hypertrophic response of cardiac cells was investigated. 
Most studies described in this thesis have been performed with cultured, sernm-
deprived cells, in order to avoid the problems arising from studies in whole tissues, which 
may contain both locally synthesized RAS components and components that are taken up 
from the circulation. 
First, we verified the synthesis of RAS components by neonatal rat cardiac 
myocytes and fibroblasts, as well as the release of Aug II by cardiomyocytes after the 
induction of stretch (Chapter 2). We then studied the effects of exogenous Ang II on 
protein and DNA synthesis in wlstirnulated and endothelin-l-stimulated neonatal rat 
cardiac cells (Chapter 3). Subsequently, the binding and internalization of recombinant 
human renin and prorenin, as well as the activation of prorenin by neonatal rat cardiac 
cells (Chapter 4) and human umbilical vein endothelial cells (Chapter 5) were 
investigated, with special emphasis on the role of the M-6-P!IGFll receptor in tIus 
process. Finally, we compared tIle cardiac tissue levels of RAS components in heart 
donors who died of non-cardiovascular disorders and subjects with dilated 
cardiomyopathy undergoing cardiac transplantation (Chapter 6), in order to answer the 
question whether (pro)rellln is synthesized in cardiac tissue under pathological conditions. 
18 
General introduction 
References 
1. Schuster VL. Effects of angiotensin II on proximal tubular reabsorption. Fed Proc. 1986; 45: 
1444-1447. 
2. Pratt JH, Rothrock JK, Dominguez JH. Evidence Umt angiotensin-II and potassium collaborate to 
increase cytosolic calcium and stimulate the secretion of aldosterone. Endocrinology. 1989; 125: 
2463-2469. 
3. ShierDN, Kusano E, Stoner GD, Franco-Saenz R. Mulrow Pl. Production ofrenin, angiotensin 
II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme 
inhibition. Endocrinology. 1989; 125: 486-491. 
4. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of 
cardiac myocytes and hyperplasia of cardiac fibroblasts; critical role of the ATJ receptor subtype. 
eire Res. 1993; 73: 413-423. 
5. Miyata S, Haneda T. Hypertrophic growth of cultured neonatal rat heart cells mediated by type 
1 angiotensin receptor. Am J Physiol. 1994; 266: H2443-H245I. 
6. Schelling P, Fischer H, Ganten D. Angiotensin and cell gro\\th: a link to cardiovascular 
hypertrophy? J Hypertens. 1991; 9: 3-15. 
7. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol 
Biochem Pharmacol. 1977; 77: 1-124. 
8. WestfuU TC. Local regulation of adrenergic neurotransmission. Physiol Rev. 1977; 57: 659-728. 
9. Regitz-Zagrosek V, Neu8 M, Holzmeister J, Warneke C, Fleck E. Molecular biology of 
angiotensin receptors and their role in human cardiovascular disease. J Mol Med. 1996; 74: 233-
251. 
10. Hanesworth 1M, Sardina MF, Drebs LT, Hall KL, Harding JW. Elucidation of a specific binding 
site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J Pharmacol E-.:p 
Ther. 1993; 266: 1036-1042. 
1 J. Mendelsohn FAD. Tissue localization of ACE and angiotensin AT!> AT2 and AT~ receptors. J 
Hypertells. 1998; 16 (SuppI2): S9 (abstraet). 
12. Stoll M, Stcckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin An-receptor 
mediates inhibition of cell proliferation in coronary endothelial cells. J eli,., Invest. 1995; 95: 651-
657. 
13. Nakajima M, Hutcbinson G, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt 
RE, Dzau VI. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI 
receptor: gain-of-funetion study using gene transfer. Proc Noll Acad Sci USA. 1995; 92: 10663-
10667. 
14. Ichiki T, Labosky Pi\, Shiota C, Okuyama S, lnmgawa Y, Fogo A, Nilmura F, Ichikawa J, Hogan 
BLM, Inagarni T. Eftects on blood pressure and exploratory behaviour of mice lacking angiotensin 
II type-2 receptor. Nature. 1995; 377: 748-750. 
15. Hein L, Barsh G, Pratt RE, Dzall VI, Kobilka BK. Behavioural and cardiovascular effects of 
disrupting the angiotensin II type-2 receptor gene in mice. Nature. 1995; 377: 744-747. 
16. Wright JW, Harding J\V. Important role for angiotensin III and IV in the brain renin-angiotensin 
system. Brain Res Brain Res Rev. 1997; 25: 96-124. 
17. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DJ. Counterregulatory actions of 
angiotensin-(l-7). Hypertensioll. 1997; 30:535-541. 
19 
Chapler J 
18. Eggena P, Zhu JH, Sannapom S, Giordani M, Clegg K, Andarsen PC, Hyun P, Barret !D. Hepatic 
angiotensin II nuclear receptors and transcription of grO\\1h-related factors. J Hyper/ens. 1996; 
14: 961-968. 
19. Haller H, Lindschau C, Erdmann B, Quass P, Luft Fe. Effects of intracellular angiotensin II in 
vascular smooth muscle cells. Orc Res. 1996; 79: 765-772. 
20. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present 
experimental and clinical evidence. Orc Res. 1991; 68: 905-921. 
21. Kim S. Tokuyama M, Hosoi M, Yamamoto K. Adrenal and circulating renin-angiotensin system 
in stroke-prone hypertensive rats, Hypertensioll. 1992; 20: 280-291. 
22. Danser AHJ, van Kats JP, Admiraal PH, Dcrkx FHM, Lamers JMJ, Verdouw PO, Saxena PR, 
Schalekamp MADH. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. 
Hyper/ellsioll. 1994; 24: 37-48. 
23. Campbell DJ, Lawrence AC, Towrie A, KJadis A. Valcntijn A Differential regulation of 
angiotensin peptide levels in plasma and kidney of the rat. Hyper/ension. 1991; 18: 763-773 
24. Pfeffer !vIA, Brnunwald E, Moye LA, Basta L, Brown Jr ER, Cuddy TE, Davis BR, Geltman EM, 
Goldman S, Flaker GC, Klein M, Lamas DA, Packer M, Rouleau J, Rouleau JL, Rutherford J, 
\Vertheirner JH. Hawkins CM. on behalf of the SAVE investigators. Effect of captopril on 
mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. 
N Ellgi J Med. 1992; 327: 669-677. 
25. TIle SOLVD investigators. Effect of enalapril on mortality and the development of heart failure 
in asymptomatic patients with reduce:d.left ventricular ejection fractions. N Eng/ J Med. 1992; 327: 
685-691. 
26. Kato H. I\Vai N. Kimoto K, Uchiyama Y, Inagami T. Regulation ofvacular angiotensin release. 
Hyper/ension. 1993; 21: 446-454. 
27. Hilgers KF, Kuczera M, Will,e~n MJ, Wieeek A, Ritz E, Ganten 0, Mann JFE. Angiotensin 
fonnation in the isolated rat hindlimb. J Hypertens. 1989; 7: 789-798. 
28, Passier RCJJ, Smits JFM, Verluyten MJA, Daemen MJAP. Expression and localization of renin 
and angiotensinogen in rat heart after myocardial infarction, Am J Physio/. 1996; 271: H1040-
Hl048. 
29. Booz GW. Dostal DE. Singer HA, Baker KM. Involvement of protein kinase C and Ca2+ in 
angiotensin II-induced mitogenesis of cardiac fibroblasts. Am J Physiol. 1994; 267: CI308-C1318. 
30. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c{os gene 
expression in cardiac myocytes in vitro; roles of phospholipid-derived sc<;ond messengers. eire 
Res. 1993; 73: 424-438. 
31. Davis RJ. 1be mitogen-activated protein kinase signal transduction pathway. J Bioi Chem. 1993; 
268: 14553-14556. 
32. Marrero ME, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct 
stimulation ofJak/STAT pathway by U,e angiotensin II AT, receptor. Na/llre. 1995; 375: 247-250. 
33. Marrero MB, Schieffer B, Paxton WG, Duff JL, Berk BC, Bernstein KE. The role of tyrosine 
phosphorylation in angiotensin II-mediated intracellular signalling. Cardiovasc Res, 1995; 30: 
530-536. 
34. Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, de Gasparo M. The angiotensin AT, 
receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate 
guanylate cyclase. Biochem Biophys Res CommuN. 1992; 198: 206-211. 
35, Nahmias C, Lazard D, Villageois P, Strosberg AD. Angiotensin II AT2 receptors are functionally 
coupled to protein tyrosine dephosphorylation in N IE-liS neuroblastoma cells. Biochem 1. 1995; 
306:87-92. 
20 
General introduction 
36. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II t)j)e 2 receptor mediates progranuned cell death. 
Proe Noll Aead Sci USA. 1996; 93: 156-160. 
37. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, 
Pratt RE, Dzau VJ. The angiotensin II type 2 (AT,) receptor antagonizes the growth effects oftlte 
AT, receptor: gain-of-function study using gene transfer. Proe Nail Aead Sci USA. 1995; 92: 
10663-10667. 
38. ~fiyata S, Haneda T, Osaki J, Kikuchi K. Renin-angiotensul system in stretch-ulduced hypertrophy 
of cultured neonatal rat heart cells. Ellr J Pharmaeol. 1996; 307: 81-88. 
39. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrinc release of angiotensin II mediates stretch-
induced hypertrophy of cardiac myocytes in vitro. Cell. 1993; 95: 977-984. 
40. Liang F, Gardner DG. Autocrineiparacrine detcnninants of strain·activated brain natriuretic 
peptide gene expression in cultured cardiac myocytes. J Bioi Chem. 1998; 273: 14612-14619. 
41. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, 
Tobe K, Kaduwaki T, Nagai R. Yazaki Y. Angiotensin II partly mediates mechanical stress-
induced cardiac hypertrophy. Cire Res. 1995; 767: 258-265. 
42. Leri A, Claudio PC, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anvers. P. Stretch 
mediated release ofangiotcllsin II induces myocyte apoptosis by activating p53 that enhances the 
local renin-angiotensin system and decreases the BcI-2-to-Ba'{ protein ratio in the cell. J Clin 
lnvesl. 1998; 101: 1326-1342. 
43. Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker KM. Intracardiac detection of 
angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Pllys/ol. 
1992; 263: C838·C850. 
44. Dostal DE, Rotltblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and 
II in cultured rat cardiac myocytes and fibroblasts. AmJ Physiol. 1992; 263: C851-C863. 
45. Ruknudin A. Sachs F. Bustamante JO. Stretch-activated ion channels in tissue-cultured chick 
heart. Am J Physiol. 1993; 264: H960-H972. 
46. Sadoshima J, Takahashi T. Jalm L, Izumo S. Roles of mechanosensitive ion charmels. 
cytoskeleton. and contractile activity in stretch-induced immediate-early gene expression and 
hypertrophy of cardiac myoc)1cs. Proc Noll Acad SCi USA. 1992; 89: 9905-9909. 
47. Parsons JT. Integrin-mediated signalling: regulation by tyrosine kinases and small GTP·binding 
proteins. Clirr Opin Cell Bioi. 1996; 6: 146-152. 
48. Schwartz tvfA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. 
AnllIl Rev Cell Dev Bioi. 1995; 11: 549·599. 
49. Sadoshima J, Izwno S. Mechanical stetch rapidly activates ruu Itiple signal transduction pathways 
in cardiac myocytes: potential involvement of an autocrinefparacrine mechanism. EAlBO J. 1993; 
12: 1681-1691. 
50. Ekker M, Tronik D, Rougeon F. Extrarenal transcription of the renin genes in multiple tissues of 
mice and rats. Proe Noll Acad Sci USA. 1989; 86: 5155-5158. 
51. Iwai N, Inagami T. Quantitative analysis of renin gene expression in extrarenal tissues by 
polymerase chain reaction method. J Hyperlens. 1992; 10: 717-724. 
52. de Lanno)' LM, Danser AHJ, van Kats JP, Schocmaker RG, Saxena PR, Sehalekamp MADH. 
Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. 
Local production of angiotensin '- Hyperlension. 1997; 29: 1240·1251. 
53. de Lannoy LM, Danser AID, Bouhuizen AMB, Saxena PRo Schalekantp MADH. Localiz.,tion 
and proouction of angiotensin II in the isolated perfused rat heart. Hypertension. 1998; 31: 111 J-
1117. 
21 
Chapter 1 
54. Muller DN, Hilgers KF, Bohlender J, Lippoldt A, Wagner J, Fischli W, Ganten D, Mann JF, Luft 
Fe. Effects of human renin in the vasculature of rats transgenic for human angiotensinogen. 
Hyper/ension. 1995; 26: 272-278. 
55. MUller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menard J, Busjahn A, Ganten D, Luft 
FC. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res. 1998; 82: 13-
20. 
56. Thurston H, Swales 10, Bing RF, Hurst BC, Marks ES. Vascular renin-like activity and blood 
pressure maintenance in the rat: studies on the effect of changes in sodium balance, hypertension, 
and nephrectomy. Hyper/ension. 1979; I: 643-649. 
57. Loudon M, Bing RF, Thurston H, Swales 10. Arterial wall uptake of renal renin and blood 
pressure control. Hypertension. 1983; 5: 629-634. 
58. Deckx FHM, Schalekamp MADH. Human prorcnin: pathophysiology and clinical implications. 
Clin Exp Hyper/ension. 1988; AIO (6): 1213-1225. 
59. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive 
renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med. 1985; 312: 
1412-1417. 
60. Sealey IE, Atlas SA, Glorioso N, Manapat H, Laragh JH. Cyclical secretion of pro renin during 
the menstrual cycle: synchronisation with luteinizing homlOne and progesterone. Proc Natl Acad 
Sci USA. 1985; 82: 8705-8709 
61. Hsueh \VA, Luetscher JA, Carlson EJ, Grislis G, Fraze E, McHargue A. Changes in active and 
inactive renin throughout pregnancy. J Clin Endocrino/ Me/ab. 1982; 54: 1010-1016. 
62. Sealey JE, Rubattu S. Prorenin and renin as separate mediators of tissue and circulating systems. 
Am J Hyper!ens. 1989; 2: 358-366. 
63. Hosoi M, Kim S, Takada T, Suzuki F, Murakami K, Yamamoto K. Effects ofprocenin on blood 
pressure and plasma renin concentrations in stroke·prone spontaneously hypertensive rats. Am J 
Physio/. 1992; 262: E234-E239. 
64. Lenz T, Sealey IE, Maack T, James GD, Heinrikson RL, Marion D, Laragh JH. Half-life, 
hemodynamic, renal, and homlOnal effects of prorenin in cynomolgus monkeys. Am J Physiol. 
1991; 260: R804-R81O. 
65. Takahashi S, Obsawa T, Miura R, Miyake Y. Purification of high molecular weight (HMW) renin 
from porcine kidney and direct evidence that the HMW renin is a complex of renin with renin 
binding protein (RnBP). J Blochem. 1983; 93: 265-274. 
66. Takahashi S, Inoue II, Miyake Y. The human gene for renin-binding protein. J Blo/ Chelll. 1992; 
267: 13007-13013. 
67. Tada M, Takahashi S, Miyano M, Miyake Y. Tissue specific regulation of renin·binding protein 
gene expression in rats. J Biochem. 1992; 112: 175-182. 
68. Marn I, Ohta Y, Murata K, Tsukada Y. Molecular cloning and identification of N-acyl-D-
glucosamine 2"Cpimerase from porcine kidney as a renin·binding protein. J BioI Chem. 1996; 271: 
16294-16299. 
69. Campbell DJ, Valentijn AJ. Identification of vascular renin-binding proteins by chemical cross· 
linking: inl,ibition of binding ofrenin by renin inhibitors. J Hyper/ells. 1994; 12: 879-890. 
70. Sealey IE, Catanzaro DF, Lavin TN, Gahnem F, Pitareesi T, Hu L-F, Laragh JH. Specific 
proreninlrenin binding (PRoBP). Identification and characterization of a novel membrane site. Am 
J Hyper/ens. 1996; 9: 491-502. 
71. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on 
hurnan mesangiai cells in culture increases plasminogen activator inhibitor-l antigen. Kidney Int. 
1996; 50: 1897-1903. 
22 
General introduction 
72. Abraham PA, Katz SA, Opsahl JA, Miller RP, Stanchfield WR Jr, Anderson RC. Renal secretion 
and hepatic clearance of human multiple renin fonns. Hypertension. 1990; 16: 669-679. 
73. Katz SA, Opsahl JA, Abraham PA, Gardner MJ. The relationship between renin isoclectric forms 
and renin glycoforms. Am J Physiol. 1994; 267: R244-R252. 
74. Kim SH, Lioyd MC, Sessler FM, Feng J, Malvin RL. Functional differences of six forms of renin 
in rats. Am J Physiol. 1988; 254: F432-F439. 
75. Kim S, Hosoi M, Hiruma M, Ikemoto F, Yamamoto K. Modification ofglycosylation of renin in 
sodium-depleted and captopril-treated rats. Am J Physio/' 1989; 256: E798-E804. 
76. Kim S, Hiruma M, !kemoto F, Yamamoto K.lmportance ofglycosylation for hepatic clearance 
of renal renin. Am J Physiol. 1988; 255: E642-E651. 
77. Marks DL, Kost LJ, Kuntz SM, Romero Je, Larusso NF. Hepatic processing of recombinant 
human renin: mechanisms of uptake and degradation. Am J Physiol. 1991; 261: G349-G358. 
78. Ezekowitz RAB. Stahl PD. The structure and function ofyertebrate mannose lectin-like proteins. 
J Cell Sci. 1988; 9 (Suppl): 121-133. 
79. Faust PL, Chirg\\'in JM, Kornfeld S. Renin, a secretory glycoprotein, acquires phosphomannosyl 
residues. JCell Bioi. 1987; 105: 1947-1955. 
80. Aced PA, Guido DM, Mathews R, Elhammer AP. Characterization of the oligosaccharide 
structures on recombinant human prorenin expressed in chinese hamster ovary cells. Biochemistry. 
1992; 31: 6951-6961. 
81. Kim S, Iwao H, Nakamura N, Ikemoto F, Yamamoto K. Fate of circulating renin in conscious 
rats. Am J Physiol. 1987; 252: E136-EI46. 
82, Hiruma M, Kim S, Ikemoto F, Murakami K, Yamamoto K. Fate of recombinant human renin 
administered exogenously to anesthetized monkeys. Hypertension. 1988; 12: 317-323. 
83. Skeggs LT, Dorer FE, lncorporation of labeled renin into tissues of the rabit. Am J Hyper/ens. 
1989; 2: 768-779. 
84. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme 
targeting. J Bioi Chen/. 1989; 264:12115-12118. 
85, Tong PY, Gregory \V, Kornfeld S. Ligand interaction of the cation-independent rnannose 6-
phosphate receptor. The stoichiometry ofmannose 6-phosphate binding. J Bioi Chem. 1989; 264: 
7962-7969. 
86. Tong PY, Kornfeld S, Ligand interaction of the cation-dependent mannose 6-phosphate receptor. 
Comparison with the cation-independent mannose 6-phosphate receptor, J Bioi Chem. 1989; 264: 
7970-7975. 
87. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like 
growth factor II receptor as a multifunctional binding protein. Nature. 1987; 329: 301-307. 
88. Tong PY, Tollefsen SE, Kornfeld S, The cation-independent mannose 6-phosphate receptor binds 
insulin-like growth factorl!. J Bioi Chem. 1988; 263: 2585-2588. 
89. Waheed A, Braulke T, Junghans U, von Figura K. Mannose 6-phosphatel insulin-like growth 
factor II receptor: the two types of ligands bind simultaneously to one receptor at different sites. 
Siochelll Biophys Res Commllil. 1988; 152: 1248-1254. 
90. Kiess W, Blickenstaff GD, Sklar MM, Thomas CL, Nissley SP, Sahagian GG. Biochemical 
evidence that the type II insulin-like growth factor receptor is identical to the cation-independent 
mannose 6-phosphate receptor. J Bioi Chern. 1988; 263: 9339-9344. 
91. Kiess W, Thomas CL, Greensteul LA, Lee L, Sklar lI-~l, Roehler MM, Sahagian GG, Nissley SP. 
Insulin-like gro\l1b factor II (IGFII) inhibits both the cellular uptake of beta-galactosidase and the 
binding of beta-galactosidase to purified 1GFlUmannose 6-phosphate receptor. J Bioi Chen/. 1989; 
264: 4710-4714. 
23 
Chapter J 
92. Dahms NM, Lobel P, Breitmeyer I, Chirgwin 1M, Kornfeld S. 46 kd mannose 6-phosphate 
receptor: cloning, expression, and homology to the 215 kd mannose 6-phosphate receptor. Cell. 
1987; 50: 181-192. 
93. Perdue IF, Chan IK, Thibault C, Radaj P, Mills B, Daughaday WH. The biochemical 
characterization of detergent-solubilized insulin-like growth factor II receptors from rat placenta. 
J Bioi Chem. 1983; 258: 7800-7811. 
94. Griffiths G, Matteoni R, Back R, Hoftack B. Characterization of the cation-independent mannose 
6-phosphate receptor-euriched prelysosomal compartment in NKR cells. J Cell Sci. 1990; 95: 441-
461. 
95. von Figura K. Hasilik A. Lysosomal enzymes and their receptors. Antill Rev Biochem. 1986; 55: 
167-193. 
96. Kornfeld S, Mellman!. The biogenesis oflysosomes. AIIII Rev Cell Bioi. 1989; 5: 483-525. 
97. Ma Z, Grubb lH, Sly WS. Cloning, sequencing, and functional characterization of the murine 46-
kDa mannose 6-phosphate receptor. J Bioi Chern. 1991; 266: 10589-10595. 
98. Stein M, Zijderhand-B1eekemolen ]E, Geuze H, HasHik A, von Figura K. Mr 46,000 mannose 6-
phosphate specific receptor: its role in targeting of lysosomal enzymes. EMBO J. 1987; 6: 2677-
2681. 
99. Oka Y, Rozek LM, Czech MP. Direct demonstration of rapid insulin-like growth factor II receptor 
internalization and recycling in rat adipocytes. Insulin stimulates 125I_insulin_like growth factor II 
degradation by medulating the IGF-ll receptor recycling process. J Bioi Chem. 1985; 260: 9435-
9442. 
100. Tally M, Li ClI, Hall K. IGF-2 stimulated growth mediated by tlte somatomedin type 2 receptor. 
Biochem Biophys Res Commllll. 1987; 148: 811-816. 
10 I. Herzog V, Neumuller W, Holzmann B. T)"oglobulin, the major and obligatory exportable protein 
of thyroid follicle cells, carries the lysosomal recognition marker mannose 6-phosphate. EMBO 
J. 1987; 6: 555-560. 
102. Lee S-I, Nathans D. Proliferin secreted by cultured cells binds 10 mannose 6-phosphate receptors. 
J Bioi Chem. 1988; 263: 3521-3527. 
103. Kovacina KS, Steele-Perkins G, Purchio AF, Lioubin M, Miyazona K, Heldin C-H, Roth RA. 
Interaction of recombinant and platelet transforming growth factor-heta 1 precursor with the 
insulin-like growth factor II1mannose 6-phosphate receptor. Biochem Biophys Res Commull. 1989; 
160: 393-403. 
104. Kang IX, Li Y, Leaf A. Mannose-6·phosphatel insulin-like growtlt factor-II receptor is a receptor 
for retinoic acid. Proc NaIl Acad Sci USA. 1998; 95: 13671-13676. 
105. Wang ZQ, Fung MR, Batiow DP, Wagner EF. Regulation of embryonic growtlt and lysosomal 
targeting by the imprinted Igf2/Mpr gene. Nalllre. 1994; 372: 2585-2588. 
106. Lau MMH, Steward CEH, Liu Z, Bhatt H, Rotwein P, Steward CL. Loss of the imprinted 
IGF2Ication-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal 
lethality. Genes Dev. 1994; 8: 2953-2963. 
107. Ludwig T, Eggenschwiler I, Fisher P, D'Ercol AJ, Davenport ML, Efstratiadis A. Mouse mutants 
lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null 
backgrounds. Dev Bioi. 1996; 177: 517-535. 
108. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks IR, Iglehart JD, Iirtle RL. M6PIIGF2 
receptor: a candidate breast tumor suppressor gene. Oncogene. 1996; 12: 2003-2009. 
109. De Souza AT, Hankins GR, Washington MK, Orton TC, Iirtle RL. M6PIIGF2R gene is mutated 
in human hepatocellular carcinomas \\;th loss of heterozygosity. Nal Genel. 1995; II: 447-449. 
24 
General introduction 
110. Wang S, Souza RF, Kong D, Yin i, Smolinski KN, Zou T-T, Frank T, Young i, Flanders KC, 
Sugimura II, Abraham JM, Meltzer Si. Deficient trnnsfomling growth factor-beta I activation and 
excessive insulin-like growth factor II OGFII) expression in IGFII receptor-mutant tumors. Cancer 
Res. 1997; 57: 2543-2546. 
Ill. Sklar MM, Kiess W, Thomas CL, Nissley SP. Developmental expression of the tissue insulin-like 
growth factor Illmannose 6-phosphate receptor in the rat. Measurement by quantitative 
immunoblotting. J Bioi Chem. 1989; 264: 16733-16738. 
112. Haskell iF, Tucker DC. Binding of insulin-like grO\\1h factors (IGF-I and IGF-II) to the IGF-
II/mannose 6-phosphate receptor in fetal rat myocardium. Endocrinology. 1994; 35: 231-239. 
113. Dahms NM. Insulin-like growth factor JIlcation-independent mannose 6-phosphate receptor and 
lysosomal enzyme recognition. Biochem Soc Trans. 1996; 24: 136-141. 
25 

CHAPTER 2 
Cultured Neonatal Rat Cardiac Myocytes And Fibroblasts 
Do Not Synthesize Renin or Angiotensinogen. 
Evidence for Stretch-Induced Cardiomyocyte Hypertrophy 
Independent of Angiotensin II. 
Chapfer 2 
Abstract 
Demonstration of renin-angiotensin system (RAS) components in cardiac tissue carmot 
be taken as definite evidence for synthesis of these components in the heart, due to 
interference \vith plasma-derived RAS components. To avoid the problems arising from 
ex-vivo measurements, we therefore measured renin, prorenin, angiotensinogen, ACE, 
angiotensin (Ang) I and Ang II in the medium and cell lysate of neonatal rat cardiac 
myocytes and fibroblasts, cultured for 5 days in a chemically defmed, serum-free 
medium. Measurements were also made in the fetal calf serum- and horse serum-
containing medium which had been used to obtain cell adherence and conflnency prior 
to the serum-free period, and in medium of serum-deprived cardiomyocytes exposed to 
cyclic stretch (20% elongation at 30 cycles per min for 24 hours). Prorenin (after its in 
vitro activation to renin), renin and angiotensinogen were measured by enzyme-kinetic 
assay; Ang I and Ang I1 were measured by radioinnmmoassay after SepPak extraction and 
HPLC separation. All RAS components were detectable in unconditioned serum-
supplemented mediwn. Prorenin, but none of the other RAS components, could be 
detected in medium of sermn-deprived cells. However, its levels were low and the Ang 
I-generating activity corresponding with these low prorenin levels could not be inhibited 
by the specific rat renin inhibitor CH-732, suggesting that it was most likely due to 
bovine and/or horse prorenin sequestered from the serum-containing mediwn to which 
the cells were exposed prior to the serum-free period. When incubated with Ang I under 
serum-free conditions, both cardiomyocytes and fibroblasts generated Ang II in a 
captopril-inhibitable matmer. Lysates of serum-deprived cells did not contain renin, 
prorenin, angiotensinogen, Ang I or Ang II in detectable quatltities. Stretch increased 
protein synthesis by 20% and was not accompanied by angiotensin release into the 
medimn. Taken together, our results suggest that cardiac myocytes and fibroblasts do not 
synthesize renin, prorenin or angiotensinogen in concentrations that are detectable or, if 
not detectable, high enough to result in Ang II concentrations of physiological relevance. 
These cells do synthesize ACE, thereby allowing the synthesis of Ang II at cardiac tissue 
sites when renin and angiotensinogen are provided via the circulation. Ang II is not a 
prerequisite to observe a hypertrophic response of cardiac cells following stretch. 
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Introduction 
The existence of a local renin-angiotensin system (RAS) in the heart, often invoked to 
explain the beneficial effects of ACE inhibitors in heart failure, ',2 is still a controversial 
issue. The presence of RAS components in cardiac tissue'" cannot be taken as direct 
evidence for local production of these components. One or more components may have 
been sequestered from the circulation. For instance, circulating renin may bind to cardiac 
cell receptors and to renin binding proteins in the heart,'" and circulating Ang II is known 
to accmnulate in cardiac tissue via AT, receptor-mediated endocytosis.' The levels of 
renin - and angiotensinogen mRNA in the heart are low or undetectable,IO·" thereby 
suggesting that the presence of these components in cardiac tissue may indeed depend on 
uptake rather than local production. 
The uncertainties with regard to local synthesis which arise from tissue 
measurements can be avoided when measurements are made in cells cultured in the 
absence of serum. The use of serum-free culture medimn is necessary to exclude the 
uptake of RAS components present in senun. 
Most so-called renin-expressing extrarenal cells produce prorenin rather than 
renin. TIlese cells do not store prorenin and secrete it in a constitutive manneL"·17 With 
regard to cardiomyocytes, both Dzau and Re18 and Dostal et al." reported on the presence' 
of renin in these cells. No distinction between renin and prorenin was made, nor did these 
authors determine (pro )renin release into the culture medilUll. Constitutive secretion of 
angiotensinogen has also been described.20·" The single report on the synthesis of 
angiotensinogen by cardiac cells focusses on its presence in these cells." ACE, a cell 
membrane-bouud enzyme, has been demonstrated in cardiac cells by enzyme-kinetic and 
inununohistochemical methods. "·26 
According to several investigations, serum-deprived cardiac cells release 
angiotensins into the culture medium. The Ang I and II levels in the medium, however, 
show huge variations, from < 10 fmoVmL to > 1000 fmoVmL."·26.29 
Ang II in the medhllll increased 100-fold after the induction of stretch," possibly by 
release from intracellular storage sites,"'" and this cell-derived Ang II may playa role in 
the stretch-induced hypertrophic response of cardiomyocytes. 26·29 
29 
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It was the aim of the present study to investigate the synthesis of RAS components by 
neonatal rat cardiomyocytes and fibroblasts by measuring renin, prorenin, 
angiotensinogen, Ang I and Ang II in the medium and cell lysate of serum-deprived cells 
with the help of well-established biochemical techniques. Cellular ACE activity was 
investigated by quantitying Ang I-to-I! conversion by intact cells in the presence and 
absence of captopril. Stretch-induced release of angiotensin I! and its role in cellular 
hypertrophy were examined in cardiomyocytes exposed to cyclic stretch for 24 hours. For 
comparison, studies were also performed in cells cultured in the presence of serum. 
Materials and Methods 
Reagents 
Fetal calf serum, horse serum, penicillin and streptomycin were purchased from 
Boehringer Mannheim, Mannheim, Genllany. Dulbecco's modified Eagle's medium 
(DMEM) and Medium 199 were from Gibco, Life Technologies, Middlesex, UK. Trypsin 
(type Ill) and captopril were from Sigma Chemical Co., St Louis, MO, USA. Methanol 
and ortho-phosphoric acid (both analytical grade) were from Merck, Darmstad~ 
Germany. Ang I was obtained from Bachem, Bubendorf, Switzerland. ['H)-leucine was 
from Amersham, Buckinghamshire, UK. The rat renin inhibitor CH-732 was a kind gift 
of dr M. Szelke, Fening Research lnstitute, Southampton, UK. 30 Rat renin was prepared 
from rat kidneys as described before." Human recombinant prorenin was a gift of dr W. 
Fischli, Hoffmann-La Roche, Basel, Switzerland. Angiotensinogen was prepared from 
plasma of nephrectOlnized rats." 
Cell culture 
All experiments were performed according to the regulations of the Animal Care 
Committee of the Erasmus University, Rotterdam, The Netherlands, in accordance with 
the Guiding Principles in the Care and Use of Animals approved by the American 
Physiological Society. 
Primary cultures of neonatal ventricular cardiomyocytes and fibroblasts were 
prepared from 1 -3 day old Wistar strain rats as described before.32 
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Briefly, ventricles from newborn 1-3 day old Wistar rats were minced, and cells were 
isolated by eight subsequent trypsinization steps at 30·C. Non-cardiomyocytes were 
separated from the cardiomyocytes by differential preplating. Cardiomyocytes were 
seeded in 20 cm' culture dishes (Falcon, Becton & Dickinson & Company, Plymouth, 
UK) at 1.5 x 10' cells/cm', giving a confluent monolayer of spontaneously contracting 
cells after 24 hours. The preplated cells (fibroblast fraction) were passaged after 4 days, 
using a 0.02% trypsinlO.05% EDTA solution, in 20 cm' culture dishes at 0.75 x 10' 
cells/cm'. The cells were maintained at 37·C and 5% CO,-95% air in 5 mL culture 
medium consisting ofDMEM and MediUIIIl99 (4:1), supplemented with 5% fetal calf 
serum, 5% horse serum, 100 U penicillinfmL and 100 Ilg streptomycinfmL. After 
incubation for 24 hours, cells were either serum-deprived or maintained in serum-
supplemented culture medium for 5 days. 
Collection of medium and cells for the measurement of RAS components 
Cardiomyocyte- and fibroblast-conditioned culture medium (5 mL) was collected for the 
measurement of RAS components after the cells had been maintained with or without 
serUIII for 5 days. TI,e RAS component content of 1m conditioned mediwn, i.e. the medium 
tI,at had not been in contact with eitller cardiomyocytes or fibroblasts, was also studied. 
MediUll\ for ti,e measurement of pro renin, renin and angiotensinogen was frozen at -70·C 
without the addition of inhibitors. MediUll\ for the measurement of Aug I and II was 
mixed with 250 ilL angiotensinase inhibitor solution (containing 125 mmolfL disodium 
EDTA and 25 IrunolfL I, lO-phenanthroline) and frozen at -70·C. 
To measure RAS components in the cells, each well was washed three tinles Witll 
6 mL ice-cold phosphate buffered saline (PBS; 140 mmoIIL NaC!, 2.6 mmolfL Kp, 1.4 
mmollL KH,PO" S.I mmolfL Na,HPO" pH 7.4). After washing, cells used for the 
measurement of prorenin, renin and angiotensinogen were lysed in 0.5 mL ice-cold PBS 
containing 0.2% triton X-100, and the celllysates were quickly frozen on dry ice. Cells 
used for the measurement of Ang I and II were scraped with a rubber policeman in a 
volwne ofO.5InLice-cold PBS. The celllPBS nUxture was centrifuged at 1,000 g at 4·C 
for lInin, after which the pellet was homogenized in 0.5 mL O.lmolfL HClISO% etllanol 
using a hand-operated douncer. The ethanol was evaporated under vacuum rotation at 
4·C using a Speed Vac Concentrator (Savant Instruments, Farmingdale, NY, USA). 
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The concentrated homogenates were dissolved in 0.5 mL 1% ortho-phosphoric acid and 
applied to SepPak colUlmlS (see below nnder 'Biochemical measurements'). 
Angiotensin J-to-ll conversion by ACE 
To determine whether 5-day old cardiomyocytes and fibroblasts contain ACE, Aug I-to-II 
conversion by these cells was studied in the presence or absence of captopril (final 
concentration in the medium: 0.5 !lmol/mL). Aug I was added to the mediUln (final 
concentration 1 pmollmL), and 150 IlL samples were obtained over a period of 40 min 
(from cells cultured in the presence of serum) or 120 min (from cells cultured in the 
absence of serutn). The samples were rapidly mixed with 10 IlL angiotensinase inhibitor 
solution and frozen at -70'C. No corrections were made for the small volume changes 
(approximately 3% per sanlple) occurring as a consequence of fluid sampling. Aug I-to-II 
conversion was also studied in unconditioned medium. 
Angiotensin generation dllring cyclic stretch of cardiomyocytes 
To study the generation of Aug II during prolonged cyclic stretch and its contribution to 
the increased protein synthesis occurring under these conditions, cardiomyocytes were 
subjected to cyclic stretch for 24 hours. Following isolation (see above nnder 'Cell 
culture') the cells were seeded in flexible-bottomed 6-well culture plates (type I collagen-
coated, 5 cm'/well; Flexcell Int. Corp., Hillsborough, NC, USA). They were maintained 
at 37'C and 5% CO,-95% air in I mL culture medimn consisting ofDMEM and Medium 
199 (4: 1), supplemented with 5% fetal calf serum, 5% horse sermn, 100 U perucillinlmL 
and 100 !lg streptomycinimL. After 24 hours the medium was replaced by DMEM and 
Medimn 199 (4:1), supplemented with 4% horse serum, 100 U penicillinlmL and 100 !lg 
streptomycinimL. The stretch experiment was performed 48 hours later under senun-free 
conditions. The cells were preincubated for 30 min with 1.5 mL serum-free medium. The 
6-well plates were then placed on a Flexcell Strain Unit (FX-2000, Flexcell Int. Corp.), 
and the cells were stretched at 30 cycles per minute (I sec strain, 1 sec relaxation) at 20% 
elongation for 24 hours. Control cells, grown on non-flexible-bottomed culture plates, 
were studied in parallel. For comparison, control cells cultured on non-flexible-bottomed 
culture plates were also incubated for 24 hours with endothelin-I (ET -1; fmal 
concentration in the medium 10" moVL), an agent known to induce protein synthesis in 
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cardiomyocytes.,,·3l The effect of stretch on protein synthesis was evaluated by adding 
['H)-leucine to the mediwn (final concentration 0.5 IlCi/mL) of control-, stretched-, and 
ET-I-treated cells two hours before the end of the 24 hour-study period. After 24 hours, 
the medium was discarded and the cells were fixed overnight with 500 ilL 10% trichloric 
acid (TCA). Cells were rinsed three times with 10% TCA to remove unincorporated label 
and then lysed during 6 hours with 500 ilL I M NaOH. TIle lysate was transferred to 
scintillation vials. After neutralization with 500 ilL I M HCI, 5 mL scintillation fluid 
(Instagel, Packard, Meriden, CT, USA) was added, and samples were counted for 5 min 
in a p-counter. Total cellular protein was measured after 24 hours in control-, stretched-, 
and ET -I-treated cells that had not been incubated with ['H)-leucine. The cells were 
washed twice with 500 ilL ice-cold PBS, dissolved in 250 ilL I mollL NaOH, and kept 
ovemight at 4°C. Subsequently, the cell Iysates were collected and protein was measured 
by tile Bradford assay," using bovine semm albumin in I M NaOH as a standard. 
The effect of stretch on Ang I and II synthesis was studied by collecting 0.15 mL 
samples from the culture mediwn of each well of two 6-well plates after I, 2, 6, and 24 
hours Wider either control or stretch conditions. The twelve 0.15 mL samples obtained 
at each time point were added together and mixed witll 0.1 mL angiotensinase inhibitor 
solution (fInal volwne 1.9 mL). All samples were stored at -70°C. 
Biochemical measurements 
Renin and prorenin Renin was quantifIed in duplicate by measuring Ang I generation at 
pH 7.4 during incubation at 37°C with a saturating concentration of rat angiotensinogen 
in the presence angiotensinase-, ACE-, and serine protease-inhibitors.'" The incubation 
mixture of the renin assay consisted of I) 100 ilL sample, 2) 100 ilL of 0.01 mollL 
phosphate buffer, pH 7.4, containing O. IS mollL NaCI, 3) 200 ilL angiotensinogen, and 
4) 14 ilL of an inhibitor solution. Two different inhibitor solutions had been used, one 
with the rat renin inhibitor CH-732 and one without renin inhibitor. Both solutions 
contained phenylmethylsulfonyl fluoride (0.0024 mollL), disodium EDTA (0.005 mollL), 
8-hydroxyquinoline sulphate (0.0034 mollL) and aprotinin (100 kallikrein-inhibiting units 
per mL) (final concentrations in tile incubation mixture). The renin inhibitor CH-732 was 
used in a [mal concentration of 5 IlmollL. 
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Inhibition of rat kidney renin is > 95% at tlus concentration (Figure 1). Incubation time 
was 2 or 4 hours and Ang I generation was linear during tltis period. AIIg I was measured 
with a sensitive radioimmunoassay.3l The lowest renin level that could be detected was 
1.0 finol Ang IImin per mL medilUn and 0.5 fmol AIIg IIlUin per 10' cells. 
ANGIOTENSIN I 100 
GENERATING 
ACTIVITY 
% or activity 
without renin 
Inhibitor 
8. 
6 • 
•• 
2 • 
• I I I I I I I I 
-11 -10 -9 -8 -7 -6 -5 -4 
log CONCENTRATION OF RENIN INHIBITOR (M) 
Figure 1. Dose-dependent inhibition of rat kidney renin by increasing concentralion of the ral 
renin inhibilor CH-732. 
Prorenin was first converted into renin by proteolytic activation and tI,en also measured 
with the above assay. Based upon our experience with ti,e activation of prorenin in 
tissues, '.7 two different activation procedures were tested, i.e. acidification only or 
acidification followed by treatment with plasmin at neutral pH. Medium or cell lysate 
were acidified by dialysis at 4°C for 48 hours against 0.05 mollL glycine buffer, pH 3.3, 
containing 0.001 mollL disodium EDTA and 0.095 mollL NaC!. 
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Tltis was followed by either I) dialysis at 4 'C for 24 hours against 0.1 mollL phosphate 
buffer, pH 7.4, containing 0.001 mollL disodium EDTA and 0.075 mollL NaCI, or 2) 
quick adjustment of pH to 7.4 with I mollL NaOH and the subsequent addition of 0.1 
volume of a solution of human plasmin (final concentration, 0.5 casein uruts/mL) in 0.15 
mol/L NaCI and incubation at 4 'C for 48 hours. Acid-treatment followed by restoration 
of pH to 7.4 and treatment with plasmin led to virtually complete activation of prorertin, 
as was demonstrated by the > 90% conversion and recovery of human recombinant 
prorerun that had been added to the samples before the activation procedure (n=3). Acid-
treatment followed by restoration of pH to 7.4 without subsequent plasmin treatment led 
to less complete activation of prorertin; the recovery of added proreltin, measured as 
renin, was 45-55% (n=3). All samples were therefore activated by the combined acid-and-
plaslftin method. 
AngiotellSil1ogen. The concentration of angiotensinogen was detenrtined as the maximum 
quantity of Ang I that was generated during incubation at 37'C and pH 7.4 with rat 
kidney rertin in the presence of a mixture of angiotensinase-, ACE- and serine protease-
inltibitors.'·3i The incubation mixture of the angiotensinogen assay consisted of I) 250 ilL 
sample, 2) 50 !IL rat kidney rertin (diluted 1150 in O.OlmollL phosphate buffer, pH 7.4, 
containing 0.15mollL NaCI), and 3) 14 ilL inltibitor solution without rat re,Un inltibitor 
(see above under 'Renin and Prorertin'). Incubation time was 1 hour, and the conditions 
of the assay were chosen in such a way that Aug I formation was completed within I 
hour. TIle lowest level of angiotensinogen that could be measured was 0.1 pmol per mL 
medium and 0.05 pmolflO' cells. 
Angiotensin I and II. The Aug I and II concentrations in medium collected during the 
measurement of ACE activity were meaSllfed directly with sensitive 
radioimmunoassays." Measurements were made in 50 ilL medium. The lowest 
measurable Ang I concentration was 15 fmolfmL, and the lowest measurable Ang II 
concentration was 10 fmolfmL. 
In all other samples (medium and cell homogenates) Aug I and II were measured 
by radioimmwlOassay, after SepPak extraction and reversed phase-high perfOlmance 
liquid chromotography separation." '2lI-labeled Aug I was added to the sanlples before 
SepPak extraction, to determine the recovery of Aug I and II. 
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The recovery was better than 90%, and the Ang I and IT results were not corrected for 
incomplete recovery. The lower limit of detection for Ang I and Ang IT in the culture 
meditun were 0.2 and 0.1 finollmL, respectively. In cell homogenates, it was 0.3 and 0.2 
fmoll106 cells. 
Calclila/iollS 
Ang I is eliminated by conversion to Ang IT by ACE, and by breakdown into small 
biologically inactive peptides by various other enzymes. The latter process is referred to 
as degradation of Ang I. The first order rate constant for Ang I elimination (kd) is taken 
to be equal to the stun of the first order rate constants for degradation (k,) and conversion 
(k,).3l 
k" can be calculated as follows: 
k" = -lit x Jo([ Ang I], I [Ang 1]0)' 
in which [Ang IJ. is the concentration of Ang I at time t and [Ang 1]0 is the concentration 
of Aug I at t=0 (inUllediately after the addition of Ang I). In the presence of captopril, 
k2=O, so that kc', "'ith captopril = kr. In the absence of captopril kcl, .... ithout caplopril = kl + k2. The 
difference between kcl. withcaptopril and ket, v.ithout captopril is equal to kz· 
The percent contribution of conversion to the total metabolism of Ang I is defmed as 
follows: contribution of conversion to metabolism (%) = [k, I (k, + k,)] x 100%. 
Results 
Renin, pro renin and angio/ellSinogen 
Renin and prorenin were detectable in unconditioned fetal calf seltll\l- and horse serum-
supplemented meditun (Figure 2). The Ang I-generating activity corresponding with these 
renin and proreninlevels was not inhibited by the renin inhibitor CH-732 (5 I'mollL), 
which is specific for rat renin. FollO\ving 5 days of incubation with either cardiomyocytes 
or fibroblasts, the levels of renin and prorenin in seltll\l-supplemented medium were 
unchanged. 
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Figllre 2. Renin, prorenin, and angiotensinogen levels in unconditioned medium (n=3), 
cardiomyocyte-conditioned medium (n=5), and fibroblast-conditioned medium (n=5) with (+, 
open bars) or without (-, hatched bars) serum. Addition of the specific rat renin inhibitor CH-732 
(5 f1moVL) did not affect the outcome ofthe renin and prorenin measurements (data not shown). 
Data are means ± SD. The dotted line represents the limit of detection. Renin and angiotensinogen 
were below the detection limit in the cell-conditioned serum-free media. 
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Renin was undetectable in cardiomyocyte- and fibroblast-conditioned serum-deprived 
medium. Low levels of pro renin were present in the cardiac cell-conditioned sennn-free 
media, but they were not inhibited by CH-732, indicating that the Aug I generation we 
measured after in-vitro prorenin activation was not caused by rat renin. Both renin and 
prorenin were Imdetectable in cell lysates of serum-deprived cardiomyocytes and 
fibroblasts. 
Low levels of angiotensinogen were detected in wlConditioned serum-
supplemented mediwn, which did not change after 5 days of incubation with cardiac cells 
(Figure 2). These levels therefore most likely represent bovine and horse angiotensinogen. 
Augiotensinogen was undetectable in cardiomyocyte- and fibroblast-conditioned serum-
free medium and in the lysates of these cells. 
Angiotensin 1-10-11 conversion by ACE 
Aug I added to Imconditioned serum-supplemented medium was rapidly metabolized, 
Ang II being a major metabolite (Figure 3). Captopril prevented the fonnation of Aug II 
completely. On the basis of Ole difference in Aug I metabolism \viOI and without captopril 
it could be calculated that more than 90% of the Aug I metabolism in unconditioned 
serum-supplemented medium was due to ACE-dependent Aug I-to-II conversion (Table 
1). During incubation with unconditioned serum-deprived medilnn, no significant Aug 
I metabolism could be demonstrated over a period of 2 hours. 
Aug I metabolism in cardiomyocyte - and fibroblasts cell cultures that had been 
maintained for 5 days in Ole presence of serum tended to be more rapid than Ang I 
metabolism in Imconditioned serum-supplemented medium (Figure 3). Ang II was again 
a major metabolite, and captopril prevented its fonnation completely. In both cell 
cultures, approximately 80% of Aug I metabolism was due to ACE-dependent Aug I-to-II 
conversion (Table 1). 
Ang I added to serum-deprived cardiomyocyte - and fibroblast cell cultures was 
also converted to Aug II, and captopril inhibited Ole fonnation of Aug II completely 
(Figure 3). This indicates that, in Ole absence of serum, cardiomyocytes and fibroblasts 
contain detectable ACE activity. Approximately 60-70 % of the Ang I metabolism was 
due to ACE (Table 1). 
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Figure 3. Metabolism of angiotensin I added to unconditioned medium (top panels, n~4), 5-day 
old cardiomyocyte cultures (middle panels, n~6) and 5-day old fibroblast cultures (bottom panels, 
n~3) with (left panels) or without (right panels) serum. Data are means ± SD. Open symbols 
represent Ang I, closed symbols represent Ang II. Circles, experiments without captopril, 
triangles, experiments with captopril. 
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Table 1. First order rate constants for degradation (kl ) and conversion (k,) of angiotensin [ added 
to unconditioned serum-supplemented medium, 5-day old serum-deprived cardiomyocyte cultures 
and 5-day old serum-deprived fibroblast cultures. The percentage of metabolism due to 
angiotensin [-to-II conversion is given for each condition. 
unconditioned serum- cardiomyocyte- fibroblast -
supplemented conditioned conditioned 
medium medium medium 
n 4 6 3 
kl WI) 0.17 ± 0.03 0.31 ± 0.09 0.05 ± 0.01 
k, (h· l) 1.69 ± 0.77 0.42 ± 0.17 0.17 ± 0.01 
% conversion 92.9 ± 10.3 55.8 ± 9.4 76.1 ±3.6 
Values are means ± SD. 
Angiotensin I and II 
Low levels of Ang [ and II were present in unconditioned serwn-supplemented medium 
(Table 2). These levels remained low or decreased to levels below the detection limit after 
5 days of incubation with cardiomyocytes or fibroblasts. The cellular levels of Ang [ and 
II at that time were also close to or below the detectionlintit of our assays (Table 2). Ang 
[and II were undetectable in cardiomyocyte- and fibroblast-conditioned senun-deprived 
medium and could also not be demonstrated in cell homogenates of cardiomyocytes and 
fibroblasts that had been serum-deprived for 5 days (Table 2). 
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Table 2. Angiotensin I and II levels in unconditioned serum-supplemented medium, 
cardiomyocyte-conditioned serum-free medium, fibroblast-conditioned serum-free medium, and 
in celllysates of serum-deprived cardiomyocytes and fibroblasts. 
Angl AngII 
MEDIUM frnollmL frnollmL 
unconditioned serum-supplemented 1.3 ± 0.3 0.4 ± 0.3 
cardiomyocyte-conditioned serum-free <0.7 ± 0.3 <0.1 
fibroblast-conditioned serum-free <0.6±0.3 < 0.1 
Angl AngII 
CELL LYSATES 
fmolllO' cells finol/IO' cells 
serum-deprived cardiomyocytes <0.3 <0.2 
serum-deErived fibroblasts <0.3 <0.2 
Ang is angiotensin. Values are means ± SD. If one or more values was below the detection limit, 
this is denoted as < mean ± SD. If all values were below the detection limit this is denoted as < 
detection limit. 
Angiotensin generation during cyclic stretch of cardiomyocytes 
Cyclic stretch of cardiomyocytes for 24 hours led to the expected increase in protein 
synthesis rate and total cellular protein, although the effects were modest as compared to 
those observed after 24 hours of exposure to ET -I (Table 3). Ang I in the medium of 
control ceUs and ceUs exposed to stretch was close to the detection limit at I hour after 
the start of the experiment «0.2-0.7 finolfmL and <0.2-0.8 finolfmL, respectively; n=3 
in both cases) and decreased to undetectable levels during prolongation of the experiment. 
Ang II was IUldetectable at all time points, both in the medium of control cells and in the 
medium of stretched cells. 
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Table 3. ['H)-Leucine incorporation and total cellular protein in untreated cardiomyocytes 
(control), cardiomyocytes exposed to cyclic stretch for 24 hours (stretch) and 
cardiomyocytes incubated with endothelin-[ (ET -I) for 24 hours. 
control stretch ET-[ 
incorporated dpmlwell 5992 ± 215 7300 ± 288' 9479 ± 397' 
['H)-leucine 
total cellular 
protein 
mg/well 0.15±0.01 0.17±0.01* 0.18±0.0I' 
Values are means ± SD. *p <0.05 vs. control. 
Discussion 
This study indicates that cultured neonatal rat cardiomyocytes and fibroblasts do not 
synthesize renin, prorenin, or angiotensinogen in concentrations that are detectable or, if 
not detectable, high enough to result in Ang I or Ang II concentrations of physiological 
relevance. Both cardiac cells do appear to synthesize ACE, and thus are capable of 
converting Ang I into Ang II. 
All RAS components are present in serum-containing medium, and will therefore 
be detected when measurements are made in the mediunl of cells cultured in the presence 
of serum. We investigated medium obtained from cells maintained in the absence of 
serum as well as medium of cells kept in the presence of serum. The specific rat renin 
inhibitor CH_73230•36 was used to distinguish Ang I-generation by rat renin from Ang I 
generation by other enzymes, such as bovine renin and/or horse renin. TIle latter two are 
present in the fetal calf serum and horse senun applied in the present study to obtain cell 
adherence and confluency prior to serum-deprivation, and both renins are known to react 
with rat angiotensinogen. 17•37 No CH-732 iullibitable Ang I-generating activity could be 
detected in the mediunl of cells maintained in the presence of senun, whereas Ang I 
generation in medium of serum-deprived cells was below the detection litnit. 
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A possible explanation for tltis lack of rertin release from rat cardiac cells right be that 
extrarenal cells release prorertin rather than renin."'" However, although the Aug 1-
generating activity of medium obtained from cells cultured with serum increased nearly 
IO-fold following prorenin activation, it could again not be inhibited by CH-732. 
Moreover, the levels of prorenin measured in serum-supplemented conditioned medium 
did not differ from tllOse in serum-supplemented lillconditioned medium. Thus, the 
increase in Aug I-generating activity following activation is most likely due to tile 
activation of bovine andlor horse prorenin. 
Interestingly, medhllll of cells cultured in the absence of senun also contained low 
levels of prorenin. None of tile Aug I-generating activity corresponding with tllese 
prorenin levels could be inltibited by CH-732, nor did the prorellln levels differ between 
cardiomyocytes and fibroblasts. Most likely therefore, this prorenin represents bovine 
andlor horse prorenin trapped or bOlllld by the cells during tlleir incubation in tile 
presence of senun and released back into the medium during incubation under serum-
deprived conditions. In support of this assmnption, we have recently shown tllat neonatal 
rat cardiac cells, during incubation witll prorertin, are capable of binding and internalizing 
prorenin, and tllat membrane-bound, non-internalized prorenin is released back into the 
medium when tile cells are subsequently incubated Witll fresh medium without prorenin.8 
TIle receptor involved in the binding process is tile marmose 6-phosphate receptor, which' 
is identical Witll tile insulin-like growth factor II receptor. 
Uptake of renin andlor prorellln ntight also explain the inll1lUnoreactivity for renin 
described by Dostal et aI." in neonatal rat cardiomyocytes and fibroblasts. These cells 
were serum-deprived for 5 days after a 48-hour incubation period in the presence of 10% 
newborn calf serum. Silnilarly, the Aug I generating activity detected in freshly isolated 
adult rat cardiomyocytes18 ntight be attributed to renin sequestered from the circulation. 
In the present study we were unable to demonstrate Aug I generating activity in 
cells that had been serum-deprived for 5 days. Possibly tile intracellular metabolism of 
renin and prorenin following internalization was too rapid to allow detection of Aug I 
generating activity after 5 days of incubation under serum-free conditions. 
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The low levels of angiotensinogen present in unconditioned serum·supplemented medium 
(corresponding to < 5% of the normal plasma angiotensinogenlevels in the rat) did not 
change during incubation with cardiac cells, nor did the cells release angiotensinogen into 
the medium when incubated under serum·free conditions. All other cells described to 
synthesize angiotensinogen20·" release this substrate into the medium, without storing it 
intracellularly. In vivo, angiotensinogen also appears to be limited to the extracellular 
fluid compartment""'" Therefore, our data do not support the synthesis of 
angiotensinogen by neonatal rat cardiomyocytes or fibroblasts. 
In view of the absence of renin, prorenin or angiotensinogen synUlesis by cardiac 
cells, it is not surprising that Ang I and II were below the detection limit in medium 
samples obtained from cardiomyocytes and fibroblasts incubated in the absence of serum. 
This finding contrasts with data obtained by others,23.26-29 who found angiotensin levels 
ranging fi'om < 10 to > 1000 finoVmL in medium of serum· deprived cardiomyocytes and 
fibroblasts. Part of this discrepancy may be due to the fact Ulat angiotensins were 
sometimes measured directly by radioimmunoassay without prior SepPak extraction 
and/or HPLC separation. Furthermore, it must be kept in mind that, in view of Ule levels 
measured in cardiac tissue in vivo (Ang I, ~ 5 finolJg; Ang II, ~ 20 finoVg),'·'·39.40 even 
levels of 5· 10 finol per mL medium are very high, since in most studies only I to 4 
million cells are incubated with a few mL of medium. 
Sadoshinla et al.27 found UIC Ang II concentration in the medium of serum·deprived 
neonatal rat cardiomyocytes to increase nearly 100·fold upon stretch (from 5 to 450 
pmoVL), whereas Ule Ang I level in the medium (5 pmolfL) did not change. The increase 
in Ang II, which occurred within 10·30 min after stretch had been initiated, was not 
affected by captopril. These data were interpreted as evidence for release of 
intracellularly stored Ang II; this Ang II is asswned to be responsible for the hypertrophic 
response of cardiomyocytes after UIC induction of stretch.26-29 lmmunoelectron microscopy 
confirmed the existence of secretory granule· like structures containing Ang II in 
ventricular cardiomyocytes prior to stretch (concentration ~ 5 finolJlO' cells) in the study 
by Sadoshima and colleagues.27 In contrast, Dostal" localized intracellular Ang I and II 
in the perinuclear region of neonatal rat serum-deprived cardiomyocytes and fibroblasts. 
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According to tltis latter study, the levels of Ang I and II in both cardiomyocytes and 
fibroblasts were approximately 25 pmol and 5 pmol per 10' cells (or ~ 5000 and ~ 500 
times the levels measured by others per g heart tissue), respectively. 
Without RAS component synthesis by cardiac cells, what right be the source of 
intracellular Aug ll? Since Ang II is synthesized in the medium during the incubation of 
the cells in the presence of serum, it might be taken up by the cells, for instance via AT,-
receptor mediated endocytosis? Release could then occur after the application of stretch. 
We studied this possibility by measuring the angiotensin levels in the cells after 5 days 
of incubation with serum and in the medium at various time points after the initiation of 
cyclic stretch. Ang I and IT were below the detection limit under all conditions. Yamazaki 
et al. reported that the concentration of exogenous Ang II needed to exert a sinillar 
hypertrophic response as stretch is ~ 10.8 M.28 Although in our study the Aug II 
concentrations in the medium were < 10.13 M, the well-known increase in cellular protein 
synthesis did occur in response to stretch. It appears therefore that the stretch-induced 
hypertroplllc response of cardiomyocytes in the present study is independent of Ang II. 
In support of tillS assumption, we could not inltibit the stretch-induced hypertroplllc 
response in cardiomyocytes witll the AT, receptor antagortist losartan (unpublished 
observations). Sintilarly, others observed Ang II-independent hypertrophic responses in 
isolated perfused hearts (wlllch do not contain rertin3l) and angiotensinogen-deficient' 
cardiomyocytes."~3 
Taken together, our data do not support the concept of cardiac angiotensin 
generation independent of the kidney and liver. TIllS does not mean that angiotensins are 
not generated locally in tile heart. In fact, in a previous study in pigs we have shown that 
the majority of cardiac Ang I and IT is synthesized at tissue sites, and not derived from tile 
circulation.'" Most likely, rertin and/or prorertin need to be taken up from the circulation 
in order to generate angiotensins locally in the heart. Mannose 6-phosphate receptors, 
present on cardiomyocytes and fibroblasts, might be involved in tile uptake process of 
rertin and prorenin' Angiotensinogen diffuses freely from tile blood into the interstitial 
fluid compartment, and may react with rertin or activated prorertin on or in the cardiac 
cells.3l ACE appears to be the only RAS component involved cardiac Ang II generation 
that does not have to be sequestered from tile circulation. 
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Angiotensin II-mediated Growth and Antigrowth Effects in 
Cultured Neonatal Rat Cardiac Myocytes and Fibroblasts. 
Chapter 3 
Abstract 
Angiotensin II (Ang II) stimulates cardiovascular growth and remodeling via AT, 
receptors. Recent experiments have shown that Ang II may also exert antiproliferative 
effects via AT, receptors. We studied the effects of Ang II on protein and DNA 
content and synthesis rate in unstimulated and endothelin-l (ET-l)-stimulated 
neonatal rat cardiomyocytes and fibroblasts, isolated from 1-3-day-old Wistar strain 
pups. Total protein and total DNA, as well as ['H]leucine and [3H]thymidine 
incorporation were measured following incubation with either vehicle, Ang II, ET -lor 
Ang II + ET-l, both in the presence or absence of the AT, receptor blocker losartan or 
the AT, receptor blocker PD123319. In myocytes, ET-l increased total protein (+38% 
relative to control) as well as [3H]leucine (+66%) and [3H]thymidine (+77%) incorpor-
ation. Ang II did not affect any of these parameters, nor did it influence the ET -1-
induced responses. However, in the presence of PD123319 Ang II stimulated [3H]leu-
cine (+24%) and ['H]thymidine (+30%) incorporation. In fibroblasts, ET-l and Ang II 
did not significantly affect total DNA and [,H]thynridine incorporation. Ang II tended 
to increase total protein in these cells, an effect which was significant only in tlle 
presence ofPD123319 (+17%). Ang II stimulated [3H]leucine incorporation (+24%) in 
fibroblasts. This effect was absent with losartan and enhanced in the presence of 
PD 123319. These data demonstrate tllat AT, receptor-mediated proliferative effects of 
Ang II in neonatal cardiac cells may become apparent only when its AT, receptor-
mediated antigrowth effects are blocked. The net growth effect of Ang II therefore 
depends on the cellular AT/AT, receptor ratio. Aug II does not appear to interfere 
with ET -I-induced effects. 
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Introduction 
Angiotensin (Ang)II, fonned from Ang I by angiotensin-converting enzyme (ACE), is 
a potent vasoconstrictor with growth-promoting properties. Its effects are mediated by 
specific receptors located on the cell surface. So far, at least two receptors for Ang II 
have been characterized: AT, and AT" selectively blocked by losartan and PD123319, 
respectively.' Both receptor types have been identified, in varying proportions, in 
membranes prepared from cardiac tissue.'''' The density of Ang II receptors appears to 
be regulated developmentally, the number of receptors reaching a maximum shortly 
after birth, and decreasing to lower values thereafter. "'.' Receptor binding studies in 
rat isolated cardiac cells support the fmdings on developmental changes in Ang II 
receptor density. AT" but not AT" receptors decrease to low munbers after birth, both 
in cardiomyocytes and cardiac fibroblasts, whereas adult cardiac cells appear to have 
AT, receptors only.'" 
Ang II has been reported to induce hypertrophy of neonatal rat cardiomyocytes 
and hyperplasia of neonatal rat cardiac fibroblasts. IO." However, these growth-
stimulatory effects of Ang II vary widely and could not always be confmned. 14•1l Both 
responses are mediated via the AT, receptor subtype. lO•ll Stimulation of this G-protein 
coupled receptor results in activation of phospholipase C, production of 
inositolphosphates and a rise in intracellular calcium.'··l7 The function of the cardiac 
AT, receptor is not yet known. Its presence in the fetal and neonatal heart suggests 
that it may be involved in cardiac growth and development. The AT, receptor is 
coupled to an inhibitory G-protein, and stimulation of this receptor leads to inhibition 
of protein-tyrosine phosphatase."·I9 In rat vascular smooth muscle cells transfectcd 
with the AT, receptor, as well as in coronary endothelial cells expressing low numbers 
of AT, receptors, AT, receptor stimulation resulted in anti-growth effects.20•21 
It is likely that the previously described effects of Ang II on neonatal rat cardiac 
cell growth are the net effect of both stimulatory (AT,-mediated) and inhibitory (AT,-
mediated) responses. It was the aim of the present study to investigate the stimulatory 
and inhibitory effects of Ang II on protein and DNA synthesis in neonatal rat 
cardiomyocytes and cardiac fibroblasts. 
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This was done under basal conditions and after stimulation of the cells with 
endothelin-I (ET-I), because inhibitory effects of Ang II might be detectable after 
stimulation only. We also studied the early intracellular activation of phospholipase C 
by Ang II and ET -I by measuring inositolphosphate accumulation. Cells were isolated 
from cardiac ventricles of 1-3-day-old rats, because at that age the heart shows the 
highest density of AT, and AT2 receptors.~'·6 ET -I was chosen as a stimulus in view of 
its known strong effects on protein and DNA synthesis in cardiac cells, which are 
mediated via the same intracellular second messenger pathways as described for Ang 
II.",22.23 In addition, endogenous ET-I has been reported to contribute to the Ang II-
induced effects in an autocrine/paracrine fashion, both in cardiomyocytes and cardiac 
fibroblasts.",22 
Materials and Methods 
Reagents 
Trypsin (type III) was from Sigma Chemical Co, St. Louis, MO, USA. Fetal calf 
senun, horse serum, endothelin-I (ET-I), penicillin and streptomycin were purchased 
from Boehringer Mannheim, Mannheim, Gennany. Dulbecco's modified Eagle's 
medium (DMEM) and Medium 199 were from Gibco, Life Technologies, Middlesex, 
UK. Ang II was obtained from Bachem, Bubendorf, Switzerland. 24-well tissue plates 
were obtained from Costar, Cambridge, MA, USA. myo-[2-'H]inositol, ['H]leucine 
and ['H]thymidine were from Amersham, Buckinghamshire, UK and Dowex AG I-X8 
(200-400 Mesh, fonniate fonn) was from Bio-Rad Laboratories, Richmond, CA, USA. 
Phenanthroline and sodium-azide were from Merck, Darmstadt, Gennany. Instagel 
was obtained from Packard, Meriden, CT, USA. The AT, receptor antagonist losartan 
(Oup 753) was a gift of dr R.D. Smith, DuPont-Merck, Wilmington, DE, USA. The 
AT 2 receptor antagonist PD 123319 was kindly provided by dr D.G. Taylor, Parke-
Davis, Ann Arbor, MI, USA. 
52 
AlIg II mediated effects ill cardiac cells 
Cell cllltllre 
Primary cultures of neonatal rat ventricular cardiomyocytes and fibroblasts were 
prepared as described before." Briefly, ventricles from newborn 1-3-day-old Wistar 
rats were minced and cells were isolated by 8 subsequent trypsinization steps at 30'C. 
Non-cardiomyocytes were separated from the cardiomyocytes by differential 
preplating. Cardiomyocytes were seeded in 24-well plates at l.5 to l. 75 x 10' 
cells/cm' giving a confiuent monolayer of spontaneously beating cells after 24 hours 
The preplated cells (fibroblast fraction) were passaged after 4 days to 24-well dishes 
at 0.75 x 10' cells/cm'. All cells were maintained at 37"C and 5% CO, - 95% air in 
complete medium consisting of DMEM and Medium 199 (4: 1), supplemented with 
5% fetal calf serum, 5% horse serum, 100 U penicillinlml and 100 IIg 
streptomycinlml. After 24 hours of culturing in complete medilUll, cells were further 
grown in serum-free medium. Experiments were performed after the cells had been 
serum-deprived for at least one day. 
Determination of Ang II stability during incubations 
To study the stability of Ang II during incubation, different amounts of Ang II (final 
concentration in the medium 1O~, 10" and 10.8 M, n=3 for each concentration) were 
added to cardiomyocyte and fibroblast cultures. Samples of 200 III were taken at 0, 
0.25, 1, 2, 6 and 24 hours after the addition of Ang II. The samples were collected in 
vials, containing l.25 mM phenanthroline and 6.25 mM disodium EDTA (fmal 
concentrations in the sample) and stored at -70'C. Within two days, Ang II was 
measured by radioimmunoassay as described before." In short, samples were vacuum-
dried, dissolved in 0.25 M Tris-buffer, pH 7.4, containing 0.35% bovine serum 
albumin and 0.02% sodilml azide, and incubated with "'I-Ang II and Ang II antiserum 
at 4 'C for 24 hours. Separation of bound and free Ang II was achieved by charcoal 
adsorption, and both the supernatant and the pellet were counted in a y-counter. The 
Ang II antiserum crossreacted with Ang III (55%), Ang (3-8) (73%) and Ang (4-8) 
(100%), but not «0.2%) with Ang (1-7).26 
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Measurement of \Vater-soluble inositol phosphates 
Cardiomyocytes and fibroblasts were labelled with 2 flCi myo-[2-'Hjinositol!ml for 24 
hours in medinm without sernrn." The cells were then washed and preincubated for 15 
min with incubation buffer (130 mM NaC!; 4.7 roM KCl; 1.3 roM CaCl,; 0.44 mM 
NaH2PO,; 1.1 mM MgSO,; 20 mM NaHC03 ; 0.2% glucose; 20 mM HEPES; pH 7.4) 
in the presence of vehicle (medinm), losartan (concentration range from 10" M to 10" 
M) or PDI23319 (10" M) at 37"C and aerated with 5% CO, - 95% air. To stimulate 
the cells, vehicle (i.e., incubation medium) or agonist (Ang II or ET -I; concentration 
range 10'9 to 10.7 M) was added to the incubation buffer without buffer change, in the 
presence of 10 mM LiCI to inhibit inositolphosphatase activity. Incubations were 
tenninated after 30 min. The cells were then rapidly washed with ice-cold buffer 
followed by two successive extractions with 250 fli ice-cold 4% (w/v) HC!O" after 
which lipids were extracted with 2 x 250 fll ice-cold methanol:HCI (100: I, v/v). The 
perchloric acid extract, containing the water-solnble intracellular products, was rapidly 
neutralized by adding a solution of 2 M KOH and I M K,CO,. The water-soluble 
inositolphosphates (InsP J in the perchloric acid extract were then quantified by 
chromatography on Dowex AG I-X8 as originally described by Berridge et al.27 
Amounts of Insp. are expressed as percentage of the total cellular amount of [2_3Hj 
inositol-labelled products, defined as the snm of water-soluble inositol-containing 
products and the inositol-containing lipids. To each sample 5 mI scintillation fluid 
(Instagel) was added, and samples were cOlmted for 5 min in aJl-counter. 
Determination of total cellular protein and DNA 
Cells were pre-incubated with either vehicle, losartan (10" M) or PDl23319 (10" M) 
for 30 min. Next, vehicle, Aug II (10" M), ET-I (10" M) or Aug II + ET-I (both 10.8 
M) were added to the cell cultures for 48 hours. After !his incubation period the cells 
were washed twice with 500 fll ice-cold PBS. Iu order to dissolve cellular protein and 
DNA, 250 fll I M NaOH was added to each well. This was followed by an ovemight 
incubation at 4 'C, after which the cellysates were collected. Protein was measured by 
the Bradford assay, using bovine serum albumin in I M NaOH as standard." DNA 
was measured fluorimetrically with 4',6-diamidino-2-phenylindole-dihydrochloride, 
using sahnon sperm DNA in I M NaOH as a standard." 
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{'HJLellcine incorporation 
Protein synthesis rate was detennined by quantitating ['H]leucine incorporation?' 
Briefly, cardiomyocytes or fibroblasts were pre-incubated for 0.5 hour in 500 J.lI 
serum-free medium with 1 J.lCi ['H]leucine/ml, in the presence of vehicle, losartan 
(IO~ M) or PD123319 (IO~ M). After tlus period, eitller velucle, Ang II (10-' M), ET-I 
(10" M), or Ang II + ET -I (both 10" M) were added and ti,e incubation was continued 
for 24 hours. Subsequently, the medium was discarded and cells were fixed oventight 
with 500 J.l1 10% trichloric acid (TCA). Cells were rinsed three times with 10% TCA 
to remove Ultincorporated label and then lysed during 6 hours with 500 J.l1 1 M NaOH. 
The lysate was transferred to scintillation vials. After neutralisation with 500 J.lI I M 
HCI, 5 ml scintillation fhud (lnstagel) was added, and samples were counted for 5 min 
in aft-counter. 
{'HJThymidine incO/paration 
DNA synthesis rate was determined by quantitating ['H]thymidine incorporation" 
Briefly, cardiomyocytes or fibroblasts were pre-incubated for 0.5 hour in 500 J.l1 
serum-free medium in tile presence of velucle, losartan (10~ M) or PD 123319 
(IO~ M). After tI,is period eitller velucle, Ang II (10" M), ET-l (10" M), or Ang II + 
ET -1 (both 10" M) were added. After 18 hours of incubation, 
['H]thynudine (1 J.lCilmI) was added for 6 hours Snbsequently, the medium was 
discarded and cells were fixed oventight Witll 500 J.l1 10% TCA. To remove 
unincorporated label, cells were rinsed three times Witll 10% TCA and tI,en lysed 
during 6 hours with 500 J.lI I M NaOH. The lysate was transferred to scintillation 
vials. After neutralisation with 500 J.l1 1 M HCI, 5 ml scintillation fluid was added, and 
samples were cotmted for 5 min in aft-counter. 
Statistics 
The data are reported as percentage change relative to control values. Data obtained in 
experiments in the presence of losartan or PD123319 are reported as percentage 
change relative to control witlliosartan or PD123319. Data are given as mean±SEM of 
at least 5 experiments (each measured in quadruplicate). 
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One-way analysis of variance (ANOVA) followed by appropriate post-hoc tests 
(Student's t test, with Bonferroni correction) was used for comparison between groups. 
Values of P < 0.05 were considered significant. 
Results 
Ang II stability during incubations 
Aug n, when added to cardiomyocytes or fibroblasts in a concentration of 10"' M, was 
slowly metabolized with a half-life of 6.9±0.7 and 13.3±1.7 h (n=3) respectively. The 
half life was not different at concentrations of Aug II that were 10 or 100 times higher 
(data not shown), indicating that Aug II metabolism at these concentrations followed 
first-order kinetics. Based on these data, we decided to add Aug II only once at the 
beginning of each experiment. 
Formation o/water-soluble inositol phosphates 
The ability ofET-l and Aug II to evoke acute production of Insp. was tested in both 
cardiomyocytes and fibroblasts. InsP, accumulation was stimulated dose-dependently 
by ET -I in cardiomyocytes, and by Aug IT in fibroblasts (Figure I). For both ET -I and 
Aug II the lowest concentration at which near-maximal effects occurred was 10" M. 
Aug II had only marginal effects on InsP, accumulation in cardiomyocytes, while 
ET -I was ineffective in fibroblasts. The modest effects of Aug n in cardiomyocytes 
tnight be explained by the low angiotensin receptor density of these cells.' 
Complete blockade of the Aug II-induced effects in fibroblasts was obtained with 
losartan in concentrations of 10~ M and higher, whereas PDI23319 at such 
concentrations had no effect (Figure 2). Tlus indicates that the Aug II-induced effects 
on phospholipase C activation were mediated via AT, receptors. When Aug II was 
added 48 h after the addition of losartan (IO~ M), the AT, receptor blocker still 
effectively blocked the Aug II-induced response (n=2; data not shown). Losartan 
(10" M) nor PD123319 (l0~ M) affected the ET-I-induced effects on InsP, 
accumulation in cardiomyocytes (n=2; data not shown). 
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Based on these [mdings, it was decided to use Ang II and ET -I in a concentration of 
10-' M and losartan in a concentration of 10" M in all further experiments_ PDI23319 
was also used in a concentration of 10" M, based upon data obtained by others. IO•2I •3I 
Furthermore, both receptor antagonists were added only once at the beginning of each 
experiment in all further studies_ 
Gl 
I/) 
os 
Gl 
... 
o 
C 
"C 
o 
u.. 
Angll 
MYOCYTES 
ET-l Angll ET-l 
FIBROBLASTS 
Figure 1_ Effect of angiotensin II (Ang II) and endothelin-I (ET-I) on inositol phosphate 
accumulation in cardiomyocytes and cardiac fibroblasts. The agonists were added in a 
concentration of 10" M (open bars), 10-' M (hatched bars) or lO"' M (black bars). The 
increase in inositolphosphate accumulation is expressed as fold increase relative to control. 
Data are mean±SEM of 3 experiments each (a * denotes that the increase was larger than 
I-fold in all three experiments). 
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Figure 2. Effects of losartan and PD 123319 on the inositol phosphate accumulation induced by 
angiotensin II (Ang II, 10" M) in cardiac fibroblasts. Losartan significantly (*, P < 0.05) 
inhibited the response at concentrations of 10" M and higher, whereas PD123319 had no 
effect at a dose of 10" M. Data are mean±SEM of 4 experiments each. 
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Total celllliar protein alld ['Hjlellcine incO/poration 
The total protein contents of cardiomyocyte and fibroblast cultnres, incubated for 48 
hours with vehicle, were 86±18 and 42±8 l1g/well, respectively (n=6). Neither losartan 
nor PD123319 affected total cellular protein in both cell types (data not shown). 
Ang 11, added alone or in the presence of losartan, also did not affect totaf cellular 
protein (Figures 3A and 4A). Ang 11, added in the presence of PD123319, tended to 
increase total cellular protein in cardiomyocytes, but the difference relative to control 
was not significant. In fibroblasts, Ang II added in the presence of PD 123319 
increased total cellular protein by 17±6% above control. 
ET -I increased total cellular protein in cardiomyocytes by 38±6% and had no 
effect in fibroblasts. The ET -I-induced effects in cardiomyocytes were not affected by 
Ang II, losartan, PD123319, or a combination of these drugs (Figure 3A). In 
fibroblasts, the effect of Ang II+ET-l in the presence ofPD123319 was similar to that 
observed with Ang II and PD123319 alone, suggesting that ET-I did not interfere with 
the Ang l1-mediated effects (Figure 4A). 
[3H)leucine incorporation by cardiomyocyte and fibroblast cultures 
(26 489±5706 and 10 801±3175 d/min/well, respectively, after 24 hours of incubation 
in the presence of vehicle) was not affected by losartan or PDI23319 (data not 
shown). Ang II increased [3H)leucine incorporation in fibroblasts by 24±5% above' 
control (Figure 4B). Losartan, but not PD 123319, inhibited tllis Ang II-mediated 
effect in fibroblasts. In cardiomyocytes, Ang II alone or in tile presence of losartan did 
not affect ['H) leucine incorporation, whereas in tile presence of PD123319, Ang II 
increased [3H)leucine incorporation by 24±1O% above control (Figure 3B). 
Incubation of cardiomyocytes Witll ET -1 led to an increase in [3H)leucine 
incorporation of 66±1l% above control, an effect wllich was not influenced by Ang II, 
losartan, PD123319, or a combination of these drugs (Figure 3B). In fibroblasts, ET-l 
caused a small, non-significant increase in [3H)leucine incorporation. The effect of 
Ang II+ET-l in these cells equalled the SIUll of tile effects of Ang II and ET-l alone, 
and could not be blocked or enhanced with losartan or PD123319 (Figure 4B). 
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Figure 3. Effect of angiotensin II (Ang II, 10" M), endothelin-I (ET-I, lO"' M) or angiotensin 
II + endothelin-l (both 10" M) on total cellular protein content (panel A) and ['H]leucine 
incorporation (panel B) in cardiomyocytes in the presence of vehicle (hatched bars), losartan 
(10"6 M) (open bars) or PDl23319 (10" M) (black bars). Data are expressed as percentage 
increase from control (mean±SEM of 5-7 experiments; *, P < 0.05 vs. control). 
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Figure 4. Effect of angiotensin II (Ang II, 10·' M), endothelin-l (ET-l, 10·' M) or angiotensin 
II + endothelin-l (both W, M) on total cellular protein content (panel A) and ['Hlleucine 
incorporation (panel B) in cardiac fibroblasts in the presence of vehicle (hatched bars), losartan 
(10·' M) (open bars) or PDl23319 (10~ M) (black bars). Data are expressed as percentage 
increase from control (mean±SEM of5-7 experiments; *, P < 0.05 vs. control). 
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Total cel/ula/' DNA and ['Hjthymidine incorporation 
Total cellular DNA was 2.S±0.2 and 1.0±0.2 J.lg/well in cardiomyocytes and 
fibroblasts, respectively, after 48 hours of incubation with vehicle. Losartan, 
PD123319, Ang 11 or ET-l or a combination of these drugs did not affect total cellular 
DNA significantly in either cardiomyocytes or fibroblasts (Figures SA and 6A). 
['H]thymidine incorporation by cardiomyocyte and fibroblast cultures 
(24 966±S396 and 16 S19±4912 dimin/well, respectively, after 24 hours of incubation 
in the presence of vehicle) was not affected by losartan or PDI23319 (data not 
shown). Ang 11 caused a modest (non-significant) increase in [3H]thymidine 
incorporation in cardiomyocytes, which was absent in tile presence of losartan and 
enhanced to 30±6% (P < O.OS) above control with PDI23319 (Figure SB). Ang 11 had 
no effect on [3H]thymidine incorporation in fibroblasts, either alone, or in the presence 
of losartan, PDI23319 or ET-I (Figure 6B). ET-I increased ['H]thymidine 
incorporation in cardiomyocytes by 77±21 %, an effect which was not influenced by 
Ang 11, losartan, PD123319, or a combination oftllese drugs (Figure SB). ET-I had no 
effect on ['H]thymidine incorporation in fibroblasts under all circumstances tested 
(Figure 6B). 
Protein/DNA ratio 
No significant changes in proteinlDNA ratio were observed under all conditions tested 
in our experiments. Changes in total cellular protein content and protein synthesis rate 
were paralleled by similar or smaller changes in total cellular DNA content and DNA 
synthesis rate (Figures 3-6), indicating that cellular hypertrophy, if occurring at all, 
was of modest proportion. 
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Figure 5. Effect of angiotensin II (Ang II, 10"' M), endothelin-I (ET-I, JO·'M) or angiotensin 
II + endothelin-I (both 10·' M) on total cellular DNA content (panel A) and ['Hlthymidine 
incorporation (panel B) in cardiomyocytes in the presence of vehicle (hatched bars), losartan 
(10-' M) (open bars) or PDI23319 (10" M) (black bars). Data are expressed as percentage 
increase from control (mean±SEM of 5-7 experiments; " P < 0.05 vs. control). 
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Figure 6. Effect of angiotensin II (Ang II, 10·' M), endothelin-l (ET-I, 10·' M) or angiotensin 
II + endothelin-l (both 10·' M) on total cellular DNA content (panel A) and [3H]thymidine 
incorporation (panel B) in cardiac fibroblasts in the presence of vehicle (hatched bars), losartan 
(10.6 M) (open bars) or PDl23319 (10" M) (black bars). Data are expressed as percentage 
increase from control (mean±SEM of 5-7 experiments; *, P < 0.05 vs. control). 
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Table 1. Swmnary of the effects of angiotensin II (Ang II, 10.8 M), endoO.elin-1 (ET-1, 10" M), or Ang 
II + ET-1 (both W-' M) on total cellular protein content, PHlleucine incorporation, total cellular DNA 
content and [lHlOtymidine incorporation in cardiomyoc)1es (M) and cardiac fibroblasts (F). 
Experiments were perfonned without AT receptor blockade (control), \\10. AT. receptor blockade 
(Iosartan) or with AT, receptor blockade (PD 123319). 
total ['Hlleucine total ['Hlthymidine 
cellular incorporation cellular incorporation 
protein DNA 
content content 
M F M F M F M F 
AngIl 
control 0 0 0 + 0 0 0 0 
losartan 0 0 0 0 0 0 0 0 
PDI23319 0 + + + 0 0 + 0 
ET-l 
control + 0 ++ 0 0 0 ++ 0 
losartan + 0 ++ 0 0 0 ++ 0 
PD123319 + 0 ++ + 0 0 ++ 0 
Ang I1+ET-l 
control + 0 ++ + 0 0 ++ 0 
losartan + 0 ++ + 0 0 ++ 0 
PD123319 + + ++ + 0 0 ++ 0 
0, no significant increase; +, modest increase « 50%); ++, large increase (> 50%). 
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Discussion 
The results obtained in this study, swnmarized in Table I, demonstrate that Aug II, via 
AT, receptors, may antagonize its AT, receptor-mediated growth-stimulatory effects in 
cardiac cells. It appears therefore that the net growth effect of Aug II in these cells 
depends on the cellular AT,IAT, receptor ratio. Aug II did not interfere with growth-
stimulatory effects induced by ET-1. 
We quantified the Aug I1- and ET-l-induced effects on cell growth by measuring 
the total cellular content of protein and DNA as well as the synthesis rate of protein 
and DNA. This approach allowed us to study whether an increased cellular protein or 
DNA content was the consequence of enhanced synthesis and/or diminished 
degradation. Both neonatal rat cardiomyocytes and fibroblasts have the capacity to 
proliferate."'" Cardiomyocytes lose the capacity to replicate DNA by week 3 of 
postnatal development. 33 It appeared that wIder ail circumstances where an increase in 
DNA or protein content was observed, the synthesis rates of these components were 
also increased. This suggests that enhanced synthesis was the tUlderlying cause of the 
increase in DNA or protein content. In fact, since the increases in synthesis rate were 
usually larger than the increase in content, enhanced rather than diminished 
degradation may have accompanied these increases in synthesis rate. We did not 
observe a significant increase in proteinJDNA ratio, suggesting that hyperplasia rather 
than hypertrophy had occurred in our experiments, or that the degree of cellular 
hypertrophy, if occurring, was of modest proportion. 
ET -I potently stimulated protein and DNA synthesis in cardiomyocytes, but was 
ineffective with regard to these parameters in fibroblasts. The latter may be attributed 
to the much lower endothelin receptor number in rat cardiac fibroblasts as compared 
to rat cardiomyocytes."·35 Phospholipase C-induced formation of inositoltrisphosphate 
and diacylglycerol may underly the growth-stimulatory effects of ET -I." Indeed, we 
found ET -I to strongly enhance inositolphosphate formation in cardiomyocytes but 
not fibroblasts (Figwe I). 
Aug II did not affect DNA synthesis in either myocytes or fibroblasts and 
stimulated protein synthesis rate in fibroblasts only. The latter effect is assumed to be 
AT, receptor-mediated and phospholipase C-dependent. 16 
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Our data on Ang II-induced inositolphosphate fonnation are in agreement with such a 
mechanism. Ang II-induced stimulation of protein and DNA synthesis in neonatal rat 
cardiomyocytes and fibroblasts has been reported by otherslO.tJ but the results vary 
widely and could not always be confmned. ".IS Our findings may offer an explanation 
for these discrepancies. We only observed significant AT, receptor-mediated increases 
in the synthesis rate of both DNA and protein in cardiomyocytes and in the total 
protein content in fibroblasts in the presence of the selective AT, receptor antagonist 
PD 1233 19. This suggests that the AT, receptor may nonnally inhibit the AT, receptor-
mediated hypertrophic (fibroblasts) and hyperplastic (cardiomyocytes) effects. 
It appears therefore that the balance between AT, and AT, receptors determines 
the net effect of Ang II. As the densities of these receptors rapidly change after birth, it 
is not unlikely that neonatal cells harvested at different times after birth may have 
different AT,fAT, receptor ratios."'" It is even possible that cells in the same culture 
have different receptor densities and that some cells have AT, receptors and others 
have AT, receptors. However, in view of the fact that most of the Ang II-mediated 
proliferative effects in our study could be demonstrated in the presence of PD 123319 
only, it seems more likely that both receptors are present on the same cell. 
AT, receptor-mediated antigrowth effects have been demonstrated earlier in rat 
coronary endothelial cells.2I In these cells Ang II inhibited the proliferative effects of 
bFGF by maxinlally 50% via AT, receptors. In the present study we could not 
demonstrate an inltibitory action of Ang II on the ET-I-indllced proliferative effects in 
cardiomyocytes. The latter effects are believed to be mediated by ETA receptors. 22." 
ET-I was applied in our study because I) it makes use of the same intracellular second 
messenger pathways as Ang II to induce proliferation," and 2) it may be involved in 
the Ang II-induced proliferative effects. tJ.22 Although our results do not argue against 
these findings, they do not snpport an AT, receptor-mediated inllibitory action on ET-
I-mediated effects. It is possible that the AT, receptor-mediated effects in cardiac cells 
are relatively modest and could therefore not be detected. However, also WIder 
conditions where the ET -I-induced effects on protein synthesis were half maxiuJal 
(ET-I concentration 10'9 M), no inhibitory effect of Ang II via AT, receptor 
stimulation could be observed (unpublished observation). Thus, altematively, there 
may be no crosstalk between AT, and ETA receptors. 
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We used the antagonists losattan atld PDI23319 to block AT, and AT, receptors, 
respectively. Without the addition of Ang II or ET-I, these inhibitors had no effect on 
protein or DNA synthesis. It seems therefore that neonatal rat cardiomyocytes and 
fibroblasts, at least under the selUm-free conditions as applied in the present study, do 
not synthesize Ang II in sufficient quantities to exert proliferative effects. Tltis 
confIrms previous fmdings on the absence of Ang II in the mediwn of cardiomyocytes. 
"." The accelerated rate of protein synthesis known to occur following stretch of 
neonatal rat cardiomyocytes may be due to an autocrine induction of Ang II synthesis 
by these cells.40•41 
How could the AT, receptor atltagOitize the AT, receptor-mediated effects? 
Studies in PC-12W pheochromocytoma cells atld in NIE-1l5 murine neuroblastoma 
cells indicate that Ang II, via AT, receptors, can stimulate protein-tyrosine 
phosphatases.42•43 This in tum will lead to inltibition of ntitogen-activated protein 
(MAP) kinases." MAP kinases, which are critical components in cellular processes 
such as growth and apoptosis,"·46 are known to be activated by Ang II binding to AT, 
receptors. Huang et al. have recently demonstrated in rat brain neuronal cultures that 
Ang II has opposite actions on MAP kinases via AT, atld AT, receptors." 
Such opposing actions may provide an intracellular basis for the modulatory effect of 
Ang II receptors on cell growth. The occurence of apoptosis, often studied by 
quantifyiug DNA fragmentation, could not be evaluated in the present study, because 
our method of DNA quantification does not allow us to draw conclusions on the 
presence of DNA fragments. 
The capacity of an agonist to induce both proliferative and antiproliferative 
effects after stimulation of different receptor subtypes enables the cell to adapt to 
different physiological circumstances. This may not only be important during cardiac 
development, but also wlder pathological conditions. For instatlCe, it has been 
described that the AT, receptor is re-expressed in rat hearts with left ventricular 
hypertrophy or after myocat'dial infarction.47•48 Our data illustrate the possible 
consequences of such receptor Chatlges. 
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While the preparation of our manuscript was at its final stage, the recent study by 
Booz and Baker carne to our attention.49 These authors demonstrated that Ang II 
(10" M) exerted a modest effect on protein synthesis in neonatal rat cardiomyocytes, 
which was markedly enhanced in the presence of an AT, receptor antagonist. Our 
study confmns these fmdings and addresses additionally the AT, receptor-mediated 
anti growth effects in neonatal rat cardiac fibroblasts as well as in ET -I-stimulated 
cardiac cells. 
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CHAPTER 4 
Mannose 6-Phosphate Receptor-Mediated Internalization and 
Activation of Pro renin by Cardiac Cells. 
Chapter 4 
Abstract 
The binding and internalization of recombinant human renin and prorenin 
(2500 JlUfmL), and the activation of prorenin were studied in neonatal rat cardiac 
myocytes and fibroblasts cultured in a chemically defmed medium. Surface-bound and 
internalized enzyme were distinguished by the addition of marmose 6-phosphate to the 
medium, by incubating the cells both at 37°C and 4°C, and by the acid-wash method. 
Maunose 6-phosphate inhibited the binding of renin and prorenin to the myocyte cell 
surface in a dose-dependent maImer. At 37°C, after incubation at 4°C for 2 hours, 
60-70% of cell surface-bound renin or prorenin was internalized within 5 minutes. 
Intracellular pro renin was activated but extracellular pro renin was not. The half-time 
of activation at 37°C was 25 minutes. Ammoniwn chloride and monensin, which 
interfere with the nonual trafficking and recycling of internalized receptors and 
ligands, inhibited the activation of prorenin. Results obtained with cardiac fibroblasts 
were comparable to those in the myocytes. This study is the first to show experimental 
evidence for the internalization and activation of prorenin in extrarenal cells by a 
maunose 6-phosphate receptor-dependent process. Our fmdings may have 
physiological significaIlce in light of recent experimental data indicating that 
angiotensin I and II are produced at cardiac aIld other extrarenal tissue sites by the 
action of renal renin and that intracellular angotensin II can elicit importaIlt 
physiologic responses. 
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Introduction 
A local renin-angiotensin system in the heart is often invoked to explain the long-term 
beneficial effects of angiotensin-converting enzyme inhibitor treatment on 
postinfarction cardiac remodelling and failure and in left ventricular hypertrophy. 
Experimental studies of the isolated perfused rat heart have indeed 
demonstrated that the heart is capable of producing Ang I and Ang II.'" However, 
attempts to provide evidence that the cardiac production of these peptides depends on 
in situ synthesized renin have failed so far. Rather, perfusion experiments in the 
isolated rat heart as well as studies of the effects of nephrectomy on the cardiac tissue 
levels of Ang I and II in the pig, indicate that the local production of these pep tides 
depends on kidney-derived renin.'" 
Uptake of renin from the circulation by vascular tissues and by the heart has 
been reported and appears to contribute to blood pressure controL'" Binding of rat 
renin to rat cardiac and other tissue membranes has also been reported, as has binding 
of human renin to human umbilical vein endothelial cells.'" A recent study has 
demonstrated specific receptor binding of human renin to cultured human mesangial 
cells.' 
Recombinant human renin synthesized by Xenopus oocytes and mouse L cells' 
contains phosphomamlOsyl residues that are recognized by specific receptors (mannose 
6-phosphate receptors), as does human prorenin synthesized by eHO cells,lO.ll Two 
different mannose 6-phosphate receptors have been identified; one is dependent on 
divalent cations, the other not. Both mamlOse 6-phosphate receptors function in the 
process of intracellular lysosomal enzyme sorting, and the cation-independent receptor 
is also capable of binding and intemalizing extracellular lysosomal enzymes.'~13 
The aim of the present study is to explore the possibility that cardiac myocytes 
and fibroblasts are capable of binding and internalizing renin and prorenin, and that 
these processes are mannose 6-phosphate receptor-mediated. We also adressed the 
possibility that receptor-mediated endocytosis of prorenin results in its activation. 
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Materials and Methods 
Reagents 
Trypsin (type III), bovine serum albmnin, monensin, mannose 6-phosphate, mrumose 
I-phosphate and glucose 6-phosphate were from Sigma Chemical Co. Fetal calf senUll, 
horse serum, penicillin and streptomycin were purchased from Boehringer-Mannheim. 
DMEM and Medium 199 were from Gibco. Six-well tissue plates were obtained from 
Costar. 
Cell culture 
All experiments were perfonned according to the regulations of the Animal Care 
Committee of Erasmus University, Rotterdrun, Netherlands, in accordrulce with the 
Guiding Principles in the Care and Use of Animals approved by the American 
Physiological Society. 
Primary cultures of neonatal rat ventricular cardiomyocytes and fibroblasts 
were prepared as described before." Briefly, ventricles from newbonl 1-3 day old 
Wistar rats were minced ruld cells were isolated by eight subsequent trypsinization 
steps at 30·C. Noncardiomyocytes were separated from the cardiomyocytes by 
differential preplating. Cardiomyocytes were seeded in 6-well plates at 1.5 x 10' 
cells/well giving a confluent monolayer of spontaneously beating cells after 24 hours. 
The preplated cells (fibroblast fraction) were passaged after 4 days to 6-well dishes at 
0.75 x 10' cells/well. The cells were maintained in a humidified incubator at 37·C and 
5% CO, in air, in growth medilUll consisting of DMEM and Medimn 199 (4: 1, v/v), 
supplemented with 5% fetal calf serum, 5% horse senun, 100 U penicillinfmL and 100 
Ilg streptomycinfmL for 72 hours. The incubations with renin and prorenin (see below) 
were carried out Ullder serum-free conditions. Prior to the start of each experiment, 
cells were washed with 3 mL warm (37"C) phosphate-buffered saline (PBS) (140 
mmolfL NaCI, 2.6 mmolfL KCI, 1.4 mmolfL KH,PO" 8.1 mmolfL NllzHPO" pH 7.4). 
The cells were then preincubated either at 37"C or 4·C for 30 minutes with 0.9 mL 
incubation medimn consisting of DMEM and Medium 199 (4:1, voVvol), 
supplemented with 1% (wtJvol) bovine serum albumin. 
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Pro renin and renin 
Recombinant human prorenin was a kind gift of dr W. Fischli (Hoffmann-LaRoche, 
Basel, Switzerland). It was produced in CHO cells transfected with a vector containing 
human prorenin cDNA. It was partially purified, to remove traces of renin, by 
Cibacron Blue Sepharose affinity chromatography." The intrinsic renin activity of the 
prorenin preparation, prior to proteolytic activation, was less than 2% of the activity 
after complete proteolytic activation. After proteolytic activation the prorenin 
preparation contained approximately 8.5xlO' ~IU/mL renin. Recombinant human renin 
was prepared by the proteolytic activation of the recombinant human prorenin with 
immobilized trypsinJ ·" Sepharose-bound trypsin (final concentration 0.25 mg 
trypsinimL) was added to the prorenin preparation and the mixture was kept at 4 'C for 
72 hours Trypsin was then removed by centrifugation. The prorenin and renin 
preparations were stored at -70'C. 
incubation of cells with renin or prorenin at 37 'C or 4 DC 
After preincubation at 37'C or 4 'C for 30 min in 0.9 mL sennn-free medimll (see 
above), experiments were started by the addition of 0.1 mL of a dilution of 
recombinant human renin or prorenin to the medhnn (final concentration in the wells 
approximately 2500 ~UlmL). Cells were then incubated at 37'C or 4 'c. Incubations' 
were also perfonned in the presence of mannose 6-phosphate (0.0 I ~lmol!mL to 50 
~mol/mL), mannose I-phosphate (l~mol/mL), glucose 6-phosphate (I ~mol/n1L), 
annnonium chloride (50 ~mol/mL) or monensin (0.0 I ~mol/mL). 
At the end of the incubation period, the culture medimll was removed and 
quickly frozen on dry ice. Each well was washed three times with 3 mL ice-cold PBS. 
Renin and prorenin were not detectable in the last PBS wash. Cells were then lysed in 
0.5 mL ice-cold PBS containing 0.2% Triton X-IOO, and the celllysates were quickly 
frozen on dry ice. Medium and cell lysate were stored at -70'C until assayed for renin 
and prorenin. 
To detennine the intemalized renin or prorenin, the acid-wash method was 
used." Briefly, after the cells had been washed three times with 3 mL ice-cold PBS, 
the cells were incubated at 4 'C with I mL of an acid solution containing 50 mmollL 
glycine and 150 mmollL NaCI, pH 3.0. 
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After 10 minutes the acid solution was removed and the cells were washed three times 
with 3 mL ice-cold PBS. Cells were then lysed in 0.5 mL ice-cold PBS containing 
0.2% Triton X-IOO, as described above. 
To determine the prorenin that was bound to mannose 6-phosphate receptors on 
the cell surface, prorenin was measured in the culture medium before and after its 
displacement from the receptor by mannose 6-phosphate. For this purpose the cells 
were pre-incubated at 37°C or 4°C with prorenin (2500 11U/mL) for 2 hours. The cells 
were then washed three times with 3 mL ice-cold PBS. After the last wash 1 mL of 
fresh incubation medium, free of serum and renin and prorenin, containing 
mannose 6-phosphate (fmal concentration 10 Ilm01lmL) was added, and the 
incubations were continued at the same temperature as during the preincubation. After 
this second incubation period, the cells were washed and lysed as described above. 
incubation of cells at 4 cc followed by incubation at 37 cC 
To study the kinetics of renin and prorenin internalization and prorenin activation in 
more detail, cells were incubated with renin or prorenin (fmal concentration 
approximately 2500 IlUlmL) for two hours at 4 cC~ After this period, free renin and 
prorenin were removed by washing the cells three times with 3 mL ice-cold PBS. After 
the last wash 1 mL of fresh incubation medium at 37"C without renin and prorenin 
was added, and the cells were incubated at 37 c C. The incubations were terminated by 
washing the cells with ice-cold PBS. The cells were then lysed as described above. 
Medium and cell lysate were assayed for renin and prorenin. Internalized renin and 
prorenin were determined with the acid-wash method as described above. 
Renin and prorenin measurements 
Measurements of renin were made by the enzyme-kinetic assay"!' Briefly, 100 ilL 
sample was incubated for 3 hours with saturating amounts of sheep renin substrate at 
37"C and pH 7.4 in the presence of serine protease and angiotensinase inhibitors. The 
generated Aug 1 was quantitated by radioinUllunoassay. Results were expressed as 
IlUlmL using the international WHO human kidney renin standard, lot 68/356 (WHO 
International Laboratory for Biological Standards and Control, Potter Bar, 
Hertfordshire, UK), as a reference. 
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The Ang I-generating activity we measured in cells that had been exposed to renin in 
the culture medium represents 'true' renin; the specific inhibitor remikiren,17 at a 
concentration of 10.8 mollmL, caused complete inhibition of the Ang I-generating 
activity of the lysates from these cells. 
Prorenin is the inactive biosynthetic precnrsor of renin. The prorenin-to-renin 
conversion in vivo is a proteolytic process by which the propeptide is cleaved from the 
renin part of the molecule. In vitro, prorenin can be activated both nonproteolytically 
(e.g., by exposnre to low pH) and proteolytically by various enzymes. The Ang J-
generating activity we measured in the lysates of cells that had been exposed to 
inactive prorenin in the culture medium represents prorenin that was activated by the 
cells. This cell-activated prorenin mayor may not be identical with renin. We also 
measured 'total' prorenin, i.e. prorenin that was activated by the cells plus prorenin 
that was not activated by the cells. For these measurements the samples were incubated 
for 48 hours at 4'C with plasmin (0.5 casein units per mL) before the incubation with 
sheep renin substrate.3 The preincubation with plasmin caused complete proteolytic 
activation of prorenin. Plasmin from the activation step was inactivated by the serine 
protease inhibitor aprotinin (final concentration 100 kallikrein-inhibiting unitstmL) that 
had been added to the incubation medium of the Ang I-generating step. 
Prorenin that could be measured without preincubation of the samples with 
plasmin is referred to as "cell-activated" prorenin. Prorenin that was measured in 
samples that had been pre-incubated with plasmin is referred to as "total" prorenin. 
Mannose 6-phosphate, arnnlOnium chloride and monensin, in the concentrations we 
used, had no influence on the renin and prorenin assays. 
Statistics 
Data were compared using Student's t-test for unpaired observations. A value of 
P<0.05 was considered to be significant. 
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Results 
Figure I (top) and figure 2 (top) show the amounts of cell-associated renin and 
prorenin after 4 hours of incubation of cardiac myocytes at either 4°C or 37°C with 
renin or prorenin respectively. At 4°C the cells bound both renin and prorenin but 
intemalization occurred only at 37°C. The cell-associated renin or prorenin after 4 
hours of incubation amounted to about 5% of the total quantity in the culture medium 
both at 4°C and 37°C. After incubation at 37°C most of the cell-associated prorenin 
was resistant to the acid-wash and was in an activated fOllll, whereas at 4°C prorenin 
was washed away by acid and remained inactive. 
Figure 3 shows the increase in cell-associated prorenin over time in the 
myocytes at 37°C. Cell-associated prorenin reached a maximum in 3-4 hours. It was 
120±37 JlUl1.5xIO' cells (mean±SD, n=9) at 4 hours of incubation, and more than 
90% was in an activated fonn at that time. When, at 2 hours of incubation at 37°C, the 
prorenin-containing medium was renewed and the cells were incubated for another 2 
hours at 37°C, the cell-associated prorenin rose to levels well above the maximlml 
obtained without renewal of the medium, and again more than 90% was in an activated 
fonn. The cell-associated prorenin at 4 hours of incubation, 2 hours after renewal of 
the medium, was 160±41% of the level at 4 hours of incubation without renewal of the 
medium (n=5, P<0.05 for difference from 100%). 
When the incubations at 37°C were carried out in the presence of mannose 6-
phosphate (10 Jlmol/mL), cell-associated prorenin at 4 hours of incubation was 24±8 
IlU/1.5xIO' cells (n=5, P<O.OI for difference from incubations in the absence of 
mallllose 6-phosphate). Figure 4 shows the effect of different concentrations of 
mannose 6-phosphate on the levels of cell-associated prorenin at 37"C and 4°C; 50% 
inllibition was reached at a mannose 6-phosphate concentration in the order of 
0.1 Jlmol/mL. Mannose I-phosphate (n=3) and glucose 6-phosphate (n=3) at a 
concentration of 1 Ilmol/mL were without effect (data not shown). 
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Figure 1. Cell-associated renin after 4 hours of incubation of cardiac myocytes and fibroblasts 
with renin. The concentration of renin in the culture medium was 2500 II U/mL, and the 
incubations were performed at 37'C or 4'C. The acid-wash method was used to determine the 
acid-resistant internalized renin. Data are meanS±SD, n=6-9. 
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Figure 2. Cell-associated prorenin after 4 hours of incubation of cardiac myocytes and 
fibroblasts with inactive prorenin. The concentration of prorenin in the culture medium was 
2500 ~U/mL, and the incubations were performed at 37°C or 4°C. The acid-wash method was 
used to determine the acid-resistant internalized prorenin. The hatched and open bars represent 
the cellular levels of cell-activated prorenin and total (cell-activated plus non-activated) 
prorenin respectively. Data are meanS±SD, n~6-9. 
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Figure 3. Increase in cell-associated prorenin over time during incubation of cardiac myocytes 
at 37'C with inactive prorenin (2500 !lU/mL) in the absence or presence of mannose 6-
phosphate (10 !lmollmL) in the culture medium. The closed and open circles represent the 
cellular levels of cell-activated prorenin and total (cell-activated plus non-activated) prorenin 
respectively. Data are meanS±SD, n~5. 
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Figure 4. Dose-dependent decrease in cell-associated total (cell-activated plus non-activated) 
prorenin by mannose 6-phosphate. Cardiac myocytes were pre-incubated with mannose 
6-phosphate for 30 minutes at 37'C or 4'C. Then inactive prorenin (final concentration 2500 
f,U/mL) was added to the culture medium and the incubation was continued for 4 hours at the 
same temperature as during the preincubation. The concentration of mannose 6-phosphate in 
the medium is here expressed as moles per liter. Open circles and triangles represent the 
cellular levels of total (cell-activated plus non-activated) prorenin after incubation at 37'C and 
4'C respectively. After incubation at 37'C 90% of the cell-associated prorenin was in the cell-
activated form, whereas after incubation at 4°C 10% was in the cell-activated fOfm. Data are 
meanS±SD, n~3. 
84 
ProYel/ili activation by cardiac cells 
Figure 5 shows the effect of maImose 6-phosphate on myocytes that had been 
incubated for 2 hours with prorenin at either 4°C or 37°C. After incubation with 
prorenin, the cells were washed with ice-cold PBS and incubated at 4°C or 37°C 
respectively for 2 hours in serum-free medium to which mrumose 6-phosphate (final 
concentration 10 IlmollmL), but not prorenin, had been added. After preincubation 
with prorenin at 4°C, maIlnose 6-phosphate displaced the cell-associated prorenin into 
the medium. No displacement by mrumose 6-phosphate was observed after 
preincubation with prorenin at 37°C. Mrumose 6-phosphate had similar effects after 
preincubation with renin (data not shown). These observations are in agreement with 
the results obtained with the acid-wash method. The two sets of results indicate that at 
4°C the cell-associated renin and prorenin remain surface-bound, whereas at 37°C 
most of it appears to be internalized. 
The marked reduction in cell-associated prorenin in response to marmose 6-
phosphate was not seen when, instead of mrumose 6-phosphate, ammonium chloride 
(50 IlmollmL) or monensin (0.01 IlmollmL) had been added to the mediwn (Figure 6). 
Both ammonium chloride and monensin, however, inhibited the cellular activation of 
prorenin. In the control incubations the fraction of cell-associated prorenin that was in 
all activated fonn rose. from 30% after 30 minutes to 90% after 4 hours. TIlls was 
reduced to 10% aIld 35% respectively by annnonium chloride aIld to 5% and 10% by 
monensin (Figure 7, left panel). 
Figure 8 and figure 9 show the results of experiments in which the myocytes 
were pre-incubated with either renin or prorenin at 4°C for 2 hours and then incubated 
at 37°C without renin or prorenin. At 37°C, after the incubation at 4°C, approximately 
70% of cell-surface-bound renin and 60% of cell surface-bound prorenin were 
internalized within 5 lninutes, and most of the remainder was released into the 
medium. Results for renin and prorenin were not sigrlificantly different. Intracellular 
prorenin was activated but most, if not all, extracellular prorenin remained inactive. 
The half-time of intracellular prorenin activation was approximately 25 minutes. There 
was no evidence that prorenin, once internalized, was released by the cells back into 
the medium. 
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Figure 5. Displacement of cell-associated total (cell-activated plus non-activated) prorenin into 
the culture medium by mannose 6-phosphate, Cardiac myocytes were pre-incubated with 
inactive prorenin (2500 ~U/mL) in the absence ofmannose 6-phosphate for 2 hours at 37'C or 
4'C. The cells were then washed with ice-cold phosphate-buffered saline, fresh medium free of 
renin or pro renin was added, and the incubation was continued at the same temperature as 
during the preincubation, in the presence or absence of mannose 6-phosphate (final 
concentration 10 ~u/mL). The cellular levels of total (cell-activated plus non-activated) 
prorenin were 60±2! ~U/1.5x!0' cells at the end of the preincubation at 37'C, and 75±24 
~U/l.5xlO' cells at the end of the preincubation at 4'C, Data are meanS±SD, F4. 
86 
Prorenin activation by cardiac cells 
NH4CI 
Ceil-associated 125 
Monensin 
prorenin 
pU 11. 5x 1 06 cells 100 
75 
50 
25 
0 • • • 
0 2 3 
I 
4 0 
I I I 
2 3 4 
hours hours 
I ncubation at 37°C Incubation at 37°C 
Figure 6. Effects of ammonium chloride and monensin on the cellular aclivation of cell-
associated prorenin. Cardiac myocytes were pre-incubated with ammonium chloride (50 
~moVmL) or monensin (0.01 flmoVmL) for 30 minutes at 37'C. Then inactive prorenin (fmal 
concentration 2500 ~U/mL) was added to the culture medium and the incubation was 
continued. The closed and open circles represent the cellular levels of cell-aclivated prorenin 
and tutal (cell-aclivated plus non-aclivated) prorenin respeclively. Data are meanS±SD, n~4. 
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Figure 7. Comparison of the effects of ammonium chloride and monensin on the activation of 
cell-associated prorenin by cardiac myocytes and cardiac fibroblasts. The cells were pre-
incubated with ammonium chloride (50 IlmoiJmL) or monensin (0.01 IlmoiJmL) for 30 minutes 
at 37"C. Then inactive prorenin (final concentration 2500 ~u/mL) was added to the culture 
medium and the incubation was continued. Data are meanS±SD, n~4 to 6. 
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Figure 8. Time course of the internalization of renin by cardiac myocytes. The cells were pre-
incubated with renin (2500 flUlmL) for 2 hours at 4°C. They were then washed with ice-cold 
phosphate-buffered saline, fresh culture medium free of renin or prorenin was added, and the 
incubation was continued at 3TC instead of 4°C. The cellular level of renin at the end of the 
preincubation at 4°C was 55±J6 flUIlO' cells. At the times indicated, the cells were washed 
with acid to remove the non-acid-resistant renin. Data are meanS±SD, n~5. 
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Figure 9. Time course of the internalization and cellular activation of prorenin. Cardiac 
myocytes were pre-incubated with inactive prorenin (2500 f,U/mL) for 2 hours at 4 'C. They 
were then washed with ice-cold phosphate-buffered saline, fresh culture medium free of renin 
or prorenin was added, and the incubation was continued at 37°C instead of 4'C. The cellular 
level of total (cell-activated plus non-activated) prorenin at the end of the preincubation at 4°C 
was 78±22 ~ UII 0' cells. At the times indicated, the cells were washed with add to remove the 
non-add-resistant prorenin. The closed and open circles represent the levels of cell-activated 
prorenin and total (cell-activated plus non-activated) prorenin respectively. Data are 
meanS±SD, n=5. 
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Experiments identical with those perfonned in the cardiac myocytes, as shown in 
figure 1 (top), figure 2 (top) and figure 7 (left) were carried out with the use of cardiac 
fibroblasts. Results of the two sets of experiments were very similar (Figure I bottom, 
figure 2 bottom and figure 7 right). The kinetics of internalization and activation of 
prorenin by cardiac fibroblasts at 37°C, after preincubation at 4°C for 2 hours, were 
also similar to those observed in the myocytes (results not shown). At 37°C, after the 
incubation at 4°C, 42±19% of the cell surface-bound prorenin was internalized within 
5 minutes (n=5), and the half-time of intracellular prorenin activation was 
approximately 25 minutes, as it was in the myocytes. Release of internalized prorenin 
from the fibroblasts back into the cnlture medium conld not be detected, which also 
corresponds with our observations in the myocytes. As in the myocytes, the binding of 
renin and prorenin to the fibroblasts was inhibited by mal1J1ose 6-phosphate. 
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Discussion 
This study indicates that renin and prorenin are intemalized by cardiac myocytes and 
fibroblasts and that prorenin, after its intemalization, is rapidly activated. At 4°C both 
renin and prorenin bound to the cell surface and at 3rc both were rapidly 
intemalized. It appears therefore that neither the catalytic domain of the enzyme nor 
the propeptide domain are essential for the processes of binding and intemalization. 
There was no indication that renin and prorenin, once intemalized, were released into 
the culture medium. The acid-wash method that we used to distinguish between 
surface-bound and intemalized renin or prorenin has been validated for a number of 
peptide hormone receptors and their ligands including lysosomal enzymes carrying the 
malmose 6-phosphate signal. Exposure to low pH causes rapid dissociation of these 
enzymes from cell surface mannose 6-phosphate receptors. I2 To check whether the 
acid-wash method is also applicable to the cell-binding of prorenin, the cells were 
incubated with prorenin at 4°C. At this low temperature the internalization process is 
known to be effectively inhibited. We found that, after incubation with prorenin for 2 
hours, the cell-associated prorenin was completely removed from the cells by the acid-
wash. In contrast, when, after incubation with prorenin at 4°C, the cells were incubated 
at 3TC with fresh meditun without prorenin, nearly all cell-associated prorenin 
became resistant to the acid-wash within 5 minutes (the first measurement point). 
Thus, it appears that the acid-treatment of the cells did not affect the non-surface 
bound, ie, internalized, prorenin. The cell sUlface-binding of renin and prorenin at 4°C 
and its internalization at 37°C were confirmed by our observations on the effects of 
mannose 6-phosphate. After incubation with prorenin for 2 hours at 4°C, the cell-
associated prorenin could be displaced into the mediUln by the addition of mannose 
6-phosphate to tile mediUlll, whereas no such displacement was observed after 
incubation with prorenin for 2 hours at 37°C. The results were similar when the cells 
were incubated with renin instead of prorenin. 
Our results strongly suggest that the intemalization is a mannose 6-phosphate 
receptor-dependent process. The inhibition of prorenin intemalization by mannose 
6-phosphate was specific and saturable, with an IC" in the order of 0.1 ~mollmL. This 
corresponds with other mannose 6-phosphate receptor-mediated responses. I8•I9 
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Our finding that most of the cell surface-bound renin and prorenin after preincubation 
with these enzymes at 4°C was internalized within 5 minutes of incubation at 37°C, is 
also in agreement with published studies of other ligands that bind to cell surface 
matmose 6-phosphate receptors via the mannose 6-phosphate signal.20 
Approximately 5% of the renin or prorenin from the culture medium was bound 
and internalized by the cardiac cells. This low percentage may be related to the fact 
that only a small percentage of the renin and prorenin molecules carries the mannose 
6-phosphate signal."· 21 That this, rather than the nmnber of cell receptors, is the rate-
limiting factor is also suggested by our experiments in which the prorenin-containing 
culture medimn was renewed after 2 hours of incubation at 37°C, at a time when the 
amomtt of internalized prorenin was at 85% of its maximum. Renewal of the medimn 
in these experiments caused a rise of intracellular prorenin to levels well above the 
maximum that was reached without renewal of the medium. These results have to be 
confioned by binding studies, using radiolabeled prorenin. 
The effects of mamlOse 6-phosphate we observed were different from the 
inhibitory effects of armnonium chloride and monensin. Mannose 6-phosphate in the 
incubation experiments with prorenin at 37"C reduced the cellular concentrations of 
both total and cell-activated prorenin to equally low levels, whereas ammonium 
chloride and monensin had a much greater effect on the cellular level of cell-activated· 
prorenin tllan on the cellular level of non-activated prorenin. This supports the view 
that matmose 6-phosphate inhibits the binding of prorenin to cell surface mat.tllose 
6-phosphate receptors, whereas atumonium chloride and monensin primarily act on 
events that follow the binding to tllese receptors. Atmuonium chloride and monensin 
are known to interfere with the noonal intracellular trafficking and the recycling and 
lysosomal degradation of internalized receptors and ligands.22 
This study provides tile first evidence of intracellular activation of prorenin, 
derived from ti,e extracellular fluid, by extrarenal cells. The evidence in our study that 
a precursor protein is converted into a biologically active agent by a mannose 
6-phosphate receptor-mediated and endocytosis-dependent process is not an isolated 
finding. It has been demonstrated for a number of precursor proteins, including tile 
aspartyl protease cathepsin D.23 Catllepsin D is a lysosomal enzyme showing a high 
degree of structural homology with renin". 
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Transfonning growth factor beta, which may modulate the growth-promoting actions 
of Ang II," is another example. This factor is produced in a latent fonn by vascular 
endothelial and smooth muscle cells, and is converted into the active fonn in co-
cultures of these cells by a mannose 6-phosphate receptor-dependent process." The 
mannose 6-phosphate receptor that is involved in the endocytosis-dependent activation 
of both pro cathepsin and the latent fonn of transfonning growth factor beta is of the 
cation-independent type, which is identical with the insulin-like growth factor II 
receptor."· 2' It seems logical to assmne that this is also the receptor that mediates the 
internalization and activation of pro renin we observed in the present study. 
Our findings may have physiological significance in light of the experiments by 
Swales' group (Thurston et al') in rats more than 15 years ago. Their experiments 
showed that the slow decrease in blood pressure after nephrectomy followed the same 
time course as the decrease in vascular renin and contrasted with the rapid decrease in 
circulating renin.' In recent years a series of perfusion studies using the isolated rat 
Langendorff heart and isolated rat hindquarters have provided direct evidence for the 
local production of Ang I and II." ~ 26 Angiotensin production in these studies was 
dependent on the presence of renin in the perfusion fluid. 
Binding of renin to cell surface receptors may not only be the first step in 
endocytosis of the renin-receptor complex but may also transduce other membrane-
associated or intracellular eveuts. Receptor-mediated binding of human renin to human 
renal mesangial cells in culture has been reported to cause an increase in 
['HJthymidine incorporation and an increase in the concentration of plasminogen 
activator inhibitor-l antigen in the conditioned medium.' The concentration of renin at 
which these responses were observed was in the order of 100,000 fmoVmL. Tlus is 
much higher than the concentration used in our experinlents, which was 2500 flU/mL 
or approximately 50 fmoVmL. Even a concentration of 50 fmoVmL is very lugh; the 
nonnal concentrations of renin and prorenin in human plasma are approximately 0.5 
fmoVmL and 5 fmoVmL, respectively.27 However, the lower in-vivo concentrations 
may be sufficient, because in the in-vivo situation the cells are continuously exposed to 
pro renin canyil1g the marmOSe 6-phosphate signal, whereas in vitro this prorenin 
disappears from the culture medimn because of uptake by the cells. 
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Cellular binding and internalization of renin and prorenin and intracellular activation 
of prorenin may lead to local levels of enzyme activity that are higher than in the 
extracellular fluid. If angiotensinogen is internalized via bulk fluid endocytosis 
concurrently with the receptor-mediated endocytosis of renin and prorenin, a scenario 
is provided for intracellular Ang I generation. Ang II is known to stimulate 
plasminogen activator inltibitor-l production by renal mesangial cells." The reported 
increase in plasminogen activator inhibitor-l antigen in response to the binding of 
renin to these cells' would therefore fit in the view that this is an Ang II-mediated 
effect. However, the question of whether Ang I and/or II are formed within the cells is 
highly controversial. It is possible that the reported responses of mesangial cells to the 
cellular binding of renin are independent of Ang I and II formation. 
Our observations on the internalization of renin and prorenin and on the 
intracellular activation of prorenin warrant further studies addressing this issue. 
Internalized Ang II has a long half life compared with circulating Ang II." It rapidly 
accumulates in cardiac and vascular muscle cell nuclei,lO where it may bind to 
chromatin and may influence transcriptional processes that are related to the growth-
promoting effects of Ang II." Finally, recent experiments, in which Ang II was 
injected into cardiac myocytes and vascular smooth muscle cells, also favor the 
concept that intracellular Ang II may serve important functions. 32•33 Studies addressing 
the possibility of intracellular angiotensin generation may therefore hold promise. 
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Uptake and Proteolytic Activation of Pro renin by Cultured 
Human Endothelial Cells 
Chapter 5 
Abstract 
Tlus study was perfornled to investigate the mechanisms of vascular uptake of pro renin 
and renin and to explore the possibility of vascular activation of prorenin. For tlus 
purpose human umbilical vein endothelial cells (HUVECs) were cultured in a chenlically 
defined medirun and incubated Witll recombinant hrunan prorenin or renin in tile presence 
or absence of putative inhibitors of renin internalization. Cell surface-bolmd and 
internalized prorenin or renin were separated by the acid-wash metllOd and were 
quantitated by enzyme-kinetic assays. The activation of prorenin was also mOlutored by 
a direct irrununoradiometric assay (IRMA) with the use of a monoclonal antibody directed 
against tile -p24-Arg to -lp-Arg C-tenninal propeptide sequence of pro renin. Prorenin and 
renin were internalized at 37'C in a dose-dependent manner; with 1000 flU prorenin/mL 
medimll, the quantity of cell-associated prorellln after 3 hours of incubation was 9.3±1.0 
J.IU/4xlO' cells, and with 75,000 J.IU1mL medium it was 670±75 J.IU14xlO' cells 
(mean±SD; n=5). Results for renin were sinlilar. Prorenin that had been treated with 
endoglycosidase H to remove N-linked oligosaccharides was not internalized. Addition 
of mannose 6-phosphate (M-6-P) to the medium caused a dose-dependent inhibition of 
renin and prorenin internalization. Fifty percent inhibition was observed at 70 J.ImollL M-
6-P, whereas maJmose I-phosphate, glucose 6-phosphate and a-methylmannoside at this 
concentration had no effect. Arrunonirun chloride (50 nunollL) aJld monensin (10 J.ImollL) 
also inlubited internalization. Prorenin was activated by HUVECs, and cell-activated 
prorenin was only found in the intemalized fraction, whereas the surface-bound prorenin 
remained inactive. Thus, it appears tllat the activation of prorenin took place at the time 
of its internalization or thereafter. The results of the prorenin IRMA indicated that 
activation was associated with proteolytic cleavage of the propeptide. Our findings 
provide evidence for M-6-P receptor-dependent endocytosis of (pro )renin and proteolytic 
prorenin activation by vascular endothelial cells. 
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Introduction 
The fonnation of angiotensin (Ang) II at the vascular endothelial surface, through 
conversion of blood Ang I, by plasma membrane-bowld angiotensin-converting enzyme 
(ACE), is well established. Whether Ang I and renin are also produced by vascular tissue 
and how this may contribute to the Ang II-mediated actions of the renin-angiotensin 
system, however, is still a matter of debate. 
Experiments in which the isolated Langendorfi' rat heart was perfused with renin 
and angiotensinogen, provide evidence for Ang I production in the tissue not only in the 
interstitial fluid but also at the sOOace of cells or within the cells.'·2 Most of the locally 
produced tissue Ang I was released into the coronary circulation rather than the cardiac 
interstitial fluid, which suggests that the blood vessel wall was the main site of tissue 
Ang I production. 
Uptake of renin from the circulation by vascular tissue has been demonstrated and 
tIlere is experimental evidence that vascular, kidney-derived, renin, in conjunction with 
circulating renin, may serve to maintain blood pressure.'" Binding of renin to vascular 
tissue membranes has also been reported' and, in intact human gastroepiploic arteries, 
renin appeared to be present in endothelial cells. ' 
Recently our group reported that cultured neonatal rat cardiomyocytes and 
fibroblasts are capable of binding and internalizing prorenin and renin and of activating 
prorenin after its internalization.' The recombinant human prorenin and renin tllat were 
used in these experiments, were produced in Chinese hamster ovary (CHO) cells 
transfected ,vi til a vector containing hlmlatl prorenin cDNA. It is known tllat this prorenin, 
on the renin part of its molecule, carries tile marmose 6-phosphate signal that is 
recognized by specific receptors, '.9 and the observed binding and internalization of 
prorenin and renin by the cardiac cells and the subsequent activation of prorenin appeared 
to depend on mannose 6-phosphate receptors.' 
In the present study, we used cultured human umbilical vein endothelial cells 
(HUVECs) to investigate tile binding, internalization and activation of pro renin. 
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Native human prorenin, which has little or no intrinsic enzymatic activity, can be 
activated proteolytically by enzymatic cleavage of the propeptide, and non-proteolytically 
by a conformational change resulting in displacement of the propeptide from the cleft of 
the prorenin molecule, in which renin's active site is located. IO•12 The activation of 
prorenin by HUVECs was therefore investigated in two ways: I) by measuring the 
increase in enzymatic activity, and 2) by monitoring the cleavage of the propeptide with 
an immunoradiometric assay (IRMA) using a monoclonal antibody directed against a C-
tenninal sequence of the propeptide. 
Materials and Methods 
Reagents 
Mannose 6-phosphate, m3lmose I-phosphate, glucose 6-phosphate, a-methyhnrumoside, 
tJypsin, bovine senun albumin (BSA) 31ld monensin were from Sigma Chemical Co, St. 
Louis, MO, USA. Human serum albumin (HSA) was purchased from Behring, Marburg, 
Germ3ll)'. It was electrophoretic ally 100% pure. Human plasmin, 25 caseinolytic units 
per mg protein, was purchased from Kabi Vitrum, Miilndal, Sweden. Endoglycosidase 
H, 40 units per mg protein, 31ld fetal calf serum were from Boehringer Marmheim, 
Marmheim, Gelm3llY. The serine protease inhibitor aprotinin (trasylol), 7000 kallikrein-
inhibitory units per mg, was from Bayer, Leverkusen, Germany. The specific active site-
directed reniu inhibitor Ro 42,5892 (remikiren), molecular mass 727 Da, was kindly 
provided by dr W. Fischli, Hoffinrum-LaRoche, Basel, Switzerland. The K, value for the 
reaction witll hlilnan renin is 0.3 nmolfL.13 Monoclonal antibody (Mab) F258-37-BI was 
a kind gift of dr S. Mathews, Hoffillarm-La Roche, Basel, Switzerland. This antibody was 
raised against a synthetic peptide consisting of the -p24-Arg to -pl-Arg sequence of 
prorenin, i.e. the C-tenninal half of the propeptide. It was purified by (NH,),SO, 
precipitation followed by chromatography with dietlIylaminoethy1cellulose." Purity, as 
assessed by sodilllll dodecylsulphate-polyacrylamide gel electrophoresis was >98%. Mab 
F258-37-BI was biotinylated." "'I-labeled Mab RI-20-5 (specific activity 360 kBq/l!g) 
was purchased from Nichols lnstitute, Wychen, The Netllerlands. This antibody reacts 
with renin as well as with non-proteolytically activated prorenin and proteolytically 
activated prorenin, and does not recognize native prorenin. 16•11 
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Pro renin and renin preparations 
Recombinant Inunan prorenin, produced in CHO cells transfected with a vector 
containing Inunan prorenin cDNA, ".19 was kindly provided by dr W. Fischli, HoftinafUl-
La Roche, Basel, Switzerland. It was partially purified, to remove traces of renin, by 
Cibacron Blue Sepharose affinity chromatography.1O The intrinsic renin activity of the 
prorenin preparation, prior to proteolytic activation, was approximately 2% of the activity 
after complete proteolytic activation. Recombinant hwnan renin was prepared by 
conversion of recombinant human pro renin into renin by itmnobilized trypsin. 10.20 
Sepharose-bound trypsin (final concentration 0.25 mg trypsin/mL) was added to the 
prorenin preparation and the mixture was kept at 4 'C for 72 hours. Trypsin was then 
removed by centrifugation. After proteolytic activation the prorenin preparation contained 
approximately 8.5xlO' flU/mL renin. The prorenin and renin preparations were stored in 
the presence of 0.1% BSA at -70'C. 
Prorenin is a glycoprotein, the oligosaccharides being attached to the renin part of 
the molecule. In order to examine the role of oligosaccharides attached to human 
prorenin, 100 flL of the above prorenin preparation was incubated at 37'C for 24 hours 
with 80 ~IL of a solution containing I un.it!mL endoglycosidase H and 25 mmollL EDT A 
in 50 mmollL phosphate buffer, pH 5.5. Endoglycosidase H-treated prorenin, after its 
conversion to renin by trypsin-Sepharose, had the same activity in the enzyme-kinetic 
assay as untreated prorenitl. 
Cell cU/lure 
HUVECs were isolated from freshly obtained umbilical cords as previously described. 
'I Umbilical cords were obtained from the Department of Gynaecology and Obstetrics of 
the University Hospital Dijkzigt, Rotterdam, The Netherlands. Isolated HUVECs were 
cultured itl 75 cm' tissue culture flasks coated with fibronectin, using growth medium 
consisting of modified Medium 199 (Flow Laboratories, Irvine, UK), supplemented with 
5% fetal calf serum, 5% human serum, 18 flg/mL endothelial cell growth factor,21 
15 VlmL heparin (LEO Pharmaceutical Products, Weesp, The Netherlands), 50 U/mL 
penicillin (Flow Laboratories), and 5 flg/mL streptomycin (ICN Biochemicals, 
Zoetermeer, The Netherlands) at 37'C and 5% CO,in air. 
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Confluent cell cultures were trypsinized with I mL of 0.1 mglmL trypsin in phosphate-
buffered saline (140 mmollL NaCl, 2.6 mmolfL KCl, 1.4 mmollL KH,PO" 8.1 mmollL 
Na,HPO" pH 7.4; PBS) per culture flask. The cells were stored in liquid nitrogeu in small 
aliquots supplemented with 5% (voVvol) dimethyl sulfoxide. 
For a typical experiment an aliquot of HUVECs was thawed, the cells were 
washed once with growth mediwn and subsequently cultured to confluence in a 75 cm' 
tissue culture flask coated with fibronectin. Cells were trypsinized and seeded in 6-well 
plates (Becton and Dickinson, Franklin Lakes, NJ, USA). For most experiments HUVECs 
of passage number 3 or 4 were used. Studies were carried out approximately one day after 
confluency (corresponding with a density of 4 x 10' cells/well) had been reached. Prior 
to the start of each experiment, cells were washed three times with 3 mL warm (37°C) 
PBS. The cells were then preincubated either at 37"C or 4°C for 30 minutes with 0.9 mL 
incubation medium consisting of modified Mediurn 199 without fetal calf serum or 
hmnan senUll, but supplemented with 1% (wtlvol) HSA. 
Incubation of HUVECs with pro renin or renin 
After preincubation at 37"C or 4°C for 30 min in 0.9 mL medium (see above), 
experiments were started by the addition of 0.1 mL of a solution of recombinant human 
prorenin or renin to the wells to give a final concentration in the medium of 2500 IlU/mL. 
Cells were then incubated at 37"C or 4°C for up to 240 minutes. Incubations were also 
performed in the presence ofmannose 6-phosphate (2 ~lmolfL to 10 mmollL), mannose 
I-phosphate (8 IlmolfL to 8 mmollL), glucose 6-phosphate (8 IlmollL to 8 mmollL), cx-
methylmarulOside (8 ~11ll01/L to 8 mmol/L), ammonium chloride (50 mmol/L) or monensin 
(10 ~lmol/L). At the end of the incubation period, the culture medium was removed and 
quickly frozen on dry ice. Each well was washed three times with 3 mL ice-cold PBS. 
Renin and prorenin were not detectable in the last PBS wash. Cells were lysed in 0.5 mL 
ice-cold PBS containing 0.2% Triton X-100, and the cell lysate was quickly frozen on dly 
ice. Medium and cell lysate were stored at -70°C IlIltil assayed for prorenin or renin. 
To study the internalization and activation in more detail, cells were incubated 
with prorenin (fmal concentration, 75,000 IlU/mL) for 2 hours at 4°C. The cells were 
then washed three times with 3 mL ice-cold PBS. 
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After the last wash, 1 mL of fresh incubation medium without prorenin was added, and 
the cells were incubated at 37"C. The incubation was tenninated after 5, 15, 30, 60 or 
120 min by washing the cells 3 times with 3 mL ice-cold PBS. The cells were then lysed 
as described above. Medium and cell lysate were assayed for "total" prorenin (Le., 
prorenin that was activated by the cells plus prorenin that was not activated by the cells), 
cell-activated prorenin, and intact propeptide-containing prorenin. 
Internalized prorenin was separated from cell surface-bound prorenin by the acid-
wash method.Zl At low pH surface-bound prorenin dissociates from the cells; internalized 
prorenin, however, is acid-resistant. 7 Briefly, after the cells had been washed three times 
with 3 mL ice-cold PBS, the cells were incnbated at 4 'C with I mL of an acid solution 
containing 50 1llll101/L glycine and 150 1llll101/L NaCI, pH 3.0. After 10 minutes the acid 
solution was removed and the cells were washed three times with 3 mL ice-cold PBS. TIle 
cells were then lysed as described above. 
Enzyme-kinetic assays of prorenin and renin 
Renin and cell-activated prorenin were measured by incubating 100 IlL sample for 3 
hours with a saturating amount of sheep renin substrate at 37'C and pH 7.4 in the 
presence of serine protease and angiotensinase inhibitors.7•20 The generated Aug I was 
quantified by radioinnnunoassay. Results were expressed as IlU/mL using the 
international WHO human kidney renin standard, lot 68/356 (WHO International 
Laboratory for Biological Standards and Control, Potter Bar, Hertfordshire, UK), as a 
reference. The lower lintit of detection was one IIU per mL medium or per 4xlO' cells. 
To measnre "total" prorenin (i.e., cell-activated plus nonactivated prOrellln) with the 
enzyme-kinetic assay, the samples were incubated for 48 hours at 4 'C with plasmin 
(0.5 caseinolytic lUuts per mL). This preincubation with plasnlln caused complete 
proteolytic activation of proreninYo The serine protease inhibitor aprotinin (fmal 
concentration 100 kallikrein-inhibiting lUtits/mL) was added to the incubation mediunl 
of the Ang I generating step in order to inactivate plasmin. Recovery of renin or prorenin 
added to the cells before cell lysis was better than 95% (n=3). Mannose 6-phosphate, 
mannose I -phosphate, glucose 6-phosphate, a-methylmannoside, anunOluum chloride, 
and monensin in the concentrations we used in the cell cultures (see above) did not affect 
Aug I generation. 
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IlIllllllnoradiollletric assay of prO renin 
In order to monitor the proteolytic activation of prorenin by HUVECs, we developed a 
sandwich IRMA specific for intact prorenin, i.e. prorenin in which the propeptide was 
still bomld to the renin part of the molecule. The primary antibody of this assay, Mab 
F258-37-B 1, which is directed against the C-terminal part of the propeptide, did not react 
with native inactive pro renin. However, it did react with prorenin after the treatment of 
native prorenin with the renin inhibitor remikiren (0.1 mmollL) for 48 hours at 4°C. The 
renin inhibitor enters the enzymatic cleft in which the active site is located, thereby 
inducing a slow conformational change of the inactive (,closed') form of the prorenin 
molecule into the active ('open') form.12 By this non-proteolytic conformational change, 
the propeptide moves to the surIace of the molecule so that it can react with Mab 
F258-37-Bl. In the IRMA, 200 ~L ofremikiren-treated sanlple was incubated for 6 hours 
at 37"C with an avidin-coated bead of8 mm diameter to which 1.6 Ilg ofbiotinylated 
Mab F258-37-B I had been bound. The bead was then washed three times with 2 mL 
PBS; and subsequently incubated with 100 ~L (250,000 cpm) of the "'I-labeled Mab 
RI-20-5 (secondaty atltibody) and 200 ~L assay buffer of the Nichols renin-kit (Nichols 
Institute, Wychen, The Netherlands) for 24 hours at room temperature. After the 24 hour-
incubation period, ti,e bead was washed three times with 2 mL PBS, atld bOlmd 
radioactivity was measured in a ganuna counter. The results of this assay were expressed 
as II U/mL using intact recombinatlt hmnan prorenin as a reference. The lower limit of 
detection was 5 ~U per mL mediUlll or per 4xlO' cells. 
Results 
Figure 1 shows the results of incubating HUVECs at 37"C or 4°C after either prorenin 
(left panel) or renin (right panel) had been added to the culture medium, both at a 
concentration of2500 IIU/mL. At 37"C the level of cell-associated prorenin rose over 
time tultil a plateau was reached after 3 hours. With initial concentrations of prorenin in 
the mediUlll ranging from 1000 ~U/mL to 75,000 ~U/mL, the maximum level of prorenin 
in the cell Iysates was proportional to the concentration in the medium (results not 
shown). 
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!twas 9.3±1.0 !!U/4xlO' cells at an initial concentration in the medium of 1000 flUlmL, 
and 670±75 !!Ul4xlO' cells at a concentration in the medium of 75,000 !!UlmL 
(mean±SD, n=5). These levels represent approximately 1 % of the amounts added to the 
mediwn. At 4 'C, less than 0.4% of prorenin added to the mediwn was bound to the cells 
(Figure 1, left panel). Similar results were obtained when renin was added to the mediwn 
(Fignre 1, right panel). 
Cell-associated prorenin was activated dnring culture at 37'C but not at 4 'C 
(Fignre 1, left panel). Prorenin in the mediwn remained inactive for the full 240-minute 
incubation period both at 37'C and at 4 'C. 
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Figure I. Increase in cell-associated prorenin (left panel) and renin (right panel) over time during 
incubation ofHUVECs at 37'C (solid line) or 4'C (dotted line) with inactive prorenin or with 
renin (both 2500 !!U/mL). The open circles in the left panel represent the cellular levels of total 
(cell-activated plus nonactivated) pro renin. The closed circles in the left panel represent the 
cellular levels of cell-activated prorenin. The open circles in the right panel represent the cellular 
levels of renin. Measurements were made by the enzyme-kinetic assay. Measurements at time zero 
were made in cells that had been separated from the medium immediately after the addition of 
prorenin or renin. Data are means and SD, n=5. 
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To investigate whether the results were influenced by the number of cell passages, 
primary HUVEC cultures and passages I to 5 were incubated with prorenin (initial 
concentration in the medium 2500 flU/mL) at 37'C. The concentration of pro renin in the 
celllysates, expressed as flU/flg protein, in the passages I to 5 was similar to that in the 
prinlary culture (Figure 2). The fraction of cell-associated prorenin that was in an 
activated form was also similar. 
J.lU prorenlni 160 
mg protein 
J.lg protelni 
4x10'celis 
120 
80 
40 
o 
200t 100 o 
number of passages 
I 
o 2 3 4 5 
Figure 2. Upper pallel. Cell-associated prorerun after 240 minutes of incubation of primary 
cultures of HUVECs and passages 1-5 with inactive prorenin (2500 llUlmL) at 37'C. Bars 
represent the levels of total (cell-activated plus nonactivated) prorerun. The hatched area 
represents the level of cell-activated prorerun. Measurements were made by the enzyme-kinetic 
assay. Lower pallel. Cellular protein content ofHUVECs. Data are means of two experiments. 
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Lysates of HUVECs that had been incubated with prorenin (initial concentration in the 
medium 2500 IlU/mL) for 180 and 240 minutes at 37'C, were prepared with and without 
acid-pretreatment of the celts, in order to distinguish between internalized (acid-resistant) 
prorenin and celt surface-bound (acid-washable) prorenin_ After incubation at 37'C, more 
than 90% of the celt-associated prorenin was acid-resistant both in the 180-minute and 
240-lninute cultures (n=5 in both cases, results not shown). When HUVECs were fIrst 
incubated with prorenin at 4 'C and then at 37'C in fresh medium to which no prorenin 
had been added, a large fraction of the celt-associated prorenin was released into the 
medium within 15 minutes (data not shown)_ The remainder (about 12%) was slowly 
internalized, with a half-tinle of internalization of approximately 15 minutes (Figure 3). 
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Figure 3. Time course of internalization and activation of prorenin by HUVECs. The cells were 
preincubated with inactive prorenin (75,000 ~UfmL) for 120 minutes at 4'C. They were then 
washed with ice-cold PBS. Fresh culture medium free of prorenin was added, and the incubation 
was continued at 37°C. The cellular level of total (cell-activated plus nonactivated) prorenin at 
the end of the preincubation at 4°C was approximately 500 f,Uf4xlO' cells (100%). The acid-
wash method was used to separate surface-bound (nonacid-resistant) prorenin and internalized 
(acid-resistant) prorenin. Measurements were made by the enzyme-kinetic assay. Data are means 
of3 experiments. 
109 
Chapter 5 
The percentage of cell-associated prorenin that was in the activated fornl rose over time, 
and all cell-activated prorenin appeared to be located in the cells, whereas all cell surface-
bound prorenin was still in the inactive form (Figure 3). These results indicate that the 
activation process took place at the time of the internalization of prorenin or thereafter. 
There was no evidence for release of activated prorenin into the medium. 
When HUVECs were incubated for 240 lninutes at 37'C with prorenin (2500 
flU/mL) that had been treated with endoglycosidase H, less than 0.2% of the prorenin was 
internalized by the cells (n=3, results not shown). Thus, it appears that N-linked 
oligosaccharides attached to prorenin are importaut for its uptake by HUVECs. 
The question of whether the internalization of renin aud prorenin could be 
mediated by maunose 6-phosphate receptors at the cell surface, was addressed by 
experiments, in which the cells were incubated at 37'C for 4 hours in a medium to which 
renin or prorenin had been added both at a fmal concentration of 2500 fl U/mL, as well 
as marUlose 6-phosphate in concentrations ranging from 2 ~lmollL to 2 lllIllollL. Figure 4 
shows the results obtained with prorenin. As mentioned above, after culture at 37'C for 
4 hours in the absence of maunose 6-phosphate, practically all cell-associated prorenin 
was resistant to the acid-wash, indicating that prorenin had been internalized by the cells. 
Maunose 6-phosphate had a dose-dependent inhibitory effect on prorenin internalization. 
Inhibition was maximally 85-90%, and the IC" was approximate'Iy 70 flmollL. Maunose 
I-phosphate also inhibited prorenin internalization but only at concentrations of 2 mmollL 
or higller. Glucose 6-phosphate aud a-methyhnaunoside up to 8 mmollL had no inhibitory 
effect. Shnilar results were obtained with renin (results not shown). 
When HUVECs were incubated with prorenhl in the presence of ammonium 
chloride (50 mmollL) or monensin (10 flmollL), the internalization of prorenin was 
markedly diminished (Figure 5). Moreover, practically all cell-associated prorenin 
remained inactive under these circumstances. This was also the case when mrumose 6-
phosphate (10 mmollL) had been added to the culture medium. 
A series of experiments was carried out to answer the question of whether the 
activation of pro renin by HUVECs was a proteolytic process. It is known that, in vitro, 
prorenin cau also be activated by a non-proteolytic proces, by exposure to acid milieu."·12 
The results, which are shown in figure 6, indicate that the activation of prorenin by 
HUVECs was associated with the proteolytic cleavage of the propeptide. 
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Figure 4. Cell-associated total (cell-activated plus nonactivated) prorenin after 240 minutes of 
incubation of HUVECs with inactive prorenin (2500 ~U/mL) at 37"C in the presence of 
increasing concentrations of mannose 6-phosphate (M-6-P), mannose I-phosphate (M-I-P), 
glucose 6-phosphate (G-6-P) or a-methylmannoside (a-MM). Measurements were made by the 
enzyme-kinetic assay. Values (means of 3 experiments) are expressed as a percentage of the 
values obtained under control conditions. 
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Cell-associated prorenln 
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Figure 5. Cell-associated prorenin after 60 minutes and 240 minutes of incubation ofHUVECs 
with inactive prorenin (2500 flU/mL) at 37°C in the presence or absence of ammonium chloride 
(50 nunoVL), monensin (10 f1moVL), and mannose 6-phosphate (10 mmoVL). Bars represent the 
levels of total (cell-activated plus nonactivated) prorenin. The hatched area represents the level 
of cell-activated prorenin. Cell-activated prorenin was not detectable in cells incubated in the 
presence of ammonium chloride, monensin or mannose 6-phosphate. Measurements were made 
by the enzyme-kinetic assay. Data are means and SD, n~4. 
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Figure 6. Time course of Ihe proteolytic activation of prorenin. HUVECs were incubated with 
prorenin (75,000 J.lUlmL) for 120 minutes at 4"C. They were then washed with ice-cold PBS. 
Fresh incubation medium free of pro renin was added, and the incubation was continued at 37"C. 
The cellular level of total (cell-activated plus nonactivated) prorenin at the end of the 
preincubation at 4"C was approximately 500 J.lU/4xlO' cells (100%). The left panel shows the 
ceUular levels of total prorenin, nonactivated prorenin and cell-activated prorenin measured by the 
enzyme-kinetic assay. The right panel shows the cellular level of propeptide-containing prorenin 
measured by an IRMA specific for intact propeptide-containing prorenin. Changes in the level of 
pro peptide-containing prorenin over time as measured by IRMA are similar to the changes of 
nonactivated prorenin as measured by the enzyme-kinetic assay, thereby demonstrating that 
activation of pro renin is associated with the proteolytic removal of the propeptide. Data are means 
of3 experiments. 
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Discussion 
Our results demonstrate that cultured HUVECs internalize recombinant human prorenin 
and renin and that these cells activate prorenin at the time of its internalization or 
thereafter. The internalization process appears to be mannose 6.phosphate receptor· 
dependent; inhibition with mannose 6·phosphate was specific and saturable. Two types 
of mannose 6.phosphate receptors have been identified, i.e. the cation·dependent and 
cation·independent types'>"" The cation·independent type receptor is identical with the 
insulin· like growth factor II receptor (IGFIIIM·6·P receptor). Both types of receptor 
function in the process of intracellular lysosomal enzyme sorting. The IGFIIIM·6·P 
receptor also mediates the endocytosis of extracellular lysosomal enzymes."'" Because 
of this and because ofthe structural homology between renin and the lysosomal enzyme 
cathepsin D, we assume that it is the IGFIIIM·6·P receptor that is involved in the 
internalization of prorenin and renin by HUVECs. TIle IC" of the inhibition of (pro )renin 
internalization by mannose 6·phosphate was approximately 70 IlmolfL, which is close to 
the IC" of other IGFIIIM·6·P receptor·mediated processes."·27 Mannose 6.phosphate, 
however, did not cause complete inhibition, which indicates that some (pro )renin was 
internalized by a mechanism independent of the M·6·P marker. 
At concentrations of pro renin in the culture medium ranging from 1000 to 75,000 
IlUlmL, which is 4·300 times the normal concentration in human blood plasma, the 
maximum level of cell·associated prorenin, which was reached after 3 hours of incubation 
at 37'C, was proportional to the prorenin concentration in the medium; it was about 1% 
of the amount of prorenin added to the medium. Apparently, the fact that the cell Iysates 
contained ouly a small fraction of the added prorenin, was not related to a high level of 
receptor occupancy. The recombinant human prorenin preparation we used had been 
produced by CHO cells.'~\91t has been reported that ouly a small fraction of this prorenin 
contains the mannose 6·phosphate signal,"u and this may explain why the amount of cell· 
associated prorenin was ouly I % of the amount added to the cultures. 
The internalization of prorenin by HUVECs was not ouly inhibited by mannose 
6.phosphate but also by anunonium chloride and monensin, which are known to interfere 
with the recycling of internalized receptors to the cell surface." 
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The low level of cell-associated prorenin in the presence of anlllOnilln chloride and 
monensin may indicate that receptor recycling is an important factor determining prorenin 
uptake by HUVECs. Receptor recycling may also explain why during incubation with 
prorenin at 37"C, cell-associated prorenin rose to levels that were several times higher 
than during incubation at 4 'C. 
Prorenin, which has no enzymatic activity, can be reversibly activated in vitro by 
exposure to acid. In vivo, this might occur in the acid milieu of endosomes. Our results, 
however, show that the activation of prorenin by HUVECs was associated with 
proteolytic cleavage of the propeptide, most likely through the action of a cell-bound 
protease. It is unlikely that this activation has occurred as an artifact during preparation 
of the cell lysates, because the lysates of cells that had been incubated with prorenin at 
4 'C were free of activated prorenin. 
A previous study of cultured neonatal rat cardiomyocytes and fibroblasts, using 
the same concentrations of (pro )renin as in the present study, also provided evidence for 
IGFIIIM-6-P receptor-dependent endocytosis of (pro )renin and for the activation of cell-
bOllld prorenin7 111ere are, however, some quantitative differences between the results 
obtained with HUVECs and the cardiac cells. At 4 'C the cardiac cells bound a larger 
fraction of the (pro )renin that had been added to the culture medi1lln than the HUVECs 
did, thereby indicating that the IGFIVM-6-P receptor density at the cell surface was 
higher in the cardiac cells. In addition, at 37'C, the internalization and activation of 
prorenin after its binding to the cell surface proceeded faster in the cardiac cells. When 
HUVECs were incubated for 2 homs with prorenin at 4 'C and then incubated at 37'C 
in the absence of prorenin, less than 15% of the cell surface-bound prorenin was 
internalized, while the remainder was released into the medium. In similar experiments 
in cardiac cells, more than 50% was internalized. Despite such differences, the 
mechanisms involved in binding, internalization and activation of prorenin might 
basically be the same for HUVECs and cardiac cells. 
Binding and internalization of lysosomal enzymes to the IGFIVM-6-P receptor 
results in intracellular degradation of these enzymes."'" This receptor may therefore 
serve as a clearance receptor for (pro )renin. 
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In view of the IGFII/M-6-P receptor-dependent prorenin activation by vascular 
endothelial cells, as observed in our study, it is also possible that these cells contribute 
to local angiotensin I and II formation by the blood vessel wall. Early experiments by 
Swales' group demonstrated uptake of kidney-derived renin by the aortic wall in vivo.' 
These experiments also indicated that vascular kidney-derived can contribute to the 
maintenance of elevated blood pressure in two-kidney, one-clip hypertension.' Our results 
reported here might provide a mechanism for the vascular uptake of renin and prorenin. 
Our results are also relevant ,vith respect to observations made in isolated rat hindquarters 
and the isolated rat Langendorffheart, which provided evidence for the release of locally 
produced angiotensins into the circulation during perfusion with renin. 1.2,"-32 Studies of 
the regional production of angiotensin I in various extrarenal vascular beds in pigs 33.34 
and hUlllans 35.36 also provided evidence for the release of locally produced angiotensin 
I into the circulation, over and above angiotensin I fonnation by the reaction of 
circulating renin ,vith circulating angiotensinogen. Since, in humans, the level of prorenin 
in circulating blood is nonnally several times higher than the level of renin, and in view 
of our finding that prorenin is activated in vitro by vascular endothelial cells, it is 
conceivable that not only renin but also prorenin contributes to angiotensin generation by 
the blood vessel wall. 
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Prorenin, Renin, Angiotensinogen and Angiotensin-Converting 
Enzyme in Normal and Failing Human Hearts. 
Evidence for Renin-Binding. 
Chapfer 6 
Abstract 
A local renin-angiotensin system in the heart is often invoked to explain the beneficial 
effects of ACE inhibitors in heart failure. The heart however produces little or no 
renin under normal conditions. In this study we compared the cardiac tissue levels of 
renin angiotensin system components in 10 potential heart donors who died of non-
cardiac disorders and 10 subjects with dilated cardiomyopathy (DCM) who underwent 
cardiac transplantation. Cardiac levels of renin and prorenin in DCM patients were 
higher than in the donors. The cardiac and plasma levels of renin in DCM were 
positively correlated and extrapolation of the regression line to nOIDlai plasma levels 
yielded a tissue level close to that measured in the donor hearts. The cardiac tissue-to-
plasma concentration (TIP) ratios for renin and prorenin were threefold the ratio for 
albumin, which indicates that the tissue levels were too high to be accOlmted for by 
admixture with blood and diffusion into the interstitial fluid. Cell membranes from 
porcine cardiac tissue bound porcine renin with high affmity. The TIP ratio for ACE, 
which is membrane-bound, was fivefold the ratio for alblllnin. Cardiac 
angiotensinogen was lower in DCM patients than in the donors and its TIP ratio was 
half that for albumin, which is compatible with substrate consumption by cardiac 
renin. These data in patients with heart failure support the concept of local angiotensin 
production in the heart by renin that is taken up from the circulation. Membrane-
binding may be part of the uptake process. 
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Introduction 
The RAS plays an important role in the regulation of blood pressure and salt and fluid 
homeostasis. The kidney releases both renin and its inactive precursor prorenin into 
the circulation. Liver-derived angiotensinogen is cleaved in the circulating blood by 
renin, to form Aug I, which is then converted by ACE, located on the luminal side of 
the vascular endothelium, into Aug II, a potent vasoconstrictor and stinmlant of the 
release of aldosterone. 
Agents that interfere with Aug II formation, the ACE inhibitors in particular, 
are now widely used for the treatment of hypertension and heart failure. Clinical 
studies indicate that the beneficial effects of ACE inhibitor treatment in heart failure 
and left ventricular hypertrophy are not solely determined by the effect of ACE 
inhibition on systemic arterial pressure.'" It is, therefore, postulated that these 
beneficial responses are independent, at least partly, of the effects of ACE inhibition 
on the circulating RAS. 
There is growing evidence to suggest that in cardiac tissue, Aug II is produced 
locally and does not originate from circulating Aug IY However, whether the cardiac 
Aug I and II production depends on renin from the kidney, remains a matter of 
dispute. In normal cardiac tissue of mice and rats, renin mRNA levels are undetectable 
or extremely low"" In support of this fmding is the fact that, after bilateral 
nephrectomy in the pig, cardiac renin, Aug I and Aug II decrease to levels at or below 
the detection limit'; the same is true for cardiac Ang I and II in the rat.' Renin 
expression, however, may be induced under pathological conditions. Renin mRNA 
can be detected in rat ventricle after myocardial infarction' and in rat atrium aft~r low-
sodium diet and treatment with the ACE inhibitor enalapril. 9 
Augiotensinogen and ACE mRNAs have been detected in nornlal cardiac 
tissue. IO·" Angiotensinogen mRNA is increased during post-infarction ventricular 
remodeling in the rat", and ACE mRNA is increased during pressure overload-
induced ventricular hypertrophy in the rat" and heart failure in humans." Increased 
levels of ACE activity have been found in left ventricular aneurysms of patients after 
myocardial infarction." 
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In the present study we measured the tissue levels of prorenin, renin, angiotensinogen 
and ACE in normal and failing human hearts. We compared the tissue levels of these 
RAS components with the levels in simultaneously obtained plasma, to address the 
possibility of cardiac angiotensin formation independent of kidney-derived renin. The 
possibility of sequestration of circulating renin by cardiac tissue through binding to 
cardiac cell membranes was investigated in renin-binding studies, with the use of 
cardiac membranes from freshly obtained porcine hearts. 
Materials and Methods 
Col/eclion of cardiac lisslle and blood samples 
Left ventricular tissue was obtained from 10 subjects (9 men and I woman; age, 30 to 
64 years) with end-stage DCM (origin: ischemic heart disease, 7; idiopathic, 2; Becker 
muscular dystrophy, I) undergoing cardiac transplantation, and from 10 subjects 
(5 men and 5 women, age, 3 to 54 years) who had died from non-cardiac causes 
(cerebrovascular accident, 4; polytrauma, 4; brain tumor, n=2) <24 hours before the 
tissue arrived in the laboratory. The heart donors were not on cardiovascular 
medication. The medication of one subject with end-stage DCM could not be retraced. 
Of the remaining 9 subjects, 9 were receiving a diuretic; 8, an ACE inhibitor 
(captopril, 5 [average dose 56.25 mg/d); enalapril, 3 [average dose 10 mg/d); 6, a 
positive inotropic drug; 3, an antiarrhythmic drug; 2, isosorbide dinitrate I, nifedipine; 
and I, hydralazine. 
The donor hearts were provided by the Rotterdam Heart Valve Bank (Bio 
Implant Services FoundationlEurotransplant Foundation) after removal of the aortic 
and pUhnonary valves for homograft valve transplantation. The hearts had been taken 
out of the body innnediate1y after circulatory arrest and maintained at 0° to 4°C in a 
sterile organ-protecting solution (University of Wisconsin-, EuroCollins-, or HTK-
Bretsclmeider-solution)." After arrival in the laboratory, a 5 to IO-g piece of left 
ventricular free wall was dissected from the heart and stored at -70°C. Pieces of left 
ventricular free wall (3 to 5 g) taken from the failing hearts were frozen in liquid 
nitrogen and also stored at -70°C, innnediately after the heart had been removed from 
the body. 
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Blood was obtained from 6 cardiac transplant recipients at the time of transplantation. 
Blood samples were collected into polystyrene tubes containing trisodimn citrate (final 
concentration in blood, 0.013 mollL), and centrifuged at 3000 g for 10 minutes at 
room temperature. Plasma was stored at -70°C and assayed within I month. 
Frozen cardiac tissue (" 1 g) was rapidly minced into small pieces and 
homogenized (1:2 [w/vol]) in 0.D1 mollL phosphate buffer, pH 7.4, containing 0.15 
mollL NaCI, with a Polytron PTlO/35 (Kinematica).' The cardiac tissue homogenates 
were stored at -20°C and assayed within 1 week. 
Measurements of renin and pro renin 
Renin in plasma was quantified by measuring Ang I generation at pH 7.4 during 
incubation at 37°C with a saturating concentration of sheep angiotensinogen in the 
presence of angiotensinase, ACE, and serine protease inhibitors (routine enzyme 
kinetic assay). Ang I generation under these conditions is linear for at ~3 hours and 
the recovery of Ang I added to plasma before the incubation step at 37°C is 98%.16 
Due to the presence of high angiotensinase activity in cardiac tissue homo-
genates, Ang I generation cannot be measured by the routine enzyme kinetic assay in 
these homogenates, despite the addition of angiotensinase inhibitors.' Thus, to reliably 
measure Ang I-generating activity in cardiac tissue homogenates, the angiotensinases· 
must be removed (e.g., through an acidification step )'.16 or the breakdown of Ang I 
must be prevented by rapidly binding it to an Ang I antibody (antibody-trapping 
enzyme kinetic assay).'·" Because acidification also leads to activation of prorenin'·I8, 
we used the antibody-trapping enzyme kinetic method to measure renin in the cardiac 
tissue homogenates. With this assay, we found Ang I-generation at 37°C to be linear 
for 30 minutes In addition, the recovery of [Ile5]-Ang I added to cardiac tissue 
homogenates before incubation at 37"C was >75% (n=4). Results of the routine 
enzyme kinetic and antibody-trapping assays show good agreement.' 
Prorenin was first converted into renin (activation) and then measured with the 
routine enzyme kinetic assay. Prorenin in plasma was activated with Sepharose-bound 
trypsin." Based on our experience with the activation of prorenin in tissues,'·" we 
tested two different procedures to convert cardiac prorenin into renin (i.e., 
acidification only or acidification followed by treatment with plasmin at neutral pH). 
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Tissue homogenate was acidified through dialysis at 4°C for 48 hours against 0.05 
mollL glycine buffer, pH 3.3, containing 0.001 mollL disodium EDTA and 0.095 
mollL NaC!. This was followed by (1) dialysis at 4°C for 24 hours against 0.1 mollL 
phosphate buffer, pH 7.4, containing 0.001 mollL disodium EDTA and 0.075 mollL 
NaCI or (2) quick adjustment of pH to 7.4 with 1 mollL NaOH and the subsequent 
addition of 0.2 vol of a solution of hlUnan plasmin (final concentration, 1 casein 
unit/mL) in 0.15 mollL NaCI and incubation at 4°C for 48 hours.',,, The acidification 
step in the two procedures effectively removed the angiotensinase activity; the 
recovery of [He5J-Ang I added to cardiac tissue homogenate at pH 7.4, after acid-
treatment or acid-and-plasmin treatment, was >95% in the routine enzyme kinetic 
assay (n=4). 
Acid-treatment of cardiac tissue homogenate followed by restoration of pH to 
7.4 and treatment with plasmin led to virtually complete activation of prorenin, as was 
demonstrated by the >90% conversion and recovery of human recombinant prorenin (a 
gift of dr W. Fischli, Hoffmann-La Roche, Basel, Switzerland)' that was added to the 
homogenates before the activation step (n=3). Acid-treatment followed by restoration 
of pH to 7.4 without subsequent plasmin treatment led to less-complete activation of 
prorenin; the recovery of added prorenin, measured as renin, was 65% to 78% (n=3). 
The cardiac tissue homogenates were therefore activated by the combined acid-and-
plaslnin method. 
All samples were assessed in duplicate. Results are expressed as flUlmL or 
flUlg with the use of the international human kidney renin standard MRC 68/356 
(Medical Research COlUlCil, National Institute of Biological Standards and Control, 
London, UK) as a reference. The normal range in plasma is 8 to 55 flU/mL for renin 
and 88 to 390 flU/mL for prorenin.20 
Identification of cardiac Ang I-generating activity as renin. 
Part of the Ang I-generating activity of cardiac tissue homogenates may be related to 
the presence of pseudorenin (e.g., cathepsin D).21 To distinguish true renin from 
pseudorenin, we used the specific renin inhibitor remikiren, which has an IC" value of 
7 x 10.10 mollL for human renin and 3.5 x 10" mollL for bovine cathepsin D." 
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Percent inhibition of Ang I-generating activity was determined at inhibitor 
concentrations ranging from lO. lI to 10·' mollL. The inhibition curves for cardiac 
tissue homogenates were compared with those for plasma and the human kidney renin 
standard MRC 68/356. 
We also used monoclonal renin antibodies to identify Ang I-generating activity 
as 'true' renin. For this pupose, renin was measured with a sandwich 
iJlllnunoradiometric assay." Monoclonal antibody R 3-36-1623, which reacts equally 
well with renin and prorenin, was biotinylated and served as a primary antibody in the 
assay." Monoclonal antibody R 1-20-5", which reacts with renin but not with 
prorenin, was labeled with "'I (specific activity, 740 kBeq/flg) and served as the 
secondary antibody. The results of this assay were expressed as flU/g using the human 
kidney renin standard MRC 68/356 as a reference. 
Binding of renin (0 cardiac membranes 
Cardiac membranes were prepared from freshly obtained porcine left ventricular tissue 
(20 g) as previously described.' The membrane fraction contained both plasma- and 
sarcoplasmic reticulum-membranes. Semipurified kidney renin was prepared from 
porcine kidney.' Twenty-five flL of the cardiac membrane fraction, containing ~ 125 
fig protein, was incubated in a shaking waterbath at 37°C and pH 7.4 for 2 hours with· 
250 IlL semi-purified porcine kidney renin at six different concentrations (20 to 400 
pmol Ang I/min per mL). Non-specific binding was measured by incubating renin with 
membranes that had been heated for 10 minutes at 95°C. The incubation was 
terminated by the addition of 3 mL of ice-cold om moVL phosphate buffer, pH 7.4, 
containing 0.15 mollL NaCl, followed by rapid vacuum filtration through a Whatman 
GFIB filter. Filters were washed four times with 3 mL phosphate buffer and incubated 
with sheep angiotensinogen to measure renin according to the routine enzyme kinetic 
assay. The dissociation constant (Kd) and the maximum number of binding sites (Em • .) 
were calculated from plots according to Scatchard." 
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Measurements of angiotensinogell, ACE alld senlln albumin 
Angiotensinogen was measured as the maximnm quantity of Aug I that was generated 
during incubation at pH 7.4 and 37°C with a high concentration of human kidney 
renin (10 mU/mL) in the presence of inhibitors of ACE and angiotensinases". The 
nonnal range in plasma is 745 to 2340 pmollmL."·" 
ACE was measured with a commercial kit (ACE Color, Fujirebio; nonnal 
range, 7 to 20 mU/mL).29 
Serum albumin was measured with single radial immunodiffusion (LC and 
NOR-Partigen plates, Behringwerke) according to the method of Mancini et al." The 
nonnal range is 22 to 43 mg/mL." 
Statistical analysis 
Differences between cardiac transplant recipients and donors were evaluated for 
statistical significance by using Student's t-test or Mann-Whitney's U-test for unpaired 
observations. Statistical significance was accepted at P<0.05. 
Results 
Levels of renin, prorenin, angiotensinogen and ACE in cardiac tissue 
The specific renin inhibitor remikiren, at concentrations of 10-' mol/L, caused virtually 
complete inhibition of the Aug I-generating activity in the acid-and-plasmin treated 
cardiac tissue homogenates (Figure 1). The inhibition curve (relating the degree of 
inhibition to the inhibitor concentration) for cardiac tissue homogenate treated with 
acid followed by plasmin was identical to the curves for untreated plasma and the 
human kidney renin standard, which supports the asslUnption that the measured Aug 1-
generating activity of cardiac tissue homogenate is a valid estimate of true renin. The 
IC" value was ~3 x 10·\0 mol/L, which is in accordance with reports in the literature." 
The inhibition curve for untreated cardiac tissue homogenate differed somewhat from 
the inhibition curves for plasma renin and kidney renin (Figure 1); the difference can 
be accounted for by assuming that 30% of the Aug I-generating activity in untreated 
cardiac homogenate was caused by pseudorenin. 
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We therefore measured true renin in untreated cardiac tissue homogenates as the 
difference between the Aug I-generating activity in the absence of remikiren and the 
Aug I-generating activity in the presence of 10" mollL remikiren. 
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log CONCENTRATION OF RENIN INHIBITOR 
Figure 1. Inhibition of angiotensin I-generating activity by increasing concentrations of the 
renin inhibitor remikiren. Closed circles indicate untreated cardiac tissue homogenate; open 
circles, cardiac tissue homogenate pretreated with acid and plasmin; open triangles, human 
kidney renin standard MRC 68/356; and closed squares, plasma. 
Comparison between the results of the enzyme kinetic and immunoradiometric assays 
of renin in cardiac tissue homogenate and plasma from 5 subjects with OCM s!lowed 
good agreement (Figure 2), confmning that the enzyme kinetic assay is indeed a valid 
measurement of true renin. According to the enzyme kinetic assay, the plasma 
concentration of naturally occurring renin in subjects with OCM was 80±23% 
(mean±SO) of the renin concentration after prorenin activation compared with 
65±33% according to the immlUlOradiometric assay (difference not significant). The 
cardiac tissue concentration of naturally occurring renin in these subjects was 59± 19% 
of the renin concentration after prorenin activation in the enzyme kinetic assay and 
77±II% in the inununoradiometric assay (difference not significant). 
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Figure 2. Renin measured by enzyme kinetic assay YS, renin measured by immunoradiometric 
assay in cardiac tissue (circles) and plasma (squares), before (open symbols) and after (closed 
symbols) prerenin activation (p.92, P<.Ol). 
Figure 3 is a comparison of the cardiac tissue levels of renin, prorenin, angio-
tensinogen, ACE and serum albumin between the DCM patients and the donors. The 
levels of renin and prorenin were more than fivefold higher in the patients, whereas 
angiotensinogen was lower. Cardiac ACE was not different between the two groups. 
The cardiac tissue level of serum albumin was somewhat higher in the DCM patients 
than in the donors. 
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Figllre 3. Renin, prorenin, angiotensinogen, ACE and albumin in cardiac tissue of heart donors 
(closed circles) and patients with dilated cardiomyopathy (open circles). Prorenin was below 
the detection limit in 7 donors and one patient. Medians (renin and prorenin) and means 
(angiotensinogen, ACE and albumin) are shown. Differences between donors and patients 
were tested by Mann-Whitney's U-test (renin and prorenin) or Student's I-test 
(angiotensinogen, ACE and albumin) for unpaired observations. Plasma levels at the time of 
heart transplantation was available for 6 of the 10 OCM cases. 
Plasma renin in these subjects ranged from 472 to 3028 IlUlmL, which is more than 
sevenfold the nonnalleve!. Plasma prorenin ranged from 180 to 1214 11UlmL, and in 3 
subjects it was above nonna!. Plasma angiotensinogen ranged from 77 to 484 
pmollmL, which is below the nonnal range. Plasma ACE ranged from 5.8 to 28.9 
mUlmL, and in 3 subjects it was above nonna!. Albumin in plasma was nonnal; it 
ranged from 22 to 34 mglmL. 
The cardiac tissue-to-plasma concentration ratio for serum albumin was ~ 12% 
(Figure 4), which is in agreement with the fact that the localization of this protein is 
restricted to the extracellular fluid. Albumin (molecular mass, 70 kD) is known to be 
present in the interstitial fluid albeit in lower concentrations than in plasma.'! 
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The cardiac tissue-to-plasma concentration ratio for angiotensiuogen (molecular mass, 
65 kD) was 6%, which is iu keeping with the contention that cardiac angiotensinogen 
is also localized ill the extracellular fluid. The lower ratio for angiotensiuogen than for 
albumin may suggest that the angiotensiuogen consumption rate, and therefore the 
Aug I production rate, is higher in cardiac tissue than iu circulating plasma. 
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Figure 4. Cardiac tissue-ta-plasma concentration ratios for renin, prorenin, angiotensinogen, 
ACE and albumin in patients with DCM. Data are meanS±SD ·P<.005 albumin; #P<.05 
albumin (Student's t-test for paired observations). 
The cardiac tissue levels of reniu and angiotensillogen were negatively correlated 
(Figure 5), most likely because increased renin leads to increased substrate 
consumption. The cardiac tissue-to-plasma ratio for ACE was 54%, which was much 
higher than the ratio for serum albumin. Most of the ACE in cardiac tissue is probably 
cell membrane-bolllld'. The cardiac tissue-to-plasma concentration ratios for renin and 
prorenin (molecular mass, 48 and 54 kD respectively) were 30% and 36%, which was 
also higher than the ratio for semm albumin. This suggests that the localization of 
these proteius is not restricted to the extracellular fluid compartment. 
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The cardiac tissue levels of renin in the subjects with DCM were directly correlated 
with the plasma levels of renin (log [cardiac renin) = 0.50 x log [plasma renin)+0.93; 
r=.84, P< 0.05). There was no significant correlation between the prorenin levels in 
cardiac tissue and plasma. 
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Figure 5. Relationship between cardiac renin and cardiac angiotensinogen in heart donors 
(closed circles) and patients with dilated cardiomyopathy (open circles) (r=.72, P<.05). 
Billdillg of rellill to cardiac membralles 
Cardiac membranes prepared from porcine left ventricular tissue (n=8) bound porcine 
renin in a dose-dependent way (Figure 6). Binding was maximal wit/lin 15 minutes. 
According to Scatchard analysis, Kd was 0.21±0.11 mllol Aug I1min per mL and Bm" 
was 0.5±0.3 pmol Aug I1min per mg protein. One nanomole of pure porcine renin 
generates during incubation at 37°C with saturating concentrations of porcine 
angiotensinogen ~200 nmol Ang I1min.'"" 
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With our semi purified preparation of porcine kidney renin we found the maximum 
reaction velocity (Vro.J when incubated with sheep angiotensinogen to be similar to 
the I/m., when incubated with angiotensinogen prepared from nephrectomized pigs." 
Thus K, was in the order of 10" mollL, and Bma< was ~2 fmollmg protein. 
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B pmal ANG I/min 0.8 
per mg protein 
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200 qOO 
F pmal ANG I/min per mL 
Figure 6. Binding of semipurified porcine'kidney renin to cardiac membranes prepared from 
porcine left ventricular tissue. Specific binding (open triangles) was taken as the difference 
between total binding (closed circles) during incubation of renin with intact cardiac 
membranes, and non-specific binding (open circles) during incubation of renin with cardiac 
membranes after their denaturation by heating. Kd and B=, were calculated from a plot 
according to Scatchard16 (inset). 
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Discussion 
The results of the present study demonstrate the presence of increased concentrations 
of renin and prorenin in left ventricular tissue from patients with OCM. The cardiac 
levels of renin and prorenin were more than fivefold the cardiac levels in the donors. 
In addition, the cardiac tissue-to-plasma concentration ratios for renin and prorenin 
(molecular mass, 48 kD and 54 kD, respectively) were about 3 times the ratio for 
serum albumin (molecular mass, 70 kD), indicating that the levels of renin and 
prorenin in cardiac tissue were too high to be explained by admixture with blood or by 
diffusion from the blood into the interstitial fluid. In nonnal porcine left ventricular 
tissue, the renin level was also higher than can be explained by its localization in 
extracellular fluid' 
Purified membrane fractions prepared from porcine left ventricular tissue 
contained renin,' and specific binding of renin and prorenin to rat renal and other 
tissue membranes has been reported. ".36 In the present study, we observed high-
affinity binding of porcine renin to porcine cardiac membranes. Since the membrane 
fraction contained both plasma membranes and sarcoplasmic reticulum, it is wlclear 
whether renin binding was specific for plasma membranes. Chemical cross-linking 
studies also suggest the presence of renin-binding proteins in rat vascular tissue 
membranes." Our fmdings in the human heart, which indicate that renin and prorenin 
in cardiac tissue are not restricted to the extracellular fluid, may therefore be explained 
by binding to cell membranes. 
ACE, which is known to be a membrane-bound enzyme, was also found in 
cardiac tissue in concentrations that were higher than could be explained by its 
presence in the extracellular fluid. Cardiac ACE levels did not differ between the 
OCM patients and the donors. It should be noted, however, that 8 of the 10 patients 
with OCM were receiving ACE inhibitor treatment at the tinle of cardiac 
transplantation. This may have led to some underestimation of ACE activity in these 
patients. In nonnal hearts, ACE appears to be limited to the vascular endothelium and 
the endocardium."·39 
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After myocardial infarction in humans, ACE can also be detected in the remaining 
viable cardiomyocytes near the infarct scar of the anetuysmalleft ventricle," as well 
as in fibroblasts, vascular smooth muscle cells and macrophages in the scar area 
itself." After coronary occlusion in rats, ACE was demonstrated in fibroblasts in the 
healthy hypertrophying part of the heart." 
The patients with OCM had markedly increased levels of renin and reduced 
levels of angiotensinogen in circulating plasma at the time of transplantation. These 
are characteristic fmdings in patients with end-stage heart failure who are treated with 
diuretics and ACE inhibitors.'I." The cardiac level of angiotensinogen in these patients 
was approximately one third of the level in the donors and was negatively correlated 
with the renin concentration. Tllis is probably related to the fact that substrate 
consumption is increased when renin is increased. Au interesting fmding was that the 
cardiac tissue-to-plasma concentration ratio for angiotensinogen (molecular mass, 65 
kO) was half the ratio for albumin (molecular mass, 70 kD). Tllis is evidence in favor 
of consumption of angiotensinogen that is present in the cardiac extracellular fluid 
through the reaction with renin, thereby implying local Aug I production occurs in the 
heart. 
In the OCM patients in whom measurements of relUn were available in cardiac 
tissue as well as in plasma, the tissue and plasma levels showed a positive correlation. 
Extrapolation of the regression line to normal plasma concentrations yielded a tissue 
concentration of renin close to the concentration measured in the donor hearts. Thus, 
there was no evidence to suggest that the regulation of cardiac renin is independent of 
the regulation of circulating renin. A previous study by our group of the effect of 
nephrectomy on the cardiac levels of renin in healthy pigs showed that most, if not all, 
renin in cardiac tissue originates from the kidney.' Studies, in wllich intravenous bolus 
injections of radiolabeled renin were given to rats and monkeys, have demonstrated 
that the enzyme accumulated in the heart.43.44 
Prorenin in cardiac tissue was not significantly correlated with prorenin in 
plasma. It should be noted, however, that the measurement of prorenin is not as 
accurate as the measurement of renin. Renin was measured as the Aug I-generating 
activity without prior in-vitro activation of prorenin, whereas prorenin was measured 
as the difference between the Aug I-generating activity after prorenin activation and 
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the Ang I-generating activity before activation. The results of this subtraction method 
are sufficiently accurate when renin is low compared with prorenin, as is the case in 
nonnal plasma. Results are less accurate when tile renin-to-prorenin ratio is higher, as 
was the case in both plasma and cardiac tissue in the patients with DCM. Another 
explanation for the apparent lack of a correlation between the measured levels of 
prorenin in cardiac tissue and plasma might be that part of the plasma-derived prorenin 
is activated in cardiac tissue. Such in vivo activation of plasma-derived prorenin in 
extrarenal tissues, however, has never been demonstrated. 
In addition to the evidence presented here, there is growing evidence from the 
literature to support the existence of local angiotensin formation in cardiac tissue. 
Perfusion of the isolated rat heart with renin leads to Ang I and II release into the 
coronary effluent' and to Ang I release into the interstitial fluid." Without the addition 
of renin to the perfusion fluid, the cardiac release of Ang I and II was practically zero. 
The study reported here provides no data on Ang I and II levels in cardiac tissue and in 
plasma. Special precautions are required when samples for measuring these pep tides 
are collected, and these precautions could not always be taken in tile setting of tlus 
study. It appears logical to assume that the elevated renin concentrations in the hearts 
affected by DCM will promote cardiac Ang I and II production. Experiments in intact 
pigs showing reduced cardiac contractility in response to intracoronary administration 
of the renin inIubitor remlkiren, support that cardiac Aug II production has functional 
significance"; the time course of this response was not correlated with tile effects of 
the inIubitor on tile levels of Ang I and II in the circulation. Intracardiac Ang I and II 
production may also participate in the long-teml processes of hypertrophy and 
remodeling after myocardial infarction.47 
In summary, our results add to the growing evidence in support of local Ang I 
and II production by the heart. So far, attempts to show that the production of these 
peptides is independent of renin from the circulation have failed, at least in normal 
hearts. The present study also fails to provide such evidence in DCM patients with 
severe heart failure; rather, our results are in keeping with the contention that relUn 
from the circulation is taken up by the heali and that tissue binding of renin is part of 
ti,e uptake process. 
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General Introduction 
Since the discovery of the kidney-derived pressor substance renin by Tigerstedt one 
hundred years ago, investigations on the renin-angiotensin system have taken an 
enormous flight. Not only are various compounds of tllis system now recognized as 
important effector molecules, a diversity of receptors that can bind these compounds has 
also been discovered. In view of the success of the renin-angiotensin system blockers in 
the treatment of cardiovascular diseases, much attention has been paid in tile past ten 
years to the concept of 'local' angiotensin production in heart and blood vessels. At first 
such production was thought to depend on locally syntllesized renin. More recent 
evidence suggests tllat it is circulating (i.e., renal) renin which contributes mostly to this 
local production of angiotensin II. In tile present tllesis we have studied whether cultured 
cardiac cells synthesize renin or its inactive precursor, pro renin. Furthermore, we have 
investigated how circulating renin (and prorenin) may reach tissue sites, and whetller 
prorenin is activated to renin at tllese sites. Finally, the hypertrophic/hyperplastic effects 
of angiotensin II were studied in cardiac cells, taking into accolUlt the various receptors 
tllat are stimulated by tills peptide. 
Chapters 2 and 3 
Demonstration of renin-angiotensin system (RAS) components in cardiac tissue cannot 
be taken as defmite evidence for synthesis of these components in tile heart, due to 
interference with plasma-derived RAS components. To avoid tile problems arising from 
ex-vivo measurements, renin, prorenin, angiotensinogen, ACE, angiotensin I and 
angiotensin II were measured in the medium and cell lysate of neonatal rat cardiac 
myocytes and fibroblasts, cultured under serum-free conditions. Measurements were also 
made in the fetal calf serum- and horse serum-containing mediUlll which had been used 
to obtain cell adherence and confluency prior to tile serum-free period, and in medium of 
serum-deprived cardiomyocytes exposed to cyclic stretch. 
All RAS components were detectable in unconditioned serum-supplemented 
medilUlI. Prorenin, but none of tile other RAS components, could be detected in medium 
of serum-deprived cells. However, its levels were low and tile angiotensin I-generating 
activity corresponding with tllese low profCIUn levels could not be inhibited by the 
specific rat relUn inhibitor CH-732. 
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Tltis suggests that the measured prorenin was most likely bovine and/or horse prorenin 
sequestered from the serum-contaiItiug medium to which the cells had been exposed prior 
to the serum-free period. When iIlcubated with angiotensin I lmder semm-free conditions, 
both cardiomyocytes and fibroblasts generated angiotensin II in a captopril-inhibitable 
manner. Lysates of semm-deprived cells did not contain renin, proreniIl, angiotensinogen, 
angiotensin I or angiotensin IT in detectable quantities. Stretch increased protein synthesis 
by 20% and was not accompanied by angiotensin release into the medium. 
Taken togeOler, Olese results suggest Olat cardiac myocytes and fibroblasts do not 
synthesize renin, prorenin or angiotensinogen in concentrations that are detectable or, if 
not detectable, high enough to result in angiotensin IT concentrations of physiological 
relevance. These cells do synthesize ACE, thereby allowing Ole synthesis of angiotensin 
IT at cardiac tissue sites when renin and angiotensinogen are provided via Ole circulation. 
Although angiotensiIl II is a well-known stinlUlator of cardiovascular growth and 
remodelling via ATI receptors, it did not appear to be a prerequisite to observe a 
hypel1ropltic response of cardiac cells following stretch. Additional experiments were 
therefore performed to study Ole effects of exogenous angiotensin II on protein and DNA 
synthesis in neonatal rat cardiac myocytes and fibroblasts. In view of the possibility that 
angiotensin IT may inhibit growth via AT, receptors, the effects of exogenous angiotensin 
II were also investigated in cardiac cells in which the protein and DNA synOlesis had' 
been stimulated with endoOlelin-1. Total protein and total DNA, as well as ['H]leucine 
and ['H]OlymidiIle iIlcorporation were measured following incubation with either vehicle, 
angiotensin II, endothelin-I or angiotensin II + endoOlelin-l, both iII Ole presence or 
absence of the ATI receptor blocker losartan or Ole AT, receptor blocker PD 123319. 
In myocytes, endothelin-I increased total protein as well as ['H]leucine and 
['H]Olymidine iIlcorporation. Angiotensin II did not affect any of these paranleters, nor 
did it iItfluence the endothelin-l-iIlduced responses. However, in Ole presence of 
PD 123319, angiotensin II stimulated ['H]leucine and ['H]thymidine incorporation. 
In fibroblasts, endothelin-l and angiotensin II did not significantly affect total 
DNA and ['H]tllymidine incorporation. Angiotensin II tended to increase total protein in 
Olese cells, an effect wltich was significant only in tlle presence ofPD123319. 
141 
Chapter 7 
Angiotensin II stimulated ['H) leucine incorporation in fibroblasts. This effect was absent 
with losartan and enhanced in the presence ofPD123319. These data demonstrate that 
AT, receptor-mediated proliferative effects of angiotensin II in neonatal cardiac cells may 
become apparent only when its AT2 receptor-mediated antigro\vth effects are blocked 
(Figure I). The net growth effect of angiotensin II therefore depends on the cellular 
AT/AT2 receptor ratio. Angiotensin II did not interfere with endothelin-I-induced effects. 
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Figure 1. Growlh·stimulatory and growth-inhibitory effects of angiotensin II (ANGII) and 
endothelin·J (ET-J) in neonatal rat cardiac myocytes and fibroblasts. 
Chapters 4 and 5 
Since (pro )renin does not appear to be synthesized in the heart and vasculature under 
normal circumstances, local generation of angiotensin II at these sites may depend on 
(pro )renin that is taken up from the circulation. Here, the binding and intemalizatioll of 
recombinant human renin and prorenin, as well as the activation of prorenin to renin, 
were studied in I) neonatal rat cardiac myocytes and fibroblasts and 2) human umbilical 
vein endothelial cells (HUVECs). 
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The cells were incubated with recombinant hmnan prorenin or rerun in the presence or 
absence of putative inhibitors of renin internalization. Surface-bound and internalized 
enzyme were distinguished by the acid-wash method. 
Prorenin and renin were bound and internalized at 3rc in a dose-dependent 
manner by all cells. At 4 ·C, (pro )renin remained stUface-bolmd and was not internalized. 
Prorenin that had been treated with endoglycosidase H to remove N-linked 
oligosaccharides was also not internalized. Prorenin was activated by the cells, and cell-
activated prorenin was only found in the internalized fraction, whereas the surface-bound 
prorenin remained inactive. Thus, it appears that the activation of prorenin took place at 
the time of its internalization or thereafter. 
Addition of marmose 6-phosphate to the medimn caused a dose-dependent 
inhibition of renin and prorenin internalization. Marmose I-phosphate, glucose 
6-phosphate and a-methylmarmoside had no effect. NlUl\onilUl\ chloride and monensin, 
which interfere with the nonnal trafficking and recycling of internalized receptors and 
ligands, inhibited the activation of prorenin. In HUVECs the activation of prorenin was 
monitored by a direct inrrnunoradiometric assay (IRMA) with the use of a monoclonal 
antibody directed against the -p24-Arg to -I p-Arg C-tenninal propeptide sequence of 
prorenin. The results indicated that activation was associated with proteolytic cleavage 
of the propeptide. 
These findings provide an explanation for recent experimental data indicating that 
angiotensin I and IT are produced at cardiac and other extrarenal tissue sites by the action 
of renal rerun. TItis local angiotensin generation may occur either on the cell surface or 
intracellularly, and may involve both renin and locally activated prorerun. 
Chapter 6 
A local renin-angiotensin system in the heart is often invoked to explain the beneficial 
effects of ACE inItibitors in herui failure. The heart however produces little or no renin 
under nonnal conditions. To investigate whether cardiac renin production occurs under 
pathological conditions, the cardiac tissue levels of renin and otiler components of tile 
rerun-angiotensin system were compared in 10 potential heart donors who died of non-
cardiac disorders and lO subjects with dilated cardiomyopathy (DCM) who undenvent 
cardiac trrulsplantation. 
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Cardiac levels of renin and prorenin in DCM patients were higher than in the donors. TIle 
cardiac and plasma levels of renin in DCM were positively correlated and extrapolation 
of the regression line to normal plasma levels yielded a tissue level close to that measured 
in the donor hearts. The cardiac tissue-to-plasma concentration (TIP) ratios for renin and 
prorenin were threefold the ratio for albumin, which indicates that the tissue levels were 
too high to be accowlted for by admixture with blood and diffusion into the interstitial 
fluid. Cell membranes from porcine cardiac tissue bound porcine renin with high affinity. 
The TIP ratio for ACE, which is membrane-bound, was fivefold the ratio for 
albumin. Cardiac angiotensinogen was lower in DCM patients than in the donors and its 
TIP ratio was half that for albwnin, which is compatible with substrate consmnption by 
cardiac renin. These data, obtained in patients with heart failure, suggest that also l\lIder 
pathological conditions local angiotensin production in the heart depends on renin that 
is taken up from the circulation. Membrane-binding may be part of the uptake process. 
Concluding Remarks 
The experiments described in this thesis focus on the cardiac synthesis of components of 
the renin-angiotensin system, the role of angiotensin II in the development of cardiac 
hypertrophy, and the uptake of (pro )renin by cultured cardiac and vascular cells. 
Despite many reports in the literature on the synthesis and release of angiotensin 
II by cardiac cells, 1~ we were unable to show that these cells are capable of synthesizing 
renin and angiotensinogen. Thus, either renin is not involved in the generation of 
angiotensin II by these cells, or the renin (and angiotensinogen) required for angiotensin 
II synthesis are derived from the serum used to culture the cells. A role for enzymes other 
than renin in the generation of angiotensins in the heart seems unlikely in view of the low 
or undetectable levels of angiotensin I and II in the heart following bilateral 
nephrectomy.'" Therefore, the second option (uptake from serum) seems the most likely 
explanation. This would be in accordance with our earlier in-vivo fmdings, which 
suggested that cardiac renin, l\lIder normal circumstances, is derived from the circulation 
and therefore of renal origin.' 
Binding to the cation-independent mannose 6-phosphate receptor (CI-MPR) might 
be (one of) the mechanism(s) by which cardiac cells, as well as endothelial cells, 
sequester circulating renin. 
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This receptor does not distinguish between renin and its inactive precursor, prorenin, as 
both enzymes contain the mannose 6-phosphate signal. Moreover, prorenin, once bound 
and internalized by the CI-MPR, is rapidly activated to renin. At present, it is not known 
whether locally activated prorenin contributes to angiotensin generation in the heart and 
vascular wall. Such local angiotensin generation may occur intracellularly, or outside the 
cell, after the release of cell-activated prorenin into the fluid surrounding the cells 
(Figure 2). The concept of prorenin contributing to local angiotensin generation is 
attractive, in view of the fact that the levels of prorenin in the circulation are tenfold 
higher than those of renin. However, since the CI-MPR is also involved in the clearance 
of enzymes (e.g., insulin-like growth factor II), 7 it is also conceivable that tllis receptor 
contributes to tile clearance of (pro )reilln. The latter would still imply a regulatory role 
with regard to local angioteusin production. 
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Figure 2. Binding and activation of pro renin by cardiomyocytes. After binding to the cell surface, 
the receptor-prorenin complex is internalized in a clathrin-coated pit, that pinches off to become 
a coated vesicle. The clathrin coat then depolymerizes, thereby leading to the fonnation of an 
endosome. Prorenin is activated to renin and dissociates from the receptor due to the acid 
environment in the endosome. The receptor returns to the cell surface, and the activated prorenin 
might participate in either intracellular or extracellular angiotensin generation. 
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It has been suggested, on the basis of mRNA measurements, that cardiac renin synthesis 
is switched on nnder pathological conditions.8•9 Our [mdings in cardiac tissue of subjects 
with heart failure do not support tItis possibility. Cardiac renin in these subjects rose in 
parallel with plasma renin. Thus, most likely also nnder pathological conditions the 
majority of cardiac renin is derived from the circulation. The density of renin binding 
sites (CI-MPRs?) may however change IUlder these circlllllstances. 
ACE appears to be the only RAS component involved in cardiac angiotensin II 
generation that does not have to be sequestered from the circulation. After the addition 
of (pro )renin and angiotensinogen, cultured cardiac cells should therefore be capable of 
synthesizing angiotensin II. It is not yet known where tltis angiotensin II is located. It 
might be present in tIle cells, either because it has been synthesized intracellularly or 
because, after its extracellular generation, it has been internalized via AT, receptor-
mediated endocytosis." 
Several studies suggest that neonatal rat cardiomyocytes release angiotensin IT 
from intracellular storage sites after tIle induction of stretch, and tIlat tItis angiotensin II 
contributes to the hypertrophic response observed after stretch.'~ 'Stretch' is assumed to 
lead to a myocyte phenotype that mintics that of load-induced cardiac hypertrophy. In the 
present study, stretch did lead to an increase in protein synthesis rate, but was not 
accompaltied by autocrine angiotensin II release. Thus, the hypertropltic response we 
observed was not due to angiotensin II. This does not rule out the possibility that 
angiotensin II nnder certain circlllllstances may contribute to myocyte hypertrophy. In 
fact, experiments in which angiotensin II was added to tIle culture medium of cardiac 
cells showed tIlat angiotensin II was capable of inducing a (modest) hypertropltic 
response, at least at concentrations> 10-9 M (i.e., more than 1000 times ltigller tIlall the 
detection lintit of our angiotensin assay) and in the presence of an AT, receptor 
antagonist. The latter is necessary since angiotensin II mediates antigrowth effects via 
AT, receptors, wltich mask its AT, receptor-mediated growth-stimulatory effects. 
Interestingly, tltis inhibitory effect was observed in relationsltip with the AT, receptor 
only, and not with other growth-stinlUlating receptors such as the ETA receptor (Figure 1). 
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Future Studies 
This study is the fIrst to show binding and activation of prorenin by extrarenal cells. In 
addition, the cOllllterregulatory role of the AT2 receptor with regard to the AT, receptor-
mediated growth-stimulatory effects was demonstrated in neonatal rat cardiac cells. 
Future studies should now address the following questions: 
How is prorenin activated to renin in extrarenal cells? 
We have observed that the intracellular activation of prorenin by cardiac cells and 
BUVECs is accompanied by proteolytic cleavage of the prosegment. It remains to be 
deternlined in which cellular compartment(s) the activation takes place, and what 
enzyme(s) is/are involved in this process. Such studies could be performed in cultured 
cells, using subsequent centrifugation steps to separate the various cellular compartments. 
Is the CI-MPR the only receptor involved in (pro)renin binding? 
All our studies on (pro )renin binding have been perfonned in isolated cells obtained from 
neonatal rats and hUlllan UIIlbilical veins. The number of CI-MPRs in these cells is most 
likely much higher than in non-fetal/neonatal cells. II,l2 Therefore, our studies should be 
extended to cells of adult animals. Moreover, the effect of carbohydrate removal (or more' 
specifIcally, malmose 6-phosphate removal) should be studied in detail, to address the 
question whether marlllose 6-phosphate-independent binding occurs. Alternatively, 
binding studies (involving a range of (pro )renin concentrations) IIlight be performed, 
preferably with '''I-labelled (pro)renin, in the presence and absence of substances that 
prevent the binding of (pro)renin to the CI-MPR. Using this approach, high affinity 
(pro )renin binding sites have been demonstrated in rat tissue membranes that were not 
blocked by marlllose 6-phosphate. l3 
Is (pro)renin binding affected by pathological conditions? 
After the detennination of the number of (pro )renin binding sites in cultured cells, 
binding studies should also be performed in tissue srunples obtained from different patient 
groups (e.g., with and without heart failure). We did not obtain evidence for cardiac rellin 
synthesis under pathological conditions. 
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However, the number of binding sites and/or the binding affmity might change under 
these conditions, thus allowing the heart (and other organs) to sequester more or less 
(pro)renin from the circulation, depending on the circumstances. For instance, Katz et al. 
observed that the rat heart preferentially retains high-matmose renin glycofornls after 
bilateralnephrectomy.J' 
Does (pro)renin binding and/or internalization result in an intracellular response? 
(Pro )renin binding may lead to angiotensin II fornlation, and thereby induce an AT 
receptor-mediated response. Alternatively, (pro )renin binding to a receptor may be 
sufficient by itself to stimulate an intracellular second messenger cascade. The latter has 
been shown in hwnan mesangial cells, where renin binding leads to an increase in DNA 
synthesis in the absence of angiotensin generation. " 11ms, second messenger formation 
by cultured cat'diac cells should be evaluated in response to (pro )renin, with or without 
the addition of angiotensinogen. 
Does angiotensin release ajler stretch depend on the presence of(pro)renin in the culture 
medium prior to stretch? 
In cardiomyocytes, we were unable to demonstrate atlgiotensin II release in response to 
cyclic stretch. The levels of (pro )renin in the serwn used to culture the cells prior to 
stretch may have been too low to lead to significant cellular angiotensin generation and/or 
storage. Therefore, these experinlents might be repeated after loading the cells with 
(pro)renin, which, in combination with the angiotensinogen present in the serwn, should 
lead to significant angiotensin II formation. 
How do patlw/ogica/ conditions affect the response to angiotensin II? 
TIle ATJ receptor-mediated growth-stimulatory effects of angiotensin II are counteracted 
by the AT, receptor. The number of AT, receptors is high in fetal tissue, and declines to 
low levels in adult animals. However, the AT/AT, receptor ratio may change 
considerably under pathological conditions (e.g., after myocardial infarction or in subjects 
with heart failure)"'" either due to a downregulation of AT I receptors, or to an 
upregulation of AT, receptors. Thus, the angiotensin II-induced hypertrophic responses 
should also be evaluated in cells obtained from infarcted and failing hearts. 
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Hoofdstuk 1 
Honderd jaar geleden werd door Tigerstedt een stof ontdekt in nierextracten die de 
bloeddruk verhoogde, het renine. Sindsdien heeft het onderzoek naar het renine-
angiotensine systeem (RAS) een enorme vlucht genomen. Het is nu bekend dat 
verschillende componenten van dit enzym-systeem (de belangrijkste is angiotensine II) 
effecten kntmen bewerkstelligen en dat hierbij diverse receptoren zijn betrokken. Het 
startpunt van het RAS is het (inactieve) prorenine dat kan worden omgezet in (actie!) 
renine. Renine gaat een reactie aan met angiotensinogeen waardoor angiotensine I 
ontstaat dat vervolgens door het angiotensine-converterend enzym (ACE) wordt omgezet 
in angiotensine II. 
Mede dankzij het succes van de blokkers van het renine-angiotensine systeem bij 
de behandeling van hart- en vaatziekten, is de afgelopen tienjaar veel aandacht besteed 
aan de hypothese dat angiotensine II lokaal (in het hart en de bloedvaten) wordt 
geproduceerd. Eerst dacht men dat deze produktie afhing van lokaal gesynthetiseerd 
renine. Recente bevindingen suggereren echter dat renine lIit de bloedsomloop, dat door 
de nieren aan het bloed wordt afgegeven, het meeste bijdraagt aan de lokale produktie van 
angiotensine II. 
In dit proefschrift is onderzocht of gekweekte hartcellen renine en diens inactieve 
voorioper, prorenme, kunnen prodllceren. Tevens is bestlldeerd hoe renine en prorenine 
lIit de bloedsomloop in hart en bloedvaten terecht kunnen komen en of op deze plaatsen 
het prorenine omgezet kan worden in het renine. Tenslotte is onderzocht of angiotensine 
II in hartcellen een groei-stimllierende werking heeft en welke angiotensine receptoren 
hierbij betrokken zijn. 
Hoofdstllkken 2 en 3 
Het aantonen van RAS componenten in hartweefsel is geen bewijs dat deze componenten 
in het hart gemaakt worden, aangezien hartweefsel ook RAS componenten bevat die 
afkomstig zijn uit bloed. Om deze problemen van ex-vivo metingen !e vermijden, werden 
de concentraties van renine, prorenine, angiotensinogeen, ACE, angiotensine I en 
angiotensine II geme!en in het kweekmedium en celextract van myocyten (spiercellen) 
en fibroblasten (tussencellen) uit neonatale ratteharten. De metingen werden uitgevoerd 
in celcultures zonder serum. 
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Ter vergelijking werden ook bepalingen uitgevoerd in het foetaal kalfsserum- en 
paardeserum-bevattende medium dat gebruikt werd om de cellen zo optimaal mogelijk 
te kweken (dlls voor ze werden blootgesteld aan serum-vrije omstandigheden), en in 
medium van cellen die, onder serum-vrije condities, cyclisch uitgerekt en gerelaxeerd 
werden ("stretch"). 
Alle RAS componenten waren meetbaar in senun-bevattend medium dat niet met 
de cellen in aanraking was geweest. Prorenine, maar geen van de andere RAS 
componenten, kon ook worden gedetecteerd in medium van cellen die onder serum-vrije 
omstandigheden verkeerden. De prorenine concentraties onder deze condities waren 
echter zeer laag, en de angiotensine I-vormende activiteit die overeen kwam met deze lage 
prorenine concentraties kon niet worden geremd met de specifieke rat renine reromer 
CH-732. Dit duidt erop dat het hier niet om rat prorenine gaat, maar waarschijnlijk om 
prorenine dat aIkomstig is uit het kalfs- en/of paardeserum waaraan de cellen eerder bloot 
waren gesteld. Onder serum-vrije condities bleken zowe! cardiomyocyten als fibroblasten 
angiotensine I in angiotensine II om te kumlen zetten, en deze ornzetting was volledig 
blokkeerbaar met de ACE reromer captopril. Extracten van serum-vrij gekweekte cellen 
bevatten geen renine, prorenine, angiotensinogeen, angiotensine I of angiotensine II in 
meetbare concentraties. Stretch van myocyten verhoogde de eiwit synthese met 20%, 
maar resulteerde niet in angiotensine afgifte aan het medium. 
Samenvattend \vijzen deze resultaten erop dat cardiomyocyten en fibroblasten geen 
renine, prorenine of angiotensinogeen produceren in concentraties die hoog genoeg zijn 
om te resulteren in angiotensine II concentraties van fYsiologische betekenis. Deze cellen 
produceren weI ACE, hetgeen de synthese van angiotensine II in hartweefse! mogelijk 
maakt als renine en angiotensinogeen via de circulatie worden aangevoerd. Hoewel van 
angiotensine II bekend is dat de cardiovasculaire groei en remodelling via AT I receptoren 
stimuleert, bleek het niet een vereiste te zijn voor de hypertrofe respons van cardiale 
cellen na stretch. 
Daarom werden vervolgens experimenten uitgevoerd om het effect van exogeen 
angiotensine II op de eiwit - en DNA synthese te bestuderen in cardiomyocyten en 
fibroblasten van neonatale ratten. Ook werd de mogelijkheid van een groei-reromend 
effect van angiotensine II via AT, receptoren onderzocht onder condities waarbij de eiwit-
en DNA synthese gestimuleerd waren met endotheline-I. 
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De eiwit - en DNA concentraties, alsmede de inbouw van [3H]leucine (een maat voor 
eiwit syuthese) en van [3Hlthymidine (een maat voor DNA syuthese) werden bepaald na 
incubatie met placebo, angiotensine II, endotheline-1, of angiotensine II + endotheline-1, 
zowel in de aan- of afwezigheid van de AT, receptor blokker losartan als de AT, receptor 
b10kker PD 123319. 
In myocyten verhoogde endotheline-l de hoeveellieid eiwit en de inbouw van 
[3H]leucine en ['Hltllymidine. Angiotensine II had geen effect op deze parameters, noch 
belnvloedde het de effecten van endotheline-l. Echter, in de aanwezigheid van PD123319 
stimuleerde angiotensine II de inbouw van [3H]leucine en ['H]thymidine. In fibroblasten 
had den zowel endotheline-l als angiotensine II geen significant effect op de DNA 
concentraties en de [3H]thymidine inbouw. Angiotensine II leek de eiwit concentratie in 
deze cellen iets te verhogen, maar dit effect was aileen significant in de aanwezigheid van 
PD123319. Angiotensine II stimuleerde tevens de ['Hlleucine inbouw in fibroblasten. Dit 
effect was afwezig na voorbehandeling met losartan en versterkt in aanwezigheid van 
PD123319. 
Deze bevindingen tonen aan dat de AT, receptor-gemedieerde proliferatieve 
effecten van angiotensine II in neonatale hart cellen aileen zichtbaar worden als de AT, 
receptor gemedieerde anti-groei effecten geblokkeerd worden. Het netto groei effect van 
angiotensine II is zodoende afhankelijk van de cellulaire AT/AT, receptor ratio. 
Angiotensine II had geen invloed op de effecten van endotheline-l. 
Hoofdstukken 4 en 5 
Omdat (pro )renine niet in het hart en de bloedvaten geproduceerd lijkt te worden onder 
nonnale omstandigheden, zal de lokale produktie van angiotensine II op deze plaatsen 
afhankelijk zijn van (pro )renine dat uit de circulatie is opgenomen. Om dit nader te 
onderzoeken, is de binding en opname van recombinant humaan renine en prorenine 
bestudeerd in myocyten en fibroblasten uit neonatale ratteharten, en in humane 
navelstreng endotheel cellen (HUVECs). Tevens is gekeken of deze cellen prorenine 
kunnen omzetten in renine. 
De cellen werden getncubeerd met recombinant humaan renine en prorenine in de 
aan- en afwezigheid van mogelijke remmers van renine internalisatie. 
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Met de zogenaamde 'zure-was' methode werd onderscheid gemaakt tussen (pro)renine 
dat zich aan het celoppervlak bevindt en (pro )renine dat door de cellen is opgenomen (en 
dus in de cellen aanwezig is). 
Wanneer de experimenten werden uitgevoerd bij 37°C, bleken de cellen zowel 
prorenine als renine dosisafhankelijk te binden en te internaliseren. Tijdens incubatie bij 
4 ° C trad aileen binding aan het oppervlak (en geen internalisatie) op. Prorenine dat 
voorbehandeld was met endoglycosidase H, een enzym dat stikstof-gebonden 
oligosaccharides verwijdert, werd ruet gebonden. Prorenine werd door de cellen 
geactiveerd. Het geactiveerde prorenine was aileen aanwezig in de gemternaliseerde 
fractie; het celoppervlak-gebonden prorenine bleef inactief. Het lijkt er dus op dat de 
activering van prorenine plaatsvindt tijdens de internalisatie of daama. 
De toevoeging van mannose 6-fosfaat aan het medium veroorzaakte een dosis-
afllankelijke remming van de (pro)renine internalisatie. Mannose I-fosfaat, glucose 6-
fosfaat en a-rnethylmannoside hadden geen remmend effect. Ammoruumchloride en 
monensine, stoffen die ingrijpen op de cyelus die receptor-ligand complexen in de eel 
doorlopen, bleken de activatie van prorenine te remmen. 
In HUVECs werd het activatieproces van prorenine nader bestudeerd met behulp 
van een directe inmlUnoradiometrische assay, welke gebruik maakt van een monoklonaal 
antilichaam tegen het -p24-Arg tot -Ip-Arg C-tem1inale propeptidegedeeJte van prorenine. 
De resultaten duidden erop dat de activatie van prorenine daadwerkelijk gepaard gaat met 
de proteolytische afsplitsing van het prosegment. 
Deze bevindingen plaatsen recente experimentele data betreffende renaal renine-
afhankelijke angiotensine produktie in hart- en ander extrarenaal weefsel in perspectief. 
Deze lokale angiotensine generatie zou aan het celoppervlak en/of intracellulair plaats 
kunnen vinden, en zowel renine als lokaal geactiveerd prorenine klllmen hierbij betrokken 
zijn. De (pro)rerunebinding door extrarenaal weefsel verloopt mogelijk via mannose 6-
fosfaat receptoren. 
Hoofds!uk 6 
Een lokaal renine-angiotensine systeem ill het hart wordt vaak genoemd ter verklaring van 
de gunstige effecten van ACE remmers bij hartfalen. He! hart produceert echter weinig 
of geen renine onder normale omstandigheden. 
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Om te onderzoeken of renine produktie in het hart wei onder pathologische condities 
plaatsvindt, zijn de concentraties van renine en andere componenten van het renine-
angiotensine systeem bepaald in de harten van 10 hartklepdonoren (overleden door niet-
cardiovasculaire aandoeningen) en van 10 pati~nten met ernstig hartfalen (gedilateerde 
cardiomyopathie, DCM) die een harttransplantatie ondergingen. 
De concentraties van renine en prorenine waren hoger in de harten van DCM 
pati~nten dan in de harten van donoren. In de DCM pati~nten bleek een positieve 
correlatie te bestaan tussen de renine concentraties in hartweefsel en bloed plasma. 
Extrapolatie van de regressielijn naar normale plasma renine concentraties gaf een 
weefsel concentratie die overeenkwam met de gemeten waarden bij de donoren. De 
hartweefsellplasma fY//P) ratio's van renine en prorenine waren drie keer zo hoog als de 
W /P ratio van albumine. Dit geeft aan dat de weefsel concentraties van renine en 
prorenine te hoog zijn om veroorzaakt te worden door vermenging van hartweefsel met 
bloed enlof door diffusie vanuit het bloed naar de cardiale interstitiele vloeistof. 
Celmembranen bereid nit hartweefsel van varkens bonden varkens renine met hoge 
affiniteit. De W/P ratio van ACE, een membraan-gebonden enzym, was vijf keer zo hoog 
als de ratio van albumine. Cardiaal angiotensinogeen was lager in DCM patienten dan in 
donoren, en de W/P ratio van angiotensinogeen bedroeg slechts de helft van die voor 
albumine, hetgeen snggereert dat angiotensinogeen in hartweefsel door renine wordt 
omgezet in angiotensine I. 
Deze resultaten, verkregen in pati~nten met hartfalen, duiden erop dat ook onder 
pathologische omstandigheden de lokale angiotensine produktie in het hart afhankelijk 
is van renine uit de circulatie. Membraanbinding kan deel uitrnaken van het opname-
proces. 
Hoofdstuk 7 
In dit hoofdstnk worden enkele concluderende opmerkingen gemaakt naar aanleiding van 
de bevindingen uit de voorgaande hoofdstukken. Ondanks de vele studies waarin wordt 
beschreven dat hartcellen angiotensine II maken, konden wij niet aantonen dat deze cellen 
zelfhet hiervoor benodigde renine synthetiseren. Het lijkt er dus op dat dit renine nit de 
bloedbaan moet worden opgenomen, bijvoorbeeld door binding aan een receptor. 
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Een receptor die hierbij betrokken zou kunnen zijn is de mannose 6-fosfaat receptor 
(MPR). Deze receptor is aanwezig op hartcellen (myocyten en fibroblasten) en 
endotheelcellen, en bindt niet aileen renine maar ook prorenine. Bovendien bleek 
prorenine, na binding en internalisatie door de cell en, sne! in renine omgezet te worden. 
Zodoende bestaat de mogelijkheid dat zowel renine als lokaal geactiveerd prorenine 
bijdragen aan de lokale produktie van angiotensine II. 
Waar deze produktie precies plaatsvindt kan nog niet worden gezegd: op het 
celoppervlak, in de cellen, ofin de vloeistoftussen de cellen na de afgifte van geactiveerd 
prorenine door de cellen? Aangezien de MPR ook betrokken is bij klaringsprocessen 
(bijv. van insulin-like growth factor II) kan op dit moment niet worden uitgesloten dat de 
receptor een rol speelt bij de klaring van renine en/of prorenine. Dit laatste zou overigens 
nog altijd betekenen dat de receptor een regulerende rol speelt bij de lokale produktie van 
angiotensine II. 
Op grond van veranderingen in mRNA concentraties werd eerder door anderen 
geconcludeerd dat de renine synthese in het hart met name op gang komt onder 
pathologische omstandigileden. Ouze bevindingen in de harten van patienten met 
hartfalen bevestigen deze conclusie nie!. Het lijkt er dus op dat zelfs onder pathologische 
omstandigheden het meeste cardiale renine alkomstig is uit de circulatie. Wei zouden 
onder dergelijke omstandigileden de (pro)renine receptoren (MPR?) in aantal kunnen 
veranderen. 
ACE is waarschijnlijk de enige RAS component benodigd voor de synthese van 
angiotensine II die in het hart zelf wordt gemaak!. Als aan hartcellen dus renine en 
angiotensinogeen wordt aangeboden moeten zij in staat zijn om zelf angiotensine II te 
maken. Of dit angiotensine II wordt opgeslagen in de cellen is vooralsnog onb~kend. 
Opgeslagen angiotensine II zou de bron kmmen zijn van het angiotensine II dat in hoge 
concentraties in het mediUl\l van hartcellen wordt aangetroffen na celstretch. Volgens 
sOlll1nigen speelt dit angiotensine II een cruciale rol bij het op gang brengen van de 
hypertrofe respons na de introductie van stretch. Hoewel onze bevindingen in 
cardiomyocyten bevestigen dat na stretch een hypertrofe respons optreedt, kon geen 
afgifte van angiotensine II worden aangetoond. Dus ook zonder angiotensine II kan 
hypertrofie optreden. 
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WeI kan angiotensine IT onder bepaalde omstandigheden toch een groei-stimulerende rol 
spelen, zo bleek uit experimenten waarbij angiotensine IT van buiten af aan de cellen werd 
toegediend. Ook dan trad hypertrofie op, althans WaImeer de AT, receptoren geblokkeerd 
waren. Deze receptoren remrnen nrunelijk de AT, receptor-gemedieerde groeirespons. De 
angiotensine II concentraties waarbij de groei-stimulerende effecten optraden lagen ver 
boven de ondergrens VaIl onze angiotensine II assay. 
Verder onderzoek is nodig om de vragen die bovenstaande experimenten hebbell 
opgewOl}len te beantwoorden: hoe vindt de activatie van prorenine precies plaats, is de 
MPR de enige receptor die betrokken is bij (pro )reninebinding, veranderen de 
(pro )reninebindingsplaatsen in aantal onder pathologische omstandigheden, leidt 
(pro )reninebinding tot een intracellulaire respons, waar haIlgt de angiotensine release na 
stretch van af, en hoe zit het met de rol van de AT, receptoren? 
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ACE 
Ang 
AT, 
AT, 
CD-MPR 
CRO 
CI-MPR 
DAG 
DCM 
DMEM 
HUVEC 
ET-l 
FAK 
HPLC 
IGFII 
IP, 
InsP, 
MAP 
M-6-P 
MPR 
PA 
PBS 
PIP, 
PLC-P 
PKC 
PLD 
RAS 
RnBP 
STAT 
TCA 
TGF-p 
angiotensin-converting enzyme 
angiotensin 
angiotensin II type 1 receptor 
angiotensin II type 2 receptor 
cation-dependent maImose 6-phosphate receptor 
chinese hrunster ovary 
cation-independent mannose 6-phosphate receptor 
diacylglycerol 
dilated cardiomyopathy 
Dulbecco's modified Eagle's mediUlll 
hUlllan UIlIbilical vein endothelial cell 
endothelin-I 
focal adhesion tyrosine kinase 
higll-performance liquid chromatography 
insulin-like growth factor II 
inositoll,4,5-triphosphate 
inositolphosphates 
mitogen-activated protein 
mannose 6-phosphate 
mannose 6-phosphate receptor 
phosphatidic acid 
phosphate-buffered saline 
phosphatidylinositol 4,5-biphosphate 
phospholipase C-p 
protein kinase C 
phospholipase D 
renin-angiotensin system 
renin-binding protein 
signal transducers and activators of transcription 
trichloric acid 
transforming growth factor-p 
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